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Epidemiology
Lung cancer is by far the leading cause of cancer death among males and the second leading 
cause of cancer death among females worldwide 1, 2. Each year, more persons die from lung 
cancer than of colon, breast, and prostate cancers combined 2. Most lung cancer cases are 
diagnosed in symptomatic patients. At that moment, the majority of patients have already 
reached an advanced stage of lung cancer, which is correlated with a poor survival 3. 
In the Netherlands, lung cancer is the leading cause of death among both genders: 
approximately 25% of cancer deaths among males and 20% of cancer deaths among females 
are caused by lung cancer (Figure 1) 4. 
Figure 1: lung cancer deaths in the Netherlands from 1990 to 2015 4
Lung cancer incidence rates vary demographically by sex and age, and geographically by 
differences in historical smoking behaviours 1, 5. Long term cigarette smoking accounts for 
approximately 85% of lung cancer cases 6-8. Time lag between the onset of smoking and the 
development for lung cancer is approximately 20 to 30 years 9. With the decrease of smoking 
prevalence in males since the 1960s, the prevalence of lung cancer among males has been 
decreasing worldwide 2. Among females, the decline of smoking prevalence started in the 
late 1980s and plateaued in the 1990s. Hence, the prevalence of lung cancer among females 
is  increasing 2. 
In the Netherlands, 12,000 people are diagnosed with lung cancer every year, of whom 
approximately 60% are male (Figure 2) 10. In the Netherlands, approximately 30% of males 
Introduction
11
Iand 22.6% of females do smoke, which corresponds to 26.3% of the Dutch population over 
18 years of age 11, 12. In 2015, the proportion of heavy smokers (people who smoke 20 or more 
cigarettes per day) decreased  since 2000 from 35.0% to 15.3%.
Figure 2: lung cancer incidence in the Netherlands, by gender 10
Aetiology 
In approximately 85% of all lung cancer cases, cigarette smoking is the primary cause for 
developing lung cancer  6-8, 13. The amount and duration of cigarette smoking is strongly related 
to the development of lung cancer 6-8, 13. In which, the duration of smoking is considered to be 
the strongest link with lung cancer risk 14. Unadjusted lifetime risk for developing lung cancer 
is approximately 6.4% 3. A current smoker who smoked one pack per day for 40 years has a 20 
to 50 times higher risk to develop lung cancer than a never smoker 15. In general, one out of 
nine smokers develops lung cancer 16. Most cases of lung cancers occur in moderate to heavy 
smokers 16. 
Other risk factors associated with lung cancer are: 1) family history of lung cancer, in which 
genetic factors can affect the risk for developing lung cancer regardless of exposure to cigarette 
smoking 17, 18; 2) other lung diseases such as COPD, chronic bronchitis or emphysema which 
may increase the risk for developing lung cancer independently from smoking 19-21; 3) passive 
smoking 22, 23; 4) asbestosis and radon exposure 24-26; and 5) a medical history of treatment 
with radiotherapy for a non-Hodgkin lymphoma or for breast cancer with increased risk for 
a second primary lung cancer 27, 28
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Histology
Lung cancer is defined as a malignant neoplasm of an unspecified part of an unspecified 
bronchus or lung according to the International Statistical Classification of Diseases and 
Related Health Problems ( ICD-10; C34) 29. Lung cancer usually arises from uncontrolled cell 
growth of the epithelium that lines in the bronchial tree and may spread to a site distant from 
the lungs and produce metastatic tumours in other parts of the body (e.g. brain, bones, liver 
or adrenal glands) 29. 
There are two main types of lung cancer: small cell lung carcinoma (SCLC) and non-small 
cell lung carcinoma (NSCLC), accounting for approximately 15% and 85% of lung cancer 
cases, respectively 1. These types are diagnosed based on the microscopic appearance of the 
malignant cells. The distinction between SCLC and NSCLC is essential for staging, treatment 
and prognosis of the lung cancer 30. 
Small cell lung carcinoma
Approximately 15% of all lung cancers are SCLCs 29, 31. They are characterised by small “blue” 
malignant cells about twice the size of lymphocytes (Figure 3). The cytoplasm is sparse 
and nuclear features include finely dispersed chromatin without distinct nucleoli. SCLC 
is histologically divided into two subtypes: oat cell carcinoma and a combined small cell 
carcinoma (usually a combination of SCLC with adenocarcinoma, squamous cell carcinoma 
or large cell carcinoma) 29, 30, 32. Large cell neuroendocrine carcinoma (LCNEC) is officially 
classified under NSCLC, but its biological behaviour is similar to that of SCLC 32. 
For SCLC and LCNEC there are standard immunohistochemical markers for lung origin 
and/or neuroendocrine features which are useful for establishing the diagnosis 33. A 
majority of the SCLC express the thyroid transcription factor (TTF-1), which can help in 
distinguishing LCNEC from other neuroendocrine carcinomas 34. Other markers that can 
be used to differentiate include CD56, chromogranin and synaptophysin 35. Up to two-thirds 
of SCLC will be negative for chromogranin and synaptophysin and CD56 will be positive in 
approximately 90–100% of cases 35. SCLC can also produce different kinds of hormones (e.g. 
ACTH and vasopressin) and antibodies which can cause various paraneoplastic neurological 
and endocrinologic syndromes 36, 37.
Lung cancer is a result of many genetic changes and exposure to tobacco and other possible 
carcinogens (e.g. radon, coal). In the case of SCLC, p53 mutations, loss of retinoblastoma 
gene (Rb) and strong expression of cKit are observed 33, 34. Unlike NSCLC, mutations in the 
EGFR and KRAS oncogenes and p16 abnormalities are rare. 
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Figure 3: small cell carcinoma 29.
Non-small cell carcinoma
NSCLC are usually adenocarcinomas, squamous cell carcinomas (SQM) or large cell 
carcinomas (LCC) 29, 30, 32. The distinguishing between the subtypes of NSCLC is necessary for 
the guidance of treatment and prediction of the clinical course. 
Adenocarcinoma
Adenocarcinomas are the most common type of lung cancer, accounting for approximately 
half of all lung cancer cases 31, 38. The incidence of adenocarcinoma is increasing, which is 
thought to be related to the introduction of low-tar filter cigarettes in the 1960s 38, 39. The use 
of filters may have led to different inhalation behaviours, e.g., taking larger puffs and retaining 
smoke longer to compensate for the lower nicotine dose in the filter cigarettes. This might have 
led to increased carcinogenic damage in the peripheral lung zones, where the majority of the 
lung adenocarcinomas arise. Another explanation could be higher nitrate contents of the low-
tar filter cigarettes. Also, lung cancer is increasing among females in whom adenocarcinoma 
seems to be more common 26. 
In the case of adenocarcinoma, the tumour tissue is commonly tested for the presence of a 
driver mutation (e.g. mutated epidermal growth factor, ALK translocation) and increasingly 
for other mutations (Figure 4) 40. This is necessary as it is possible to treat types of lung cancer 
in an advanced stage based on the genotype (so-called, personalised, genotype-directed 
therapy) 41, 42. 
Bronchioalveolar carcinoma (BAC) develops in cells near the alveoli in the outer region of 
the lungs. This type of lung cancer is characterised by growth near the alveolar septae without 
evidence of stromal, vascular, or pleural invasion. Since 2016, the term BAC has ceased to be 
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used. Instead, the term “lepidic” is used, which describes non-invasive growth along intact 
septae 32. Previous lesions classified as BAC are now classified under adenocarcinomas as: 
I. Atypical adenomatous hyperplasia (AAH): ≤5mm. Previously recognised as pre-
invasive lesion for lung adenocarcinoma. 
II. Adenocarcinoma in situ (AIS): a localised adenocarcinoma, smaller than 3 cm, in 
which growth is restricted to tumour cells growing along alveolar structures (lepidic 
growth patter) and lacks any component of invasion. Most AIS are non-mucinous and 
just a small subset of such tumours are mucinous.
III. Minimally invasive adenocarcinoma: a new category which describes a small, solitary 
adenocarcinoma (≤3cm) with predominantly lepidic growth patterns and 5mm 
invasion.
Figure 4: adenocarcinoma ( A: Lepidic predominant pattern with mostly lepidic growth and B: invasive 
acinar adenocarcinoma) 29.
Squamous cell carcinoma 
SQM used to be the most frequent type of lung cancer until the midst 1980s 29, 38. Currently, it 
accounts for about 30% of all lung cancers 31, 38. SQM arises in 60 to 80% in the proximal area 
of the tracheobronchial tree, although it is increasingly occurring as a peripheral lesion 43. 
Together with SCLC, it shows a stronger correlation with cigarette smoking than LCC and 
adenocarcinomas 44, 45.
SQM most often arise in segmental bronchi, and involvement of lobar and main stem 
bronchus occurs by extension (Figure 5) 29. In well-differentiated squamous cell carcinoma, 
squamous differentiation is suggested by intercellular bridging, squamous pearl formation 
and individual cell keratinisation which can readily be observed. In poorly differentiated 
squamous cell carcinoma, these features are difficult to find. 
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IThe diagnosis of SQM is mainly based on the presence of keratin production by the tumour 
cells and/or intercellular desmosomes, or by immunohistochemistry (expression of p40, p63, 
CK5, or CK5/6, desmoglein) 40, 46.
Figure 5: squamous cell carcinoma 29 and large cell carcinoma 29.
Large cell carcinoma 
LCC comprises 3% of all lung cancers 1, 31. The incidence of LCC is decreasing, due to 
reclassification of these tumours to mainly adenocarcinoma and squamous cell carcinoma 
30. These tumours are mostly found in the lung periphery, although they may have a central 
location. They frequently appear as large necrotic tumours.
LCC are malignant epithelial neoplasms lacking both glandular and squamous differentiation 
by light microscopy and immunohistochemistry, and lacking cytologic features of small cell 
carcinoma  (Figure 5) 40, 47. In other words, they are diagnosed by exclusion. 
Other types of NSCLCs 
Adenosquamous carcinomas are tumours which consist of at least 10% squamous cell 
carcinoma cells and at least 10% adenocarcinoma cells 48. 
Carcinoids are neuroendocrine lung cancers with neuroendocrine differentiation lower than 
LCNEC and SCLC, and can further be divided into typical and atypical types 32. This type of 
lung cancer can usually be diagnosed on the basis of light microscopy alone 29.
Non-small cell carcinoma, not otherwise specified (NSCLC NOS) is for cases where there is 
no evidence of squamous or adenocarcinomatous differentiation on immunohistochemistry 
and the endoscopic biopsies or cytology specimens are too small (sampling problems) 29. 
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Clinical manifestation
Unfortunately, the majority of patients is in advanced stage of disease at the time of lung cancer 
diagnosis. Symptoms of lung cancer do result from local effects of the tumour, from regional 
or distant spread, and/or from distant effects not related to metastases (e.g. paraneoplastic 
syndromes) 49-51. 
Local effects of lung cancer: 
I. Coughing: reported in more than 50% of the lung cancer patients at presentation and 
most frequently in those with a squamous cell and small cell carcinoma because of the 
central localization of the tumours 52-54. 
II. Haemoptysis: reported in up to 30% of the patients with lung cancer 52-54.
III. Chest pain: reported in up to 40% of the patients with lung cancer 52-54.
IV. Dyspnoea: reported in approximately 50% of patients with lung cancer at presentation 
52-54. 
V. Other more general reported symptoms are: chest pain (20-49%), weight loss (27-
68%), weakness (0-10%) and obstruction of the superior vena cava (0-4%) 52-55. 
The most frequent sites of distant metastasis at the time of diagnosis or during the course of 
the disease are the liver, adrenal glands, bones and/or brain 56. 
Lung cancer can also lead to symptoms which are mediated by hormones, cytokines or 
by an immune response against the tumour 36, 37. Some commonly observed effects are: 
hypercalcemia (leading to anorexia, nausea, vomiting), syndrome of inappropriate antidiuretic 
hormone secretion (SIADH) in which the degree of hyponatremia leads to various symptoms, 
neurological paraneoplastic syndromes (e.g. difficulty to rise from a chair, dry mouth or stiff 
muscles), haematological symptoms such as thrombocytosis and Cushing’s syndrome, in 
which an ectopic production of adrenal corticotropin (ACTH) is observed. 
Treatment 
Lung cancer is staged by using the International Association for the Study of Lung Cancer 
(IASCL) TNM staging system 57. Lung cancers have been staged using the 8th edition of the 
TNM staging system, since 2017. However, lung cancers are described by the 7th edition in 
this thesis. Therefore the 7th TNM staging system is summarised and presented in Table 
1 and Table 2. The choice how to treat the patient with lung cancer depends on the TNM 
staging system 58. 
In Table 3 an overview is presented of the stage distribution at time of lung cancer diagnosis 
based upon the Surveillance, Epidemiology, and End Results (SEER) data of the United States 
between 2005 and 2014 3.
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ITable 1: 7th edition TNM staging for lung cancer. Adapted from: Goldstraw et al (2007) 59. 
Primary tumour (T)
T1
Tumour ≤3 cm diameter in greatest dimension, surrounded by lung or visceral pleura, 
without invasion more proximal than lobar bronchus.
  1a Tumour ≤2 cm in diameter in greatest dimension.
  1b Tumour >2 cm but ≤3 cm in diameter in greatest dimension.
T2
Tumour >3 cm but ≤7 cm, or tumour with any of the following features:
- Involves main bronchus, ≥2 cm distal to carina;
- Invades visceral pleura;
- Associated with atelectasis or obstructive pneumonitis that extends to the 
hilar region but does not involve the entire lung.
  2a Tumour >3 cm but ≤5 cm in greatest dimension.
  2b Tumour >5 cm but ≤7 cm in greatest dimension.
T3
Tumour >7 cm or any of the following:
- Directly invades any of the following: chest wall, diaphragm, phrenic nerve, 
mediastinal pleura, parietal pericardium, main bronchus <2 cm from carina 
(without involvement of carina);
- Atelectasis or obstructive pneumonitis of the entire lung;
- Separate tumour nodules in the same lobe.
T4
Tumour of any size that invades the mediastinum, heart, great vessels, trachea, 
recurrent laryngeal nerve, esophagus, vertebral body, carina, or with separate tumour 
nodules in a different ipsilateral lobe.
Regional lymph nodes (N)
N0 No regional lymph node metastases.
N1
Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and 
intrapulmonary nodes, including involvement by direct extension.
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s).
N3
Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral 
scalene, or supraclavicular lymph node(s).
Distant metastasis (M)
M0 No distant metastasis.
M1 Distant metastasis.
  1a
Separate tumour nodule(s) in a contralateral lobe; tumour with pleural nodules or 
malignant pleural or pericardial effusion.
  1b Distant metastasis (in extra thoracic organs).
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Table 2: stage grouping according to the seventh edition TNM staging. Adapted from: Goldstraw et al 
(2007) 59.
Stage groups T stage N stage M stage 
Ia Ia,Ib 0 0
Ib IIa 0 0
IIa
Ia, Ib
IIa
IIb
I
I
0
0
0
0
IIb
IIb
III
I
0
0
0
IIIa
I-II
III
IV
II
I, II
0, I
0
0
0
IIIb
IV
I-IV
II
III
0
0
IV I-IV 0-III Ia, Ib 
Table 3: stage distribution of lung cancers at time of diagnosis 3.
Stages Spread %
Ia- IIb Localised 18.2
IIIa-IIIb Regional 21.9
IV Distant 53.2
Unstaged Unknown 6.7
Treatment of NSCLC
The NSCLCs are a heterogeneous group of lung cancers. In the case of curable disease, surgical 
resection offers the best opportunity for long-term survival of NSCLC patients. Molecular 
characterisation of tumour tissue serves as a guide to treatment in patients with metastatic 
disease and in those who relapse after primary treatment 60, 61. 
In general, patients with stage I or stage II NSCLC are treated with surgical resection of the 
tumour combined with a surgical resection of the mediastinal lymph nodes 62, 63. Surgical 
resection of the tumour is performed through a thoracotomy or increasingly by using video-
assisted thoracoscopic surgery (VATS), a minimally invasive surgical method 64. After an 
irradical resection of the tumour, or in the case of unexpected pathological N2 disease, adjuvant 
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Iradiotherapy is recommended 11. For stage II resected tumours adjuvant chemotherapy is 
recommended 65. For patients with compromised lung function or other co-morbidities (such 
as heart failure) who cannot undergo curative surgery for lung cancer, stereotactic radiation 
may be applied 66, 67. 
Patients with a stage III NSCLC and a good clinical performance are treated with concurrent 
chemoradiation 62, 68. Curative surgery plays a role in those patients with a down staging of the 
tumour after concurrent chemoradiation. 
Patients with stage IV NSCLC, are treated with systemic therapy (e.g. chemotherapy) or 
symptom-based palliative approach (e.g. radiation for metastases) 62. Therapy is guided by the 
mutation status of the tumour and by the clinical performance of the patient. Patients with 
metastasis may also benefit from resection of the metastasis (in case of isolated metastasis) as 
well as radiation (e.g. pain control). Local palliative measures (e.g. stenting of the vena cava, 
stenting of the oesophagus, coagulation of the bronchial vessels) may also be beneficial to 
control the pulmonary disease and increase the quality of life.
Table 4: overview of the NSCLC stage I or stage II treatment in the Netherlands 62.
Tumour status Type of treatment 
Tumour located in one lobe Lobectomy with mediastinal lymph node 
resection
Tumour located in one lobe, but the patient 
does have a limited lung function
- Segmentation or wedge resection of 
the lobe with tumour
- Or stereotactic radiotherapy
Tumour grows from one lobe into the next lobe - Lobectomy of the main lobe with 
wedge resection of the next lobe 
- In case of central located tumour, 
bilobectomy or pneumonectomy
Tumour grows near by the central blood vessels Sleeve lobectomy 
Tumour grows in to the thorax wall ‘En bloc’ resection of the thorax wall next to 
surgical resection of the tumour
More than one tumour in one lobe Lobectomy 
More than one tumour in different lobes Primary resection could be an option 
Treatment of SCLC
At the time of diagnosis, SCLC is usually disseminated (extensive). As SCLC is very responsive 
to chemotherapy, systemic chemotherapy is the main treatment for SCLC 69. 
In general, patients with a limited (not extensive) SCLC are treated with a combination 
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of chemotherapy and radiotherapy 62, 70. Surgery is only used in patients with a solitary 
pulmonary nodule without metastasis or lymph node involvement 71. Patients without disease 
progression and with a good clinical performance are recommended to receive a prophylactic 
cranial radiation (PCI) within 60 days after chemotherapy 72. 
For patients with extensive SCLC, chemotherapy is used as the only initial therapy 62. PCI 
is considered in patients with a complete or partial response, or stable disease after the 
chemotherapy. Radiation therapy can also be used for symptom-based control. 
Survival 
In general, the 5-year survival rate for lung cancer is about 11-18% 3, 5, 31. Survival decreases 
progressively with later stages of the disease. In Table 5 an overview is presented of the 5-year 
survival rate based upon the Surveillance, Epidemiology, and End Results (SEER) data of lung 
cancer survival in the United States between 2007 and 2013 3. 
In an analysis of surgical NSCLC cases from the IASLC lung cancer staging project, next to 
stage, age and gender were prognostic factors for survival 73. Patients less than 70 years of 
age had significantly a better overall survival compared to patients older than 70 years of 
age. BACs carried a better prognosis than all other subtypes of lung cancer. Squamous cell 
carcinomas were slightly favoured over adenocarcinomas and LCC, but only after adjusting 
for gender (male only) and stage. Adjusting for smoking status did not modify the effects of 
histology. 
Furthermore, histologic grade has significant a prognostic value for the survival of NSCLC 
lung cancer patients, in which undifferentiated carcinoma have an elevated risk of death 
compared to well-differentiated and moderate-differentiated carcinoma 74. The majority of 
lung cancer patients who died perioperative are current smokers 75, 76. Non-smokers, former 
smokers and recent quitters do have a significantly better prognosis than current smokers 
with lung cancer 75, 77. 
Table 5 : five-year survival rate (%) of NSCLC and SCLC by stage 3.
Stages Spread NSCLC SCLC
Ia- IIb Localised 59.5 28.9
IIIa-IIIb Regional 32.3 15.3
IV Distant 5.2 2.9
Unstaged Unknown 13.4 7.6
All stages - 22.1 6.5
NSCLC: non-small cell carcinoma; SCLC: small cell carcinoma. 
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ILung cancer screening 
The majority of lung cancers are clinically diagnosed at an advanced disease stage. As a result, 
treatment options are limited which leads to a low 5-year lung cancer survival rate 3, 5, 31. 
Preventing lung cancer by controlling the risk factors for lung cancer is called ‘primary 
prevention for lung cancer’. As approximately 85% of lung cancer cases are related to tobacco 
smoking, the abstinence of smoking and prevention of initiating the use of tobacco leads to 
a decrease in lung cancer incidence 1. Currently, in the United States 15.1% of the population 
is a prevalent smoker and in the Netherlands 26.3% of the population older than 18 years 
currently smokes 11, 12, 78. In low-income countries the prevalence of smoking is increasing 2, 
31, 49, 79. Smoking cessation is an important prevention method for decreasing the incidence 
of lung cancer in the long term 80, 81. However, the efficacy of the current smoking cessation 
programmes aimed at the general population is insufficient 82, 83. Moreover, increasingly lung 
cancers are being diagnosed in former smokers 84, 85. This underscores the need for early 
detection and treatment (secondary prevention) of lung cancer. 
Secondary prevention (screening) is detection of pre-clinical lung cancer lesions in 
asymptomatic persons, aiming to increase the opportunities for treatment and prevent 
progression of the cancer. The target population are people who are at high risk for developing 
lung cancer, but who are not already diagnosed with the disease. 
Before the 1990s, chest X-ray and sputum cytology were studied in clinical trials as a potential 
screening test for lung cancer and showed no significant lung cancer mortality reduction 86-89. 
By the introduction of low-dose Computed Tomography (CT) scanning in the 1990s a new 
period started of investigating CT scanning as a screening test for lung cancer. Different single-
arm studies of lung cancer screening with CT scanning showed that more lung cancers can be 
detected in an early stage using this method 90-94. However, to overcome various biases, such 
as, lead-time, length-time and overdiagnosis (discussed in more depth below), a randomised-
controlled setting with a control group without intervention was necessary. 
The largest randomised-controlled lung cancer CT screening trial is the National Lung 
Screening Trial (NLST), which took place in the United States from 2002 until 2011 95, 96. The 
primary aim was to investigate whether low-dose Computed Tomography (LDCT) leads to a 
lung cancer mortality reduction of at least 20% in subjects at a high risk for developing lung 
cancer. In total, 53,434 current or former smokers (who had smoked at least 30 pack years 
and did not quit smoking more than 15 years ago) aged between 55 and 74 years without 
symptoms or signs of lung cancer were enrolled. Participants received three annual screenings 
either with LDCT (screen group) or with standard chest radiography (control group). In 
2011, the study demonstrated that LDCT screening led to a lung cancer mortality reduction 
in high-risk subjects by 18 to 20% compared to chest radiography screening. Fewer deaths 
per 1,000 screened participants in the LDCT group were observed compared to the chest 
radiography group over an average of 6.5 years of follow-up (17.6 per 1,000 vs. 20.7 per 1000, 
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respectively) 96, 97. Furthermore, the all-cause mortality was 6.7% lower in the LDCT screening 
group compared to the chest radiography group. The number of scanned individuals required 
to prevent 1 lung cancer death was 320 and the number to prevent 1 death overall was 219 
over 6.5 years.
Based on the positive outcomes of the NLST, the United States Preventive Services Task Force 
(USPSTF) requested an independent review and a comparative modelling study to investigate 
the effectiveness of lung cancer screening using CT scans 98, 99. In 2013, this led to a grade B 
recommendation of annual CT lung cancer screening in subjects aged between 55 and 80 and 
who have a 30 pack year smoking history and who are current smokers or quit in the past 15 
years 96, 98. A grade B recommendation is suggested for practice, which means that there is a 
high certainty that the net benefit is moderate or there is a moderate certainty that the net 
benefit is moderate to substantial. 
Figure 6: prevention stages of lung cancer. 
CT: Computed Tomography. LC: lung cancer.
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IIn Europe, seven randomised-controlled trials of LDCT have been conducted or are still 
in progress at this moment (Table 6) 100-106. The main difference with the NLST is that the 
European trials all used a control group in which no screening was offered. So far, four 
European trials have shown no significant lung cancer mortality reduction (Table 7), but 
it should be noted that these trials were strongly underpowered (e.g. small sample size)  to 
be able to show a possible benefit. The mortality analyses of the NELSON, LUSI and UKLS 
studies are expected in the coming years.
Table 6: an overview of the seven European CT lung cancer screening trials and their study protocol.
n Recruitment 
method
Age 
group
Smoking 
history
Smoking 
cessation
Study 
groups
Screening 
interval
NELSON 
100, 107
15,792 Population-
based
50-75 >15 cigarettes 
p/d for >25 
years or
>10 cigarettes 
p/d for >30 
years
≤10 years CT vs 
usual 
care 
Four screenings 
with
screening 
intervals of 1, 2,
and 2,5 years
DLCST
 101
4,104 Volunteers 50-70 ≥20 pack-
years
≤10 years CT vs 
usual 
care
Five annual 
screenings
MILD
 102
4,099 Volunteers >49 ≥20 pack-
years
≤10 years CT vs 
usual 
care
Five annual 
screenings vs 
three biennial 
screenings
UKLS
 103
4,061 Population-
based
50-75 5-year lung 
cancer risk, 
and predicted 
risk of ≥5% of 
lung cancer 
diagnosis 
within 5 years
≤10 years CT vs 
usual 
care
One screening 
LUSI
 104
4,052 Population-
based
50-69 ≥15 cigarettes 
p/d for ≥25 
years or
≥10 cigarettes 
p/d for ≥30 
years
≤10 years CT vs 
usual 
care
Four annual 
screenings
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ITALUNG 
105
3,206 Through 
general 
practitioners
55-69 ≥20 pack-
years
≤10 years CT vs 
usual 
care
Four annual 
screenings
DANTE
 106
2,472 Volunteers 60-74 ≥20 pack-
years
≤10 years CT vs 
baseline 
chest 
radio-
graphy 
Four annual 
screenings
NELSON: The Dutch-Belgian Lung cancer Screening Trial; DLCST: Danish Lung Cancer Screening 
Trial; MILD: Multicentric Italian Lung Detection trial; UKLS: UK Lung cancer Screening pilot trial; 
LUSI: Lung tumour screening and intervention trial; ITALUNG; The Italian Lung Study; DANTE: 
Detection And screening of early lung cancer with Novel imaging Technology. 
Table 7: an overview of the seven European CT lung cancer screening trials and their end-point analysis. 
NELSON DLCST 108, 109 MILD 99 UKLS LUSI ITALUNG 110 DANTE 111
LC mortality, 
RR (95%CI)
- 1.03 
(0.66-1.60)
1.641 
(0.73-4.01)
- - 0.70 
(0.47-1.03)
0.99 
(0.69-1.43)
All-cause 
mortality, RR 
(95%CI)
- 1.02 
(0.82-1.27)
1.402 
(0.82-2.38)
- - 0.83 
(0.67-1.03)
0.95 
(0.77-1.17)
1There was no significant difference between the annual and biennial screening arm (p=0.21). This 
presents the HR when comparing the two LDCT arms together with the control group; 2There was no 
significant difference between the annual and biennial screening arm (p=0.13). This presents the HR 
when comparing the two LDCT arms together with the control group
Criteria for lung cancer screening programme 
To justify a screening programme it should meet the following requirements: 
1) there should be substantial positive health outcomes (e.g. mortality reduction, life years 
gained, significant increase in management or treatment options); 2) the adverse side-effects 
(e.g. extent of early detection, overdiagnosis and side-effects) should be limited; and 3) the 
ratio between costs and benefits should be reasonable. 
Table 6: continued. an overview of the seven European CT lung cancer screening trials and their study 
protocol.
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IThe most important benefit of lung cancer screening is the reduction in lung cancer mortality 
(Table 8). This has been demonstrated by the NLST and has been an important factor in the 
implementation of LDCT screening for lung cancer in the United States 98. The lung cancer 
mortality rate is widely accepted as a measurement to determine the effectiveness of a lung 
cancer screening programme. Case-specific survival of lung cancer (or survival rate) is not 
recommended since it refers to the number of people with lung cancer remaining alive at a 
certain point in time after diagnosis. Moreover, survival rate does not adjust for the effects of 
lead-time, length-time and overdiagnosis biases (Figure 7 and Figure 8):
- Lead-time bias: length of time between early diagnosis of cancer by screening and the 
time in which the diagnosis would have been made without screening. In this case, the 
survival time is increased without affecting the actual course of the disease. In other 
words, there is no benefit of screening. 
- Overdiagnosis bias: detection of tumours by screening, which may have remained 
subclinical before death from another cause. 
- Length-time bias: screening is most likely to detect relatively slow-growing tumours, 
because they have a longer interval of being visible to be detectable by CT scan and 
have a longer asymptomatic phase. It gives the appearance that screening prolongs life. 
Therefore, in mortality analyses mortality of both the screen group and control group 
should be investigated. 
Other benefits of lung cancer screening are the reduction in all-cause mortality and increase 
of early staged lung cancers with more favourable treatment options 96, 112. Furthermore, 
participation in LDCT screening may be a teachable moment to quit smoking 113, 114. 
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Figure 8: length time bias. CT: computed tomography.   
Bullet: fast-growing tumours. Squares: slow-growing tumours.
Figure 7: lead-time bias and overdiagnosis bias.
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IHowever, screening might unintentionally expose the screened population to a variety of 
harms. One of the primary potential harm is a false positive test result: a benign nodule 
identified by CT-scanning which may leads to unnecessary invasive investigation. The false-
positive rate across the three screening rounds in the NLST was quite high (23.3%) 96. Another 
example is the delay of lung cancer diagnosis by a false negative test result 115. Moreover, 
screening will also lead to detection of lung cancers which may have not affected the patient’s 
lifetime if left untreated (overdiagnosis). True extent of overdiagnosis in lung cancer is 
difficult to determine because most of the current information what we know about lung 
cancer is derived from symptomatic patients. One study using excess-incidence reported that 
more than 18% of all lung cancers detected by LCDT in the NLST are indolent 116.  While, 
another study using Microsimulation SCreening Analysis (MISCAN) Lung model with the 
NLST data estimated that at year eight overdiagnosis rate to be 12.5% compared to 18.5%117. 
Hence, it is important to maximise the benefits while simultaneously minimizing the harms. 
Table 8: benefits and harms of lung cancer screening. 
Benefits Harms 
Overall mortality and lung cancer mortality 
reduction 
Complications of screen result and diagnostic 
work-up (false positives, invasive diagnostic 
work-up associated with morbidity and 
mortality)
Reduction in lung cancer incidence and 
advanced stage lung cancers
Delay of lung cancer diagnosis by a false 
negative test result 
DALY/QALY/life-years gained Overdiagnosis 
Increase of curative treatment options Radiation exposure (induces the risk for 
developing cancer)
A teachable moment for smoking cessation Psychological consequences (patient distress, 
anxiety)
Improvement in diagnostic procedures and 
cancer treatment
Possible negative effect on smoking cessation 
and false reassurance 
DALY=disability-adjusted life-year; QALY=quality-adjusted life-year
Chapter I
28
The NELSON trial 
Study design 
The largest European lung cancer screening trial, the NELSON trial was initiated in the 
Netherlands and in Belgium in 2003 107. 
The primary aims of this trial are: 
I. To establish whether LDCT screening in high-risk subjects would lead to a reduction 
of ≥25% in lung cancer mortality;
II. To estimate the impact of lung cancer screening on health-related quality of life and 
smoking cessation;
III. To estimate cost-effectiveness of LDCT screening for lung cancer.
Study participants were randomised (1:1) into no screening (control group) or screening using 
LDCT. Screening took place at baseline (round 1), after one year (round 2), after three years 
(round 3) and after five and half years (round 4). Participants of both groups are followed-up 
and the difference in lung cancer mortality between the study groups will be determined ten 
years after randomisation (Figure 9).
Figure 9: study design of the NELSON trial.
Population-based recruitment method
To minimise the “self-selection bias” that occurs when healthy volunteers are more eager to 
participate in a screening programme, a population-based recruitment strategy was used. 
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Population-based recruitment method
To minimise the “self-selection bias” that occurs when healthy volunteers are more eager to 
participate in a screening programme, a population-based recruitment strategy was used. 
Between the second half of 2003 and the second half of 2005, addresses of approximately 
600,000 subjects aged 50-74 years were obtained from seven districts in the Netherlands and 
14 municipalities around Leuven (Belgium) 100. These subjects received a questionnaire about 
their general health status, medical check-ups and history, physical activity, body weight 
and length, smoking history, alcohol consumption, their own medical history and family 
history of cancer, level of education and their opinions on screening programmes 100, 118. The 
questionnaire did not contain any information about the upcoming lung cancer screening 
trial. 
The information obtained from this first questionnaire was used to decide who met the 
inclusion- and/or exclusion criteria of the trial (Table 9) 100. Respondents who were eligible 
received an information leaflet about the NELSON trial, an  invitation to participate, an 
informed consent form for participating in the NELSON trial and a second questionnaire 
(about smoking habits and exposure to asbestos in more detail). 
Finally, those subjects who provided the informed consent and completed the second 
questionnaire (initially n=15,822, later adjusted to 15,792) were randomised (1:1) to either 
the screening group or the control group. 
The inclusion criteria were:
I. Aged between 50 and 74 at randomization;
II. Smoking history >15 cigarettes per day during >25 years or >10 cigarettes per day 
during >30 years; 
III. Smoking cessation ≤ 10 years ago. 
The exclusion criteria were: 
I. A moderate or poor self-reported health who were unable to climb two flights of stairs; 
II. A body weight ≥140 kilogram; 
III. A lung cancer diagnosis <5 years ago or ≥5 years ago but still under treatment; 
IV. A current or past renal cancer, breast cancer or melanoma; 
V. A CT chest examination <1 year ago; 
VI. A uncompleted informed consent. 
Screening procedure and protocol 
Screen group participants were invited by mail for an LDCT scan at one of the four screening 
sites: University Medical Centre Groningen, University Medical Centre Utrecht and Kennemer 
Gasthuis Haarlem in the Netherlands or at University Hospital Gasthuisberg Leuven in 
Belgium 107, 119. For the LDCT examination, 16-detector, or in later rounds 64-detector CT 
scanners in low-dose settings were used, without the administration of intravenous contrast 
media 120. Data acquisition and scanning conditions were kept standard across the four 
screening centres for the duration of the trial.
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Images were analysed using semi-automatic software (LungCARE, version Somaris/5 
VA70C-W, Siemens Medical Solutions), in which the semi-automatic segmentation of nodules 
and determination of the nodule volume took place. In case the software could not segment 
the nodule accurately, the radiologist measured the diameter manually 107. 
A nodule was defined as a small, spherical, non-linear circumscribed focus of abnormal tissue. 
The nodule characteristics (e.g. diameter, volume, density, location, lung segment and surface 
characteristics as smooth, speculated or other) were recorded and uploaded immediately in 
the NELSON Nodule Management System (NMS) 107. 
In the first two rounds, two radiologists independently reviewed the images in NMS. In case 
of a discrepancy, a third expert reader made the final decision 107, 120. However, for the last two 
rounds a single reading was performed, as Wang et al. showed that there was no benefit for 
double reading consensus with the use of semi-automated software 121. 
The screening test had three possible results, depending on the presence of one or more 
nodule(s), nodule volume and volume doubling time (VDT) 119:
I. Negative: no nodule detected, screen result not suspicious for lung cancer. No further 
diagnostic tests warranted;
II. Indeterminate: a small abnormality identified for which at this moment no further 
investigation is needed, however, in order to see whether there has been a change in 
this abnormality over time a follow-up scan will be made; 
III. Positive: abnormalities suspicious for lung cancer. Participant referred to a 
pulmonologist for a diagnostic work-up. 
In the case of newly detected solid nodules and the solid component of the part-solid nodules, 
the volume determined the screening outcome. In the case of previously detected nodules, the 
volume growth (change in volume of the nodule) and the VDT of the nodule determined the 
outcome. 
I. Negative screening outcome: a newly detected nodule volume of <50mm3 or, in the 
case of a previously detected nodule, volume growth of ≤25% or a volume growth of 
>25% and a VDT of >600 days. These participants were invited for the next screening 
round. For those in the fourth round, this was the end of the screening programme; 
II. Indeterminate screening outcome: a newly detected nodule volume of 50mm3-500mm3 
or, in the case of a previously detected nodule, a volume growth of >25% and a VDT of 
400-600 days. These participants received a follow-up LDCT examination according 
to protocol (after 6-12 weeks, or after 3-4 months) to classify the final result as positive 
or negative; 
III. Positive screening outcome: a newly detected nodule volume of >500mm3 or, in the 
case of a previously detected nodule a volume growth of >25% and a VDT of <400 
days. These participants were immediately referred to a pulmonologist for a diagnostic 
work-up. If the work-up did not lead to the diagnosis of lung cancer, they were invited 
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Ifor the next screening round. For those in case of the fourth round, this was the end of 
the screening programme. 
All lung cancers were staged using the 7th TNM staging system 57, 59. 
Data collection
Prospectively, all relevant medical data about the participants in the two groups is being 
collected. Relevant medical data contains information about the diagnosis, treatment 
and follow-up of the lung cancer, and about the cause of death. Furthermore, it contains 
information about the diagnostic work-up performed in the participants with positives 
screen test results. 
Information about the participants from whom all relevant medical data needs to be collected,
is obtained through data linkages with the Dutch Cancer Registry (NKR) and the Belgian 
Cancer Registry. 
After collecting medical data it was first verified whether the participant was indeed diagnosed 
with lung cancer during the course of the study or at the time of autopsy. 
End point verification
Linkages with Statistics Netherlands provided the cause of death of deceased participants. 
However, a clinical expert death review committee has been formed in the NELSON trial 
in order to accurately verify the cause of death of the study participants. The committee 
consists of two main reviewers: a pulmonologist-oncologist and  a pathologist specialised 
in lung oncology. Only in case when no consensus is reached between the two reviewers 
a third reviewer (an epidemiologist specialised in screening) is consulted. This committee 
reviews the blinded medical files of the deceased participants diagnosed with lung cancer, 
independently and in a uniform way by using a death review process protocol 122. 
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Research questions 
In this thesis three research topics are addressed: 1) the optimization of the NELSON screening 
rounds; 2) the implications and generalizability of the NELSON trial results; and 3) the cause 
of death verification process of the deceased NELSON study participants 
Part I: the optimization of the NELSON screening rounds
I. What is the added value of a fourth screening round with an interval of 2.5 years after 
the previous three screening rounds? 
II. Which NELSON subgroups with different risks for detecting lung cancer can be 
identified based on their previous screening history? 
Part II: interim stage shift results in the NELSON trial
III. What is the level of cancer and treatment shift between the two study groups in a 
selection of the study cohort? 
Part III: the cause of death of the NELSON study participants 
IV. What are the differences in characteristics and mortality profile of NELSON 
participants and eligible non-responders? 
V. What is the outcome of the Cause of Death verification process in the NELSON trial, 
and how does it relate to the official death certificates? 
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IOutline of this thesis
The research questions are divided into three parts. Part 1 consists of two chapters that 
address the “Optimization of the NELSON screening rounds” by determining the added value 
of a fourth screening round (Chapter II), and in which NELSON subgroups with various 
risks for detecting lung cancer can be identified based on their previous screening results 
(Chapter III). Part 2 consists of one chapter, which presents the interim stage shift results 
of the NELSON trial (Chapter IV). Part 3 addresses the difference in characteristics and 
mortality profile of the NELSON participants and eligible non-responders (Chapter V) and 
makes a comparison between the cause of death verification process in the NELSON trial and 
the official death certificates (Chapter VI). This is essential for the primary end results of this 
trial (lung cancer specific mortality). 
A general discussion is presented in Chapter VII, in which the published articles referred 
to in this thesis are reviewed in order to interpret important results, answer the research 
questions and to formulate general conclusions and recommendations.
Chapter I
34
References
1. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016;893:1-19.
2. Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. 
Transl Lung Cancer Res. 2015;4(4):327-38.
3. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich 
Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 
1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, 
based on November 2016 SEER data submission, posted to the SEER web site, April 2017. 
Access date 19-07-2017.
4. Dataset regarding lung cancer deaths provided by Statistics Netherlands (CBS), publically 
accesable from statline.cbs.nl, access date 04-04-2017.
5. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.
6. Wynder EL, Graham EA. Landmark article May 27, 1950: Tobacco Smoking as a possible 
etiologic factor in bronchiogenic carcinoma. A study of six hundred and eighty-four proved 
cases. By Ernest L. Wynder and Evarts A. Graham. Jama. 1985;253(20):2986-94.
7. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic 
carcinoma; a study of 684 proved cases. J Am Med Assoc. 1950;143(4):329-36.
8. Bach PB. Smoking as a factor in causing lung cancer. Jama. 2009;301(5):539-41.
9. Thun M, Peto R, Boreham J, Lopez AD. Stages of the cigarette epidemic on entering its second 
century. Tob Control. 2012;21(2):96-101.
10. Netherlands Comprehensive Cancer Organisation, IKNL. Publicaly accessible data available on 
www cijfersoverkanker nl, 2016. Access date 19-07-2017 by www.cijfersoverkanker.nl 
11. Billiet C, Decaluwe H, Peeters S, Vansteenkiste J, Dooms C, Haustermans K, et al. Modern post-
operative radiotherapy for stage III non-small cell lung cancer may improve local control and 
survival: a meta-analysis. Radiother Oncol. 2014;110(1):3-8.
12. van Laar MW, Nationale Drug Monitor. Published in 2016 by Trimbos Institute. Accesable from 
www.trimbos.nl/kerncijfers/nationale-drug-monitor. Access date 23-08-2017.  
13. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123(1 Suppl):21S-49S.
14. Pesch B, Kendzia B, Gustavsson P, Jockel KH, Johnen G, Pohlabeln H, et al. Cigarette smoking 
and lung cancer--relative risk estimates for the major histological types from a pooled analysis 
of case-control studies. Int J Cancer. 2012;131(5):1210-9.
15. Villeneuve PJ, Mao Y. Lifetime probability of developing lung cancer, by smoking status, Canada. 
Can J Public Health. 1994;85(6):385-8.
16. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 
1970-2002. Jama. 2005;294(10):1255-9.
17. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction 
of lung cancer. J Natl Cancer Inst. 2007;99(9):715-26.
18. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family 
history and lung cancer risk. Br J Cancer. 2005;93(7):825-33.
19. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic 
review and meta-analysis. PLoS One. 2011;6(3):e17479.
Introduction
35
I20. Yu YH, Liao CC, Hsu WH, Chen HJ, Liao WC, Muo CH, et al. Increased lung cancer risk among 
patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol. 2011;6(1):32-
7.
21. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence 
is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 
2009;34(2):380-6.
22. Besaratinia A, Pfeifer GP. Second-hand smoke and human lung cancer. Lancet Oncol. 
2008;9(7):657-66.
23. Brennan P, Buffler PA, Reynolds P, Wu AH, Wichmann HE, Agudo A, et al. Secondhand smoke 
exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two 
large studies. Int J Cancer. 2004;109(1):125-31.
24. Villeneuve PJ, Parent ME, Harris SA, Johnson KC, Canadian Cancer Registries Epidemiology 
Research G. Occupational exposure to asbestos and lung cancer in men: evidence from a 
population-based case-control study in eight Canadian provinces. BMC Cancer. 2012;12:595.
25. Darby S, Hill D, Auvinen A, Barros-Dios JM, Baysson H, Bochicchio F, et al. Radon in homes 
and risk of lung cancer: collaborative analysis of individual data from 13 European case-control 
studies. Bmj. 2005;330(7485):223.
26. Kligerman S, White C. Epidemiology of lung cancer in women: risk factors, survival, and 
screening. AJR Am J Roentgenol. 2011;196(2):287-95.
27. Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin’s 
lymphoma: a systematic review. Lancet Oncol. 2005;6(10):773-9.
28. Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A. Risk of second 
malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution 
review. Int J Radiat Oncol Biol Phys. 2007;68(2):359-63.
29. Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32(4):669-92.
30. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International 
association for the study of lung cancer/american thoracic society/european respiratory 
society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 
2011;6(2):244-85.
31. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016;893(0065-2598 
(Print)):1-19.
32. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, et al. The 2015 World 
Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic 
Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243-60.
33. Karachaliou N, Pilotto S, Lazzari C, Bria E, de Marinis F, Rosell R. Cellular and molecular 
biology of small cell lung cancer: an overview. Transl Lung Cancer Res. 2016;5(1):2-15.
34. Kitamura H, Yazawa T, Sato H, Okudela K, Shimoyamada H. Small cell lung cancer: significance 
of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology. Endocr 
Pathol. 2009;20(2):101-7.
35. Kasprzak A, Przewozna M, Surdyk-Zasada J, Zabel M. The expression of selected neuroendocrine 
markers and of anti-neoplastic cytokines (IL-2 and IL-12) in lung cancers. Folia Morphol 
(Warsz). 2003;62(4):497-9.
Chapter I
36
36. Bentea G, Sculier C, Grigoriu B, Meert AP, Durieux V, Berghmans T, et al. Autoimmune 
paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 
3: Neurological paraneoplastic syndromes, involving the central nervous system. Lung Cancer. 
2017;106:83-92.
37. Richardson GE, Johnson BE. Paraneoplastic syndromes in lung cancer. Curr Opin Oncol. 
1992;4(2):323-33.
38. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung 
Cancer. 2003;41(3):245-58.
39. Janssen-Heijnen ML, Coebergh JW, Klinkhamer PJ, Schipper RM, Splinter TA, Mooi WJ. Is there 
a common etiology for the rising incidence of and decreasing survival with adenocarcinoma of 
the lung? Epidemiology. 2001;12(2):256-8.
40. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for 
differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of 
whole-tissue sections with validation in small specimens. Mod Pathol. 2011;24(10):1348-59.
41. Kumarakulasinghe NB, van Zanwijk N, Soo RA. Molecular targeted therapy in the treatment of 
advanced stage non-small cell lung cancer (NSCLC). Respirology. 2015;20(3):370-8.
42. Hensing T, Chawla A, Batra R, Salgia R. A personalized treatment for lung cancer: molecular 
pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014;799:85-
117.
43. Funai K, Yokose T, Ishii G, Araki K, Yoshida J, Nishimura M, et al. Clinicopathologic characteristics 
of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol. 2003;27(7):978-84.
44. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-
analysis. Lung Cancer. 2001;31(2-3):139-48.
45. Yun YH, Lim MK, Jung KW, Bae JM, Park SM, Shin SA, et al. Relative and absolute risks of 
cigarette smoking on major histologic types of lung cancer in Korean men. Cancer Epidemiol 
Biomarkers Prev. 2005;14(9):2125-30.
46. Kim MJ, Shin HC, Shin KC, Ro JY. Best immunohistochemical panel in distinguishing 
adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected 
lung cancer specimens. Ann Diagn Pathol. 2013;17(1):85-90.
47. Rossi G, Mengoli MC, Cavazza A, Nicoli D, Barbareschi M, Cantaloni C, et al. Large cell 
carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and 
molecular biology. Virchows Arch. 2014;464(1):61-8.
48. Filosso PL, Ruffini E, Asioli S, Giobbe R, Macri L, Bruna MC, et al. Adenosquamous lung 
carcinomas: a histologic subtype with poor prognosis. Lung Cancer. 2011;74(1):25-9.
49. Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, et al. Longitudinal analysis of 2293 
NSCLC patients: a comprehensive study from the TYROL registry. Lung Cancer. 2015;87(2):193-
200.
50. Buccheri G, Ferrigno D. Lung cancer: clinical presentation and specialist referral time. Eur 
Respir J. 2004;24(6):898-904.
51. Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before 
the diagnosis is made? A population based case-control study. Thorax. 2005;60(12):1059-65.
Introduction
37
I52. Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest. 1974;65(3):299-306.
53. Chute CG, Greenberg ER, Baron J, Korson R, Baker J, Yates J. Presenting conditions of 1539 
population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. 
Cancer. 1985;56(8):2107-11.
54. Spiro SG, Gould MK, Colice GL, American College of Chest P. Initial evaluation of the patient 
with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP 
evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):149S-60S.
55. Eren S, Karaman A, Okur A. The superior vena cava syndrome caused by malignant disease. 
Imaging with multi-detector row CT. Eur J Radiol. 2006;59(1):93-103.
56. Riihimaki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic 
sites and survival in lung cancer. Lung Cancer. 2014;86(1):78-84.
57. Marshall HM, Leong SC, Bowman RV, Yang IA, Fong KM. The science behind the 7th edition 
Tumour, Node, Metastasis staging system for lung cancer. Respirology. 2012;17(2):247-60.
58. Little AG, Gay EG, Gaspar LE, Stewart AK. National survey of non-small cell lung cancer in the 
United States: epidemiology, pathology and patterns of care. Lung Cancer. 2007;57(3):253-60.
59. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC 
Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the 
forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 
2007;2(8):706-14.
60. Villalobos P, Wistuba, II. Lung Cancer Biomarkers. Hematol Oncol Clin North Am. 
2017;31(1):13-29.
61. Minuti G, D’Incecco A, Cappuzzo F. Targeted therapy for NSCLC with driver mutations. Expert 
Opin Biol Ther. 2013;13(10):1401-12.
62. Dutch Guidelines regarding lung cancer. Adapted from www.oncoline.nl Access date 04-05-
2017. 
63. Vansteenkiste J, Crino L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, et al. 2nd ESMO 
Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on 
diagnosis, treatment and follow-up. Ann Oncol. 2014;25(8):1462-74.
64. Scott WJ, Allen MS, Darling G, Meyers B, Decker PA, Putnam JB, et al. Video-assisted thoracic 
surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American 
College of Surgeons Oncology Group Z0030 randomized clinical trial. J Thorac Cardiovasc 
Surg. 2010;139(4):976-81; discussion 81-3.
65. Group NM-aC, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, et al. Adjuvant 
chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung 
cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267-77.
66. Solda F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic radiotherapy 
(SABR) for the treatment of primary non-small cell lung cancer; systematic review and 
comparison with a surgical cohort. Radiother Oncol. 2013;109(1):1-7.
67. van den Berg LL, Klinkenberg TJ, Groen HJ, Widder J. Patterns of Recurrence and Survival after 
Surgery or Stereotactic Radiotherapy for Early Stage NSCLC. J Thorac Oncol. 2015;10(5):826-
31.
Chapter I
38
68. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis 
of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung 
cancer. J Clin Oncol. 2010;28(13):2181-90.
69. Califano R, Abidin AZ, Peck R, Faivre-Finn C, Lorigan P. Management of small cell lung cancer: 
recent developments for optimal care. Drugs. 2012;72(4):471-90.
70. Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, Kester A, Rutten I, Lambin P. Timing of 
chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and 
meta-analysis of randomised controlled trials. Cancer Treat Rev. 2007;33(5):461-73.
71. Schneider BJ, Saxena A, Downey RJ. Surgery for early-stage small cell lung cancer. J Natl Compr 
Canc Netw. 2011;9(10):1132-9.
72. Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic 
cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic 
Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476-84.
73. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P, et al. The 
International Association for the Study of Lung Cancer Staging Project: prognostic factors 
and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 
2009;4(7):792-801.
74. Sun Z, Aubry MC, Deschamps C, Marks RS, Okuno SH, Williams BA, et al. Histologic grade is 
an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 
hospital- and 712 population-based cases. J Thorac Cardiovasc Surg. 2006;131(5):1014-20.
75. Sardari Nia P, Weyler J, Colpaert C, Vermeulen P, Van Marck E, Van Schil P. Prognostic value of 
smoking status in operated non-small cell lung cancer. Lung Cancer. 2005;47(3):351-9.
76. Kobayashi N, Toyooka S, Soh J, Ichimura K, Yanai H, Suehisa H, et al. Risk factors for recurrence 
and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor 
diameter of 20 mm or less. J Thorac Oncol. 2007;2(9):808-12.
77. Zhou W, Heist RS, Liu G, Park S, Neuberg DS, Asomaning K, et al. Smoking cessation before 
diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer. 
2006;53(3):375-80.
78. Jamal A, King BA, Neff LJ, Whitmill J, Babb SD, Graffunder CM. Current Cigarette Smoking 
Among Adults - United States, 2005-2015. MMWR Morb Mortal Wkly Rep. 2016;65(44):1205-
11.
79. Didkowska J, Wojciechowska U, Manczuk M, Lobaszewski J. Lung cancer epidemiology: 
contemporary and future challenges worldwide. Ann Transl Med. 2016;4(8):150.
80. Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, et al. Impact of reduced 
tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer 
Inst. 2012;104(7):541-8.
81. Nagelhout GE, Levy DT, Blackman K, Currie L, Clancy L, Willemsen MC. The effect of tobacco 
control policies on smoking prevalence and smoking-attributable deaths. Findings from the 
Netherlands SimSmoke Tobacco Control Policy Simulation Model. Addiction. 2012;107(2):407-
16.
82. Heckman CJ, Egleston BL, Hofmann MT. Efficacy of motivational interviewing for smoking 
cessation: a systematic review and meta-analysis. Tob Control. 2010;19(5):410-6.
Introduction
39
I83. Cahill K, Lancaster T. Workplace interventions for smoking cessation. Cochrane Database Syst 
Rev. 2014(2):CD003440.
84. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 
5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 
2005;128(1):452-62.
85. Mong C, Garon EB, Fuller C, Mahtabifard A, Mirocha J, Mosenifar Z, et al. High prevalence 
of lung cancer in a surgical cohort of lung cancer patients a decade after smoking cessation. J 
Cardiothorac Surg. 2011;6:19.
86. Manser R. Screening for lung cancer: a review. Curr Opin Pulm Med. 2004;10(4):266-71.
87. Manser RL, Irving LB, Byrnes G, Abramson MJ, Stone CA, Campbell DA. Screening for lung 
cancer: a systematic review and meta-analysis of controlled trials. Thorax. 2003;58(9):784-9.
88. Humphrey LL, Teutsch S, Johnson M, Force USPST. Lung cancer screening with sputum 
cytologic examination, chest radiography, and computed tomography: an update for the U.S. 
Preventive Services Task Force. Ann Intern Med. 2004;140(9):740-53.
89. Eddy DM. Screening for lung cancer. Ann Intern Med. 1989;111(3):232-7.
90. International Early Lung Cancer Action Program I, Henschke CI, Yankelevitz DF, Libby DM, 
Pasmantier MW, Smith JP, et al. Survival of patients with stage I lung cancer detected on CT 
screening. N Engl J Med. 2006;355(17):1763-71.
91. Sone S, Li F, Yang ZG, Honda T, Maruyama Y, Takashima S, et al. Results of three-year mass 
screening programme for lung cancer using mobile low-dose spiral computed tomography 
scanner. Br J Cancer. 2001;84(1):25-32.
92. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Sloan JA, Sykes AM, et al. Lung cancer screening 
with CT: Mayo Clinic experience. Radiology. 2003;226(3):756-61.
93. Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi T, Tsuchiya R, et al. Screening for 
lung cancer with low-dose helical computed tomography: anti-lung cancer association project. 
J Clin Oncol. 2002;20(4):911-20.
94. Nawa T, Nakagawa T, Kusano S, Kawasaki Y, Sugawara Y, Nakata H. Lung cancer screening using 
low-dose spiral CT: results of baseline and 1-year follow-up studies. Chest. 2002;122(1):15-20.
95. Aberle Dr Fau - Berg CD, Berg Cd Fau - Black WC, Black Wc Fau - Church TR, Church Tr Fau 
- Fagerstrom RM, Fagerstrom Rm Fau - Galen B, Galen B Fau - Gareen IF, et al. The National 
Lung Screening Trial: overview and study design. (1527-1315 (Electronic)).
96. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp 
JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N 
Engl J Med. 2011;365(5):395-409.
97. Patz EF, Jr., Greco E, Gatsonis C, Pinsky P, Kramer BS, Aberle DR. Lung cancer incidence and 
mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence 
screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening 
trial. Lancet Oncol.May;17(5)(1474-5488 (Electronic)):590-9.
98. de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, et al. Benefits and harms of 
computed tomography lung cancer screening strategies: a comparative modeling study for the 
U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(5):311-20.
Chapter I
40
99. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening 
for lung cancer with low-dose computed tomography: a systematic review to update the US 
Preventive services task force recommendation. Ann Intern Med. 2013;159(6):411-20.
100. van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, Nackaerts K, et al. Risk-based 
selection from the general population in a screening trial: selection criteria, recruitment and 
power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). 
Int J Cancer. 2007;120(4):868-74.
101. Pedersen JH, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P, et al. The Danish 
randomized lung cancer CT screening trial--overall design and results of the prevalence round. 
J Thorac Oncol. 2009;4(5):608-14.
102. Pastorino U, Rossi M, Rosato V, Marchiano A, Sverzellati N, Morosi C, et al. Annual or biennial 
CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J 
Cancer Prev. 2012;21(3):308-15.
103. Baldwin DR, Duffy SW, Wald NJ, Page R, Hansell DM, Field JK. UK Lung Screen (UKLS) nodule 
management protocol: modelling of a single screen randomised controlled trial of low-dose CT 
screening for lung cancer. Thorax. 2011;66(4):308-13.
104. Becker N, Motsch E, Gross ML, Eigentopf A, Heussel CP, Dienemann H, et al. Randomized 
study on early detection of lung cancer with MSCT in Germany: study design and results of the 
first screening round. J Cancer Res Clin Oncol. 2012;138(9):1475-86.
105. Lopes Pegna A, Picozzi G, Mascalchi M, Maria Carozzi F, Carrozzi L, Comin C, et al. Design, 
recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose 
CT. Lung Cancer. 2009;64(1):34-40.
106. Infante M, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Ceresoli G, et al. A randomized study 
of lung cancer screening with spiral computed tomography: three-year results from the DANTE 
trial. Am J Respir Crit Care Med. 2009;180(5):445-53.
107. van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, et al. Management 
of lung nodules detected by volume CT scanning. N Engl J Med. 2009;361(23):2221-9.
108. Saghir Z, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, et al. CT screening for 
lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: 
status after five annual screening rounds with low-dose CT. Thorax. 2012;67(4):296-301.
109. Wille MM, Dirksen A, Ashraf H, Saghir Z, Bach KS, Brodersen J, et al. Results of the 
Randomized Danish Lung Cancer Screening Trial with Focus on High-risk Profiling. (1535-
4970 (Electronic)).
110. Paci E, Puliti D, Lopes Pegna A, Carrozzi L, Picozzi G, Falaschi F, et al. Mortality, survival and 
incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax. 2017.
111. Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, et al. Long-Term Follow-
up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral 
Computed Tomography. Am J Respir Crit Care Med. 2015;191(10):1166-75.
112. Aberle DR, DeMello S Fau - Berg CD, Berg Cd Fau - Black WC, Black Wc Fau - Brewer B, Brewer 
B Fau - Church TR, Church Tr Fau - Clingan KL, et al. Results of the two incidence screenings 
in the National Lung Screening Trial. (1533-4406 (Electronic)).
Introduction
41
I113. Ashraf H, Tonnesen P, Holst Pedersen J, Dirksen A, Thorsen H, Dossing M. Effect of CT 
screening on smoking habits at 1-year follow-up in the Danish Lung Cancer Screening Trial 
(DLCST). Thorax. 2009;64(5):388-92.
114. van der Aalst CM, van den Bergh KA, Willemsen MC, de Koning HJ, van Klaveren RJ. Lung 
cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian 
randomised controlled lung cancer screening trial. Thorax. 2010;65(7):600-5.
115. Horeweg N, Scholten ET, de Jong PA, van der Aalst CM, Weenink C, Lammers JW, et al. 
Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of 
screening test performance and interval cancers. Lancet Oncol. 2014;15(12):1342-50.
116. Patz EF, Jr., Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemagi MC, et al. Overdiagnosis in 
low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174(2):269-
74.
117. Ten Haaf K, de Koning HJ. Overdiagnosis in lung cancer screening: why modelling is essential. 
J Epidemiol Community Health. 2015;69(11):1035-9.
118. van der Aalst CM, van Iersel CA, van Klaveren RJ, Frenken FJ, Fracheboud J, Otto SJ, et al. 
Generalisability of the results of the Dutch-Belgian randomised controlled lung cancer CT 
screening trial (NELSON): does self-selection play a role? Lung Cancer. 2012;77(1):51-7.
119. Xu DM, Gietema H, de Koning H, Vernhout R, Nackaerts K, Prokop M, et al. Nodule 
management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer. 
2006;54(2):177-84.
120. Xie X, Zhao Y Fau - Snijder RA, Snijder Ra Fau - van Ooijen PMA, van Ooijen Pm Fau - de 
Jong PA, de Jong Pa Fau - Oudkerk M, Oudkerk M Fau - de Bock GH, et al. Sensitivity and 
accuracy of volumetry of pulmonary nodules on low-dose 16- and 64-row multi-detector CT: 
an anthropomorphic phantom study. (1432-1084 (Electronic)).
121. Wang Y, van Klaveren RJ, van der Zaag-Loonen HJ, de Bock GH, Gietema HA, Xu DM, et 
al. Effect of nodule characteristics on variability of semiautomated volume measurements in 
pulmonary nodules detected in a lung cancer screening program. Radiology. 2008;248(2):625-
31.
122. Horeweg N, van Klaveren RJ, Groen HJ, Lammers JW, Weenink C, Nackaerts K, et al. Blinded 
and uniform cause of death verification in a lung cancer CT screening trial. Lung Cancer. 
2012;77(3):522-5.
 
Part I
the optimization of the NELSON screening rounds

CHAPTER II
Final screening round of the NELSON lung cancer
screening trial: the effect of a 2.5-year screening interval
Uraujh Yousaf-Khan, Carlijn van der Aalst, Pim A de Jong, Marjolein Heuvelmans,  Ernst 
Scholten, Jan-Willem Lammers, Peter van Ooijen, Kristiaan Nackaerts, Carla Weenink, 
Harry Groen, Rozemarijn Vliegenthart, Kevin ten Haaf, Matthijs Oudkerk, Harry de Koning 
Thorax 2017; 72 (1):48-56.
Final screening round
45
II
ABSTRACT
Background 
In the USA annual lung cancer screening is recommended. However, the optimal screening 
strategy (eg, screening interval, screening rounds) is unknown. This study provides results 
of the fourth screening round after a 2.5-year interval in the Dutch-Belgian Lung Cancer 
Screening trial (NELSON). 
Methods 
Europe’s largest, sufficiently powered randomised lung cancer screening trial was designed to 
determine whether low-dose CT screening reduces lung cancer mortality by ≥25% compared 
with no screening after 10 years of follow-up. The screening arm (n=7,915) received screening 
at baseline, after 1 year, 2 years and 2.5 years. Performance of the NELSON screening strategy 
in the final fourth round was evaluated. Comparisons were made between lung cancers 
detected in the first three rounds, in the final round and during the 2.5-year interval.
Results 
In round 4, 46 cancers were screen-detected and there were 28 interval cancers between the 
third and fourth screenings. Compared with the second round screening (1-year interval), 
in round 4 a higher proportion of stage IIIb/IV cancers (17.3% vs 6.8%, p=0.02) and higher 
proportions of squamous-cell, bronchoalveolar and small-cell carcinomas (p=0.001) were 
detected. Compared with a 2-year interval, the 2.5-year interval showed a higher non-
significant stage distribution (stage IIIb/IV 17.3% vs 5.2%, p=0.10). Additionally, more 
interval cancers manifested in the 2.5-year interval than in the intervals of previous rounds 
(28 vs 5 and 28 vs 19).
Conclusions 
A 2.5-year interval reduced the effect of screening: the interval cancer rate was higher 
compared with the 1-year and 2-year intervals, and proportion of advanced disease stage in 
the final round was higher compared with the previous rounds.
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2.1. INTRODUCTION
Lung cancer remains the leading cause of cancer death worldwide, mainly due to its advanced 
stage at the time of diagnosis 1. Based on the results of the National Lung Screening Trial 
(NLST), the US Preventive Services Task Force recommends annual lung cancer screening 
with CT 2, 3. People eligible for screening are aged 55 years through 80 years, have smoked at 
least 30 pack-years, and currently smoke or have quit within the past 15 years 4, 5. However, 
little is known about the effect of longer screening intervals in lung cancer screening trials: 
thus far, only the Multicentric Italian Lung Detection trial which consisted of two low-dose 
CT (LDCT) arms (annual vs biennial screening), reported no differences in mortality or in 
screening test performances between the two arms (n=1,190 and n=1,186) 6, 7. 
The Dutch-Belgian Lung Cancer Screening trial (NELSON) is the largest European 
randomized lung cancer screening trial, which was designed to investigate whether LDCT 
screening reduces lung cancer mortality by ≥25% compared with no screening after 10 
years of follow-up 8, 9. The trial randomised (1:1) 15,822 current or former smokers into a 
screening group and a control group. Compared with the NLST control group who received 
screening by chest radiography, NELSON control group participants received no screening. 
Furthermore, the NELSON screening group received LDCT screening at baseline (round 
1), after 1 year (round 2), after 3 years (round 3) and after 5.5 years after baseline (round 
4), whereas the NLST provided three annual screenings 10.  The use of variable screening 
intervals in one LCDT arm in the sufficiently powered NELSON trial is unique and presents 
an opportunity to investigate the influence of the intervals on the screening test performances 
(eg, lung cancer detection rate, false-positive (FP) rate) and the characteristics of screening-
detected lung cancers. 
Analyses of the first three rounds of the NELSON trial indicated that a 2-year interval between 
the second and the third screening rounds did not lead to a significantly higher proportion 
of advanced stage lung cancers compared with a 1-year screening interval between the first 
and second rounds 11. Furthermore, the lung cancer detection rate was relatively stable across 
the first three rounds 11-13.  Analyses also indicated that, despite the 2-year interval between 
the second and third rounds, specificity and sensitivity of the first three rounds were higher 
compared with other screening trials, which suggests that lung cancer screening using 
biennial screening regimens after an initial screening round could be effective 14. 
The primary aim of this study is to investigate the additional value of the final fourth 
screening round, 2.5 years after the previous screening round. The performance of the 
NELSON screening strategy in the final screening round is evaluated, and comparisons are 
made between the lung cancers detected in the first three rounds, those detected in the final 
round and cancers detected in the 2.5-year screening interval between the third and fourth 
rounds (ie, interval cancers).
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2.2. METHODS
NELSON trial
Details of the design and conduct of the NELSON trial have been reported previously 8, 9. In 
brief, eligible participants were selected after completing questionnaires about general health, 
lifestyle and smoking habits. Based on this information, persons aged 50–75 years, who had 
smoked ≥15 cigarettes per day for ≥25 years or ≥10 cigarettes per day for ≥30 years, and 
who were current smokers or former smokers with cessation ≤10 years ago, were invited to 
participate in the NELSON trial. Eventually, 15 822 eligible high-risk subjects for developing 
lung cancer participated in this population-based randomised trial. The primary aim of 
NELSON is to determine whether LDCT screening reduces lung cancer mortality by ≥25% 
compared with no screening after 10 years of follow-up 8 . 
To perform a fourth screening round an additional informed consent was obtained, as the 
original protocol consisted of only three screening rounds. The final screening round was 
conducted from November 2009 through March 2012. 
Study population
For this study, all 7,915 participants randomised to the screening arm were included. 
Screening procedures 
Screening group participants were invited to one of the four screening sites (University 
Medical Centre Groningen, University Medical Centre Utrecht and Kennemer Gasthuis 
Haarlem in the Netherlands, and University Hospital Gasthuisberg Leuven in Belgium). For 
the screening, 16-detector or, in later rounds 64-detector CT scanners in low-dose setting 
were used, without the administration of intravenous contrast media. Images were analysed 
using semiautomated software (LungCARE, version Somaris/5 VA70C-W, Siemens Medical 
Solutions) 9, 15. The analysis included the semiautomated segmentation of nodules and 
determination of the nodule volume. In case the software was not able to segment a nodule 
accurately, the diameter was measured manually by the radiologist 16. In the first two rounds, 
two radiologists independently reviewed the images. In case of a discrepancy, a third expert 
reader made the final decision. In the last two rounds, a single reading was performed by a 
radiologist with at least 6 years of  experience in thoracic imaging. Wang et al 17 showed that 
there was no benefit for double reading consensus with the use of semiautomated software. 
More detailed descriptions of the equipment and execution of the screening examination 
have been provided in previous reports 9, 15, 18
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Screening outcomes and the nodule management protocol
The screening test had three possible results, depending on the presence of nodules, nodule 
volume and volume doubling time (VDT): negative, indeterminate or positive 10. Negative 
results led to invitation to the next screening round, or in case of the final round to the end of 
the screening programme. Indeterminate results led to invitation for a repeat scan (after 6–8 
weeks or after 12 months, depending on nodule size and screening round) in order to classify 
the final result as positive or negative, based on volume change (growth) and growth rate, 
expressed in VDT 10. Positive results led to referral to a pulmonologist for a diagnostic workup. 
If lung cancer was diagnosed, a participant received treatment according to (inter)national 
guidelines. Medical data of these participants were collected prospectively. If a workup after 
a positive screening did not lead to lung cancer diagnosis, participants were invited for the 
next screening round, or, in case of the fourth round, to the end of the screening programme.
Nodule management protocol
Briefly, in case of newly detected solid nodules and the solid component of part-solid 
nodules, the volume determined the screening result: <50 mm3 was negative, 50–500 mm3 
was indeterminate and >500 mm3 was positive 10, 12, 15, 17, 18.  In case of previously detected 
nodules, evaluation was based on growth (defined as change in volume) and VDT. If volume 
growth was <25%, the screening result was negative, and if the volume growth was ≥25%, 
the VDT of the nodule was calculated: for nodules with VDT of 400–600 days, the result 
was indeterminate, and the result was positive if the VDT was <400 days and/or a new solid 
component emerged in a previously non-solid nodule.
Definitions
A regular round scan is the first CT examination performed for a specific participant in one 
of the predefined screening rounds. Follow-up scans are repeat scans which were performed 
in between screening rounds if a participant had an indeterminate result in one of the four 
regular scans. The result of a regular scan was defined as the result of the first CT examination 
in a screening round, while the definitive outcome of the screening round was determined 
after inclusion of the results of the repeat scans performed within that particular screening 
round. 
Lung cancers diagnosed by a pulmonologist within 24 months after referral for a positive 
screening were defined as screening-detected lung cancers. Interval lung cancers were defined 
as: lung cancers diagnosed after a negative screening test and before a next screening round; 
lung cancers diagnosed after an indeterminate screening test, without a follow-up CT scan 
before the next screening round; or lung cancers diagnosed after a positive screening result 
if the diagnostic workup initiated for the positive screening result did not yield a diagnosis 
of lung cancer, and the diagnosis was made later because symptoms had triggered diagnostic 
assessment that eventually yielded diagnosis of lung cancer. Overall lung cancer detection 
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rate was defined as the number of screening-detected lung cancers divided by the number of 
screened participants. Lung cancer detection rate of a round was defined as the number of 
screening-detected lung cancers in that round divided by the number of screened participants 
in that round. An FP test result was defined as a positive result in a participant when lung 
cancer was not diagnosed after referral to a pulmonologist for a diagnostic workup; a true-
positive (TP) test result was defined as a positive result in a participant diagnosed with lung 
cancer after workup by a pulmonologist. The overall FP rate result of a screening round was 
defined as the total number of FP screenings divided by the total number of scans performed 
in that round; the overall FP rate of the NELSON trial was defined as the total number of 
FP screenings across all screening rounds divided by the total numbers of scans performed 
across the four screening rounds.
Statistical analyses
Continuous variables were tested for normality by using the Kolmogorov-Smirnov test and 
examining Q-Q-plots. None of the tested variables were distributed normally, so they were 
described by using medians and IQRs. Differences between nominal variables were calculated 
by using a χ2 test, and differences between categorical variables by using a Mann-Whitney U 
test. To calculate the 95% CI for the lung cancer detection rate, positive predictive value, the 
TP rate, and the FP rate, bootstrapping was performed with 5000 samples. For all analyses, a 
p value <0.05 was considered statistically significant, and IBM SPSS Statistics V.21 was used 
for all analysis.
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2.3. RESULTS
The fourth screening round
The participation rates in the first three rounds were: 7,557 (95.5%) in round 1, 7,295 (92.2%) 
in round 2 and 6,922 (87.5%) in round 3. All eligible participants from the third round were 
invited to participate in the final round; in total 6,735 of the 6,922 participants screened in 
the third screening round were eligible, since they were alive and had not been diagnosed 
with lung cancer. Of these eligible participants, 80.7% (5,437/6,735) responded positively, 
and 97.1% (5,279/5,437) of these attended the final round (Figure 1). Participants with solely 
negative screening results were more willing to participate in the final round, compared 
with those with at least one non-negative screening result in the previous screening rounds 
(p=0.006, data not shown). Moreover, a higher proportion of current smokers attended the 
last round compared with former smokers (54.5% vs 45.5%, p=0.04).
Figure 2 presents an overview of the screening outcomes of the final round: 5,380 scans were 
performed of which 98.1% (5,279/5,380) were regular round scans, and 1.9% (101/5,380) 
were follow-up scans performed to assess the VDT of intermediate nodules. 
In total 5,336 nodules were detected on 2,507 of 5,380 performed scans in this round. Of these, 
35.2% were indeterminate (NODCAT III), and 2.8% were potentially malignant (NODCAT 
IV). Most of the nodules were solid (93.9%) and had a VDT of >600 days (98.1%; Table 1). 
In round 4, 46 lung cancers were detected in 43 of 105 participants with a positive result, 
representing a TP rate of 41.0% (43/105). Of these cancers, 60.9% were detected in stage I, 
15.2% in stage II, 10.8% in stage III and 13.1% in stage IV. Most cancers were localised in the 
right lung (67.4%, online supplementary Table S1). Four participants with lung cancer had 
symptoms before diagnosis. Half of the lung cancers were adenocarcinomas, and these tended 
to be more frequently detected in lower stage (stage I–IIIa) compared with small-cell lung 
cancers which were diagnosed in stage IIIa or stage IV (small cell lung carcinoma (SCLC); 
p=0.06). No significant correlations were found between disease stage and the following 
factors: age (p=0.81), gender (p=0.38), smoking status (p=0.89) or starting age of smoking 
(p=0.28; data not shown) (Table 2).
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Figure 1: flow chart of the NELSON lung cancer screening study. Dashed lines: 
25 participants did not receive screening in the first screening round but were screened in the second 
screening round; 27 participants received no screening in the second screening round, but were screened 
in the third round. Red dashed box: screened participants invited for the fourth screening round. 
 
1Interval cancer data of only Dutch screening group participants. 2Only participants who gave their 
additional consent were screened in the last screening round. 3Reasons for no further screening: 
49 participants weren’t traceable, 40 participants declined due to illness, 4 participants found the 
participating centre too far, 3 participants didn’t receive travelling expenses, 4 participants had a negative 
experience with other trials, 3 participants declined because of a ill family relative and 1,353 participants 
didn’t respond.  Eventually, 5,279 participants provided additional consent and were screened in the 
final screening round.
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Figure 2: screening results of the fourth screening round
* Follow-up scans are scans performed after an indeterminate screening result. 
Dotted line: four participants with a negative regular scan result received accidently a follow-up scan. 
Their screening results remained negative. 
1 In the follow-up scan one participant received an indeterminate result, so the participant received a 
second follow-up scan: the final scan was negative.
2 From one participant the scan data was lost, the participant received a new follow-up scan. The final 
screening result was negative. 
3 Seven participants received no follow-up scan (dashed line): two participants declined further screening, 
one participant did not respond anymore and four participants had an indeterminate screening result 
but were accidentally not invited for a follow-up scan. Hence, for these seven participants the final 
screening outcome remained indeterminate. As these participants received no follow-up scans, the sum 
of follow-up scans is: 80 + 1+ 19 + 1 = 101. 
4 Three participants with a positive screening were not referred to a pulmonologist: in one case the 
radiologist judged the growing nodule, despite a volume doubling time of less than 400 days, as non-
malignant; one participant was already diagnosed with an interval cancer and should not have been 
invited and screened in the final round; and in one case the work-up was started, but ended shortly after 
the patient was deemed too ill to undergo invasive diagnostics. 
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Table 1: overview of the nodules detected in the scans performed in the fourth screening round
n %
Total scans performed in round four 5,380 100.0
 Scans with nodules 2,507 46.6
 Scans without nodules 2,873 53.4
Total nodules detected on scans performed in 
round 4 5336 100.0
Nodule size category†
 NODCAT I* Benign 254 4.8
 NODCAT II** Non-significant small 3,057 57.3
 NODCAT III*** Indeterminate 1,875 35.2
 NODCAT IV**** Potentially malignant 149 2.8
Nodule growth category†
 GROWCAT A‡ 2,348 98.1
 GROWCAT B‡‡ 14 0.6
 GROWCAT C‡‡‡ 29 1.3
Type
 Solid 5,012 93.9
 Partial solid 39 0.7
 Non-solid 47 0.9
 Disappeared nodules 161 3.0
 Calcified/benign 97 1.6 
Location
 Right lung§ 3,109 58.3
 Left lung 2,227 41.7
*NODCAT I: Nodule with benign characteristics such as benign calcification patterns or fat depositions
**NODCAT II: Solid nodules with volume < 50 mm³; Pleural-based solid nodules with minimum 
diameter < 5 mm; Non solid component part solid SSNs with average diameter < 8 mm; Solid component 
part solid SSNs with volume < 50 mm³; Non solid nodules with average diameter < 8 mm
***NODCAT III: Solid nodules with volume 50 - 500 mm³; Pleural-based solid nodules with minimum 
diameter 5 - 10 mm; Non solid component part solid SSNs with average diameter ≥ 8 mm; Solid 
component part solid SSNs with volume 50 - 500 mm³; Non solid nodules with average diameter ≥ 8 
mm
****NODCAT IV: Pleural-based solid nodules with minimum diameter > 10 mm; Solid component part 
solid SSNs with volume > 500 mm³
† One nodule without outcome 
‡GROWCAT A: Percentage volume change ≥ 25% and VDT > 600 days
‡‡GROWCAT B: Percentage volume change ≥ 25% and VDT 400 - 600 days
‡‡‡GROWCAT C: Percentage volume change ≥ 25% and VDT < 400 days; New solid component in 
previously non solid nodule
§One nodule was located in the trachea
GROWCAT, nodule growth category; NODCAT, nodule size category; VDT, volume doubling time.
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Screening outcomes of 2.5-year versus 1-year screening intervals
Compared with round 2, performed after a 1-year screening interval, a lower proportion of 
stage I (60.9% vs 75.9%) and a higher proportion of stage IIIb/IV (17.3% vs 6.8%) cancers 
was detected in the final round (p=0.02, Table 3). Relative to the results of a 1-year screening 
interval, higher proportions of squamous-cell carcinomas (SQM), bronchoalveolar carcinomas 
(BAC) and SCLC were detected (p=0.001, Table 4). In round 4, no large cell carcinomas, 
large cell neuroendocrine carcinomas (LCNECs) or carcinoids were detected. The locations of 
lung cancer or proportion of female participants with lung cancer did not differ between the 
second and fourth rounds (p=0.91 and p=0.78, respectively, online supplementary Table S1).
Screening outcomes of 2.5-year versus 2-year screening intervals
In the final round (performed after an interval of 2.5 years) a lower proportion of cancers 
was diagnosed in stage I (60.9% vs 72.7%) and a higher proportion in stage IIIb/IV (17.3% vs 
5.2%), compared with round 3 with a 2-year screening interval. However, this difference did 
not reach statistical significance (p=0.10). Compared with the final round, in round 3 more 
cancers of other histology types (two large-cell carcinomas, two carcinoids, one LCNEC, one 
mixed non-small cell lung carcinoma (NSCLC)/SCLC and seven without a diagnosis) were 
detected (p=0.06). The localisations of lung cancers or proportion of female participants 
with lung cancer did not differ between the third and the last screening rounds (p=0.66 and 
p=0.73, respectively, online supplementary Table S1). 
Screening test performance across the four screening rounds
The lung cancer detection rate in the fourth round was slightly lower compared with the 
detection rate in the third round, however, not statistically different (0.8%, 95% CI (0.6% 
to 1.1%) vs 1.1%, 95% CI (0.8% to 1.3%)). Compared with the first and second rounds, no 
differences in lung cancer detection rates were observed (Table 5). The ratio of the TP and 
FP results tended to improve over time, from 0.69 in round 1 to 0.72 in round 2 and 0.83 in 
round 3. However, in the last screening round it dropped to 0.69. The other screening test 
performances did not differ.
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Interval cancers diagnosed between the third and fourth screening rounds
Participants with an interval cancer diagnosed between the third and fourth screening rounds 
were slightly older (p=0.06) and had smoked more pack-years (<0.001) compared with 
participants screened in the fourth round (Table 6). Relative to the previous rounds, in this 
2.5-year interval a higher proportion of participants was diagnosed with an interval cancer 
(Figure 3). 
In the first 24 months after the third round, 12 participants were diagnosed with an interval 
cancer, while in the last 6 months 16 extra participants were diagnosed with an interval 
cancer. The median age of participants with an interval cancer in the first 24 months was 
slightly lower than that of the participants with an interval cancer in the last 6 months (64.2 vs 
65.4, respectively, p=0.05). No differences were seen in stage distribution (p=0.77), histology 
(p=0.32), proportion of women (p=0.29) or in proportion of current smokers (p=0.22) 
between the interval cancers diagnosed in the first 2 years after the third round or in the last 6 
months before the fourth screening round (see online supplementary Tables S2–4).
Compared with the screening-detected cancers in the final round, the interval cancers between 
the third and fourth screening rounds were more often diagnosed at stage IIIb/IV (64.3% vs 
17.3%, p<0.001). They were also more often SCLC (10.7% vs 6.5%), large cell-carcinoma and 
LCNEC (14.3% vs 0%), and less often adenocarcinoma (32.1% vs 50.0) or BAC (0% vs 8.7%, 
p=0.02; all data not shown) compared with the lung cancers detected in round 4.
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Table 6: baseline characteristics of participants
Characteristics Participants with 
interval cancer in 2.5-
year interval after R3 
(n=27)*
Participants 
screened in R4 
(n = 5,279)
Participants with 
screening-detected 
lung cancer in R4  
(n=43)
p-value
Male n, (%) 23 (85.2) 4,437 (84.1) 37 (86.0) 0,93
Age median, (IQR) 59,0 (8.0) 58,0 (8.0) 60,0 (9.0) 0.06
Current smokers 
n, (%)
18 (66.7) 2,878 (54.5) 27 (62.8) 0.25
Pack years median, 
(IQR)
49,5 (28.8) 38,0 (19.8) 43,7 (23.0) <0.001
*27 participants with 28 interval cancer in the 2.5-year interval; p-value: across all subgroups, Kruskal-
Wallis test.
Figure 3: overview of the screening-detected lung cancers and interval cancers across the four rounds.
The numbers of lung cancers presented are not equal to the number of participants with lung cancer: as 
12 participants with screening-detected lung cancer (round 1 n = 4; round 2 n = 3; round 3 n = 2; and 
round 4 n =3), and one participant with an interval lung cancer (second year round 3) were diagnosed 
with synchronous double tumors.
2.4. DISCUSSION
In this study, the NELSON screening strategy of the final screening round was evaluated. 
Compared with the first three rounds a higher proportion of new lung cancers was detected 
at an advanced disease stage (stage IIIb/IV) and the interval cancer rate was higher in the 2.5-
year interval compared with the 1-year and 2-year screening intervals.
Relative to the first three rounds, the participation rate in round 4 was slightly lower (80.7% vs 
87.5–95.5%) 12. One explanation could be that the original NELSON study protocol consisted 
of three screening rounds and in order to perform a fourth screening round an additional 
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informed consent was necessary. At that time, 6 years after randomisation, some participants 
were no longer traceable. Another explanation could be that at the time of dispatching the 
invitations for the fourth screening round, participants may have lost interest in further 
screening.
Participants with exclusively negative test results were more willing to participate in the 
additional screening round than participants with at least one non-negative screening result.
Moreover, eligible participants who were screened in the fourth round, were more often 
current smokers. This could support results of previous analyses in the NELSON trial, 
indicating that screening may have an unintended health certificate effect that permits 
continued smoking 19. This indicates that lung cancer screening should be coupled with a 
smoking cessation intervention.
In the final round, 2.0% (105/5,380) of the screenings had a positive screening result. This 
resulted in a total of 2.0% (598/ 29,737) positive screenings in the NELSON study across 
all four rounds, which is comparable to the Danish Lung Cancer Screening Trial (DLCST; 
2.0%) 20. Compared with the NLST, the proportion of positive screenings in the NELSON 
trial is substantially lower (2.0% vs 24.2%) 3, 21. At the same time, the NLST also reported 
a substantially higher FP rate after a positive screening than the NELSON trial (96.4% vs 
59.4%) 3, 21. 
In round 4, a lower proportion of screenings yielded an indeterminate or positive result than 
in round 3, which took place 2 years after the second round 12. This could be due to the 
NELSON nodule management protocol allowing the radiologist to categorise abnormalities 
that remained stable across the previous rounds as negative 15, 17, 18. Another influencing factor 
could be the finding that substantially more participants were diagnosed with an interval 
cancer in the 2.5-year interval compared with the 1-year and 2-year intervals, leading to fewer 
participants with suspicious abnormalities at the time of screening in round 4. 
The cumulative lung cancer detection rate across the four rounds is 3.2%, which is  comparable 
with the DLCST 22. Relative to the NLST, the cumulative lung cancer detection rate of the 
NELSON trial is substantially higher: 3.2% vs 2.4%. However, the NLST had three annual 
screenings, a different nodule management protocol, and a different study population 3, 21. 
The effectiveness of the NELSON trial (including the proportion of screening-detected lung 
cancers that are overdiagnosed) is yet to be determined.
Analysis of the first two intervals showed that a 2-year interval between the second and third 
screening rounds did not lead to significantly more advanced stage lung cancers compared 
with a 1-year interval between the first and second rounds (p=0.09) 11. However, the fourth 
round led to a stage shift in screening-detected cancers that was significantly less favourable 
than after a 1-year screening interval (eg, more stage IIIb/IV cancers) 3, 20. It also led to 
significantly higher proportions of SQM, BAC and SCLC (p<0.001). A higher proportion of 
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SQM and SCLC could be a result of more current smokers and a higher age at the moment 
of screening in round 4. However, the absolute numbers of these detected cancers were 
small. Compared with a 2-year screening interval, there was a similar tendency towards 
unfavourable change in stage distribution for a 2.5-year screening interval although this did 
not reach statistical significance. Also, the interval cancer rate was 1.47 (28/19) times higher 
in the 2.5-year interval compared with the 2-year interval. Moreover, in the last 6 months 
before the final fourth screening round the interval rate was 1.3 (16/12) times higher than in 
the first 24 months after the third round, suggesting that a 2.5-year interval may be too long. 
On average, 69.4% of the screening-detected lung cancers across the four screening rounds 
in the NELSON trial were diagnosed in stage I and 9.8% in stage IIIb/IV 11. This cumulative 
stage distribution of the screening-detected lung cancers in the NELSON trial appears to be 
favourable compared with those of the DLCST and the NLST (68.1% and 61.6% of cancers at 
stage I, and 15.9% and 20.0% at stage IIIb/IV, respectively) 3, 20. However, this finding should 
be interpreted with caution because (1) the NLST used the 6th edition of the TNM (tumour, 
node, metastases) staging system, while the NELSON trial used the 7th edition, (2) the NLST 
and DLCST applied different eligibility criteria than the NELSON trial and (3) the proportion 
of overdiagnosed lung cancers in the screening group is yet unknown. The lung cancers found 
in the NELSON control group have yet to be investigated.
The strengths of this study include its population-based randomized setting, with a large 
number of participants in the screening and control groups. Second, by incorporating an 
indeterminate test outcome in the nodule management protocol instead of only two possible 
outcomes (eg, negative or positive), it seems possible to arrive at a better distinction between 
participants who might and who might not benefit from a diagnostic workup, leading to 
fewer FP results (ie, a better harm-benefit ratio). The limitations of this actual substudy were 
the relatively small absolute number of screening-detected lung cancers in the fourth round 
and the small absolute numbers of interval cancers between the third and fourth rounds. 
Furthermore, data on interval cancers after the fourth round were not yet available, and 
therefore no analyses of screening sensitivity of the final round could be performed. 
In conclusion, a 2.5-year screening interval after the third round likely reduces the effectiveness 
of screening: in the final round significantly more advanced disease stage lung cancers were 
detected compared with a 1-year screening interval and compared with a 2-year screening 
interval a similar unfavourable change in stage distribution was seen, however not statistically 
significant. The proportion of interval cancers in the 2.5-year interval was substantially higher 
compared with a 1-year and a 2-year screening intervals. Modelling will give more insight 
into the potential effect of the different screening intervals in the NELSON trial.
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SUPPLEMENTARY MATERIALS
Table 1: localisations and proportion female participants of screen-detected lung cancers in round 2, 
round 3 and round 4 
Round 2 p-value1 Round 3 p-value2 Round 4
n % 0.91 n % 0.66 n %
Localisation
 Right lobes 37 63.8 48 62.3 31 67.4
 Left lobes 21 34.5 29 37.7 15 32.6
 Total 58 100 77 100 46 100
Females 10 17.2 10 13.0 7 15.2
 1p-value: comparison between localization of screen-detected lung cancers of round 2 vs. round 4
 2p-value: comparison between localization of screen-detected lung cancers of round 3 vs. round 4
Table 2: stage distributions of interval cancers detected in the 2.5 years interval between the third and 
fourth screening round 
Interval cancers Detected in the first 24 months Detected in the last six months p-value 
Stage n (%) n (%) 0.77
Ia 2 (16.7) 1  (6.2)
Ib - 1  (6.2)
IIa - 1  (6.2)
IIb 2 (16.7) 1  (6.2)
IIIa - 2 (12.5)
IIIb 1 98.3) 3 (18.8)
IV 7 (58.3) 7 (43.8)
Total 12 (100) 16 (100)
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Table 3: histology of interval cancers detected in the 2.5 years interval between the third and fourth 
screening round 
Interval cancers Detected in the first 24 months Detected in the last six months p-value 
n (%) n (%) 0.32
Histology
Adenocarcinoma 4 (33.3) 5 (31.2)
Squamous-cell 
carcinoma
1 (8.3) 4 (25.0)
Large cell 
carcinoma
2 (16.7) 1 (6.2)
SCLC - 3 (18.8)
Others 2 (16.7) -
No diagnosis 
possible 
1 (8.3) 2 (12.5)
NSCLC, not 
specified
1 (8.3) 1 (6.2)
Large cell neuro-
endocrine tumor
1 (8.3) - 
Total 12 (100) 16 (100)
Table 4: proportion of female participants and current smokers in the participants with interval cancers 
detected in the 2.5 years interval between the third and fourth screening round 
First 24 months Last 6 months p-value
Female, n (%) 3 (25.0%) 1 (6.2%) 0.29
Current smokers, 
n (%)
10 (83.3%) 2 (16.7%) 0.22
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ABSTRACT
Background 
Debate about the optimal lung cancer screening strategy is ongoing. In this study, previous 
screening history of the Dutch-Belgian Lung Cancer Screening trial (NELSON) is investigated 
on if it predicts the screening outcome (test result and lung cancer risk) of the final screening 
round.
Methods 
15,792 participants were randomised (1:1) of which 7,900 randomised into a screening group. 
CT screening took place at baseline, and after 1, 2 and 2.5 years. Initially, three screening 
outcomes were possible: negative, indeterminate or positive scan result. Probability for 
screening outcome in the fourth round was calculated for subgroups of participants.
Results 
Based on results of the first three rounds, three subgroups were identified: (1) those with 
exclusively negative results (n=3,856; 73.0%); (2) those with ≥1 indeterminate result, but 
never a positive result (n=1,342; 25.5%); and (3) with ≥1 positive result (n=81; 1.5%). Group 
1 had the highest probability for having a negative scan result in round 4 (97.2% vs 94.8% 
and 90.1%, respectively, p<0.001), and the lowest risk for detecting lung cancer in round 4 
(0.6% vs 1.6%, p=0.001). ‘Smoked pack-years’ and ‘screening history’ significantly predicted 
the fourth round test result. The third round results implied that the risk for detecting lung 
cancer (after an interval of 2.5 years) was 0.6% for those with negative results compared with 
3.7% of those with indeterminate results.
Conclusions 
Previous CT lung cancer screening results provides an opportunity for further risk 
stratifications of those who undergo lung cancer screening. 
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3.1. INTRODUCTION
Lung cancer is the leading cause of cancer-related death worldwide 1. Lung cancer is often 
diagnosed at an advanced disease stage and occurs increasingly among former smokers 2. 
This underlines the need for preventive measures. Since 2013, lung cancer screening has been 
recommended by the United States Preventive Services Task Force 3, 4. People aged 55 through 
80, who have smoked at least 30 pack-years, and currently smoke or have quit smoking within 
the past 15 years are invited for an annual low-dose CT (LDCT) examination in the USA. 
However, debate about the optimal screening strategy (eg, the optimal screening interval) is 
still ongoing 5-9.
Currently, lung cancer screening is not implemented in Europe. The main reason is that 
none of the (underpowered) European lung cancer screening trials have shown a mortality 
reduction so far 10-13. However, Europe’s largest trial the Dutch-Belgian lung cancer screening 
trial (NELSON) is now in its final follow-up phase and is sufficiently powered to detect a 
lung cancer mortality reduction of at least 25% 14-16. Main differences between NELSON and 
the National Lung Screening Trial (NLST) are as follows: (1) the age of the selected subjects 
(50–74 vs 55–74 years), (2) the use of increasing screening intervals versus annual screening, 
(3) volumetric-based nodule management versus a diameter-based nodule management and 
(4) a control group with no screening versus a control group screened with annual chest 
radiography. The differences in screening interval enable to investigate the optimal screening 
strategy for lung cancer screening to reduce the probability on potential harms (eg, false-
positive examinations leading to unnecessary (non)-invasive diagnostic procedures) for those 
without lung cancer 4, 17, 18 The NLST showed that lung cancer risk and mortality benefit vary 
within the screened population: the largest mortality benefit was achieved in the subgroup 
with the highest risk for developing lung cancer 4. The ratio between benefits and harms of 
lung cancer screening could be improved by more precisely identifying a high-risk population 
for developing lung cancer 19-21 and by risk stratification of subjects based on the individual’s 
screening history (eg, previous screening outcome or presence of a nodule) 6 22-24. Recently, the 
NLST showed that participants with a negative screening result at baseline have a lower lung 
cancer detection risk at subsequent screening rounds compared with all screened participants 
and therefore may not need annual lung cancer screening 7. In line with this, the baseline 
scan in the NELSON trial allowed the identification of three subgroups with different risks 
for detecting lung cancer in the second and third screening rounds 23. Since all NELSON 
screening rounds with different screening intervals (with a unique 2.5-year interval) have 
been completed, this study aims to investigate whether NELSON subgroups with different 
risks for detecting lung cancer can be identified based on their previous screening history. 
This information might be useful for further risk stratification of subjects who undergo lung 
cancer screening. 
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3.2. METHODS
NELSON trial
In brief, the NELSON trial is a randomised-controlled, population-based lung cancer 
screening trial. The primary aim is to the investigate whether LDCT screening of high-risk 
subjects for developing lung cancer can lead to a reduction of lung cancer mortality by ≥25% 
compared with no screening at 10 years of follow-up 15. High-risk subjects, mainly males, 
were defined as aged between 50 and 74 years, who had smoked at least 15 cigarettes/day for 
≥25 years or 10 cigarettes/day for ≥30 years, and were still smoking or had quit <10 years ago 
14.
Initially, 15,822 participants were randomised (1:1). However, through linkages with the 
national cancer registries and death registries of the Netherlands and Belgium (Statistics 
Netherlands and the Flemish Agency for Care and Health, respectively), it appeared 
that 30 participants (15 screening group and 15 control group participants) died before 
randomisation and should therefore be ruled out from further analysis. After this correction, 
15,792 participants were randomised (1:1) into a CT screening group (7,900) and into a 
control group (n=7,892). Screening took place at baseline, after 1 year, 3 years and 5.5 years. 
The control group received usual care (no screening). The baseline screening round was 
conducted from January 2004 through December 2006, and the final screening round was 
conducted from November 2009 through March 2012.
Study participants
For the risk stratifications based on the regular scan results of the first three screening rounds, 
only participants who attended both one of the first three regular screening rounds and 
round 4 were included (n=5,279). For the risk stratification based on the results of the third 
screening round alone, participants who attended both the third and fourth rounds were 
included (n=5,268). To compare participants with and without a screening-detected lung 
cancer across all the screening rounds, all screened participants were included (n=7,582). 
Screening procedures, outcomes and the nodule management protocol
Screening was performed using 16-detector CT scanners in low-dose setting at four screening 
sites (University Medical Center Groningen, University Medical Center Utrecht, Kennemer 
Gasthuis Haarlem in the Netherlands and University Hospital Gasthuisberg Leuven in 
Belgium) 25. More detailed descriptions of the equipment, the execution of the screening 
examination and the nodule management protocol have been published previously 15, 23, 25-27. 
In short, screening could lead to the following test results: (1) negative: no nodule, newly 
detected nodule with a volume of <50 mm3 or previously detected nodule with a growth 
(change in volume between scans) of <25% or ≥25% but with a volume doubling time (VDT) 
of >600 days; (2) indeterminate: newly detected nodule with a volume of 50–500 mm3 or 
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previously detected nodule with a VDT of 400–600 days; or (3) positive: newly detected 
nodule with a volume of >500 mm3 or previously detected nodule with a VDT of <400 days 15. 
Participants with a negative screening result were invited for the next regular screening round. 
Those with an indeterminate screening result underwent a low-dose follow-up CT scan to 
measure volume growth and VDT after 6 weeks to 4 months or after 12 months (depending 
on nodule volume and screening rounds), to define their definitive screening result (negative 
or positive). Those with a positive screening result were referred to a pulmonologist for a 
diagnostic work-up. If no lung cancer was diagnosed, the participant was referred to the 
next regular screening round. If lung cancer was confirmed, the patient received treatment 
according to the Dutch National guidelines. Medical data of these patients were collected 
prospectively. 
Definitions
Current smokers were those who were smoking or who had smoked in the last 7 days before 
completion of the baseline (risk) questionnaires. Former smokers have quit smoking for 10 
years or less. Variables that were calculated were pack-years (20 cigarettes smoked per day for 
1 year) and body mass index (BMI) (body weight (in kilograms)/the square of body length (in 
meters)). New nodules were nodules which were labelled as ‘new nodule’ or labelled as ‘not 
new, but too small in previous scan to be detectable’ by radiologists 24.
Regular round scans were the first CT examinations in a regular screening round (years 1, 2, 4 
and 6.5). Follow-up scans were repeat LDCT scans after an  Indeterminate result in one of the 
four regular rounds. A screening-detected lung cancer was defined as a lung cancer diagnosed 
by a pulmonologist within 12–24 months, depending on the screening round, after referral 
for a positive screening. Lung cancer detection rate was defined as the number of screening-
detected lung cancers divided by the number of screened participants. Regular scan result 
was defined as the result of the first CT examination in a screening round, while the definitive 
outcome of the screening (screening result) was made after inclusion of the results of the 
follow-up scans at the conclusion of that screening round.
Risk groups
Three unique subgroups were identified based on regular scan results of the first three 
screening rounds: (1) participants with solely negative results (n=3,856; 73%); (2) participants 
with ≥1 indeterminate result and never a positive result (n=1,342, 25.5%); and (3) participants 
with ≥1 positive result (n=81, 1.5%; online supplementary table S1). 
Based on the regular scan results of round 3, three other unique subgroups were identified: 
(1) those with a negative result in round 3 (n=4,925, 93.5%); (2) those with an indeterminate 
result in round 3 (n=324, 6.2%); and (3) those with a positive result in round 3 (n=19, 0.4%).
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Statistical analyses
None of the continuous variables were distributed normally, tested by using the Kolmogorov-
Smirnov test and examining Q–Q plots. Therefore, the variables were described by using 
medians and IQRs. Differences between the continuous variables across the subgroups 
were calculated by using the median test or analysis of variance, depending on number 
of subgroups. Differences between nominal variables were calculated by using a χ2 test. 
Differences between categorical variables were tested by using a Mann-Whitney U test or 
Kruskal-Wallis test, depending on the number of subgroups. To test differences between 
the subgroups regarding the probability of having a negative or nonnegative (indeterminate 
or positive test result) in the fourth round, and to test differences between the subgroups 
regarding the risk for detecting lung cancer in the fourth round, a logistics regression analysis 
was used. The associations of gender, pack-years smoked, age at randomisation, Smoking 
status at randomization and age of starting smoking with the screening outcome of the fourth 
round were assessed through univariate and multivariate analyses. For multivariate analyses, 
an ordinal logistic regression model was developed using backward selection. In addition, 
variables were also tested for interactions. For all analyses, a p value <0.05 was considered 
significant, and IBM SPSS Statistics V.21 was used. 
3.3. RESULTS
In the first three rounds, 7,557, 7,295 and 6,922 participants were screened, respectively 23. In 
round 4, 5,279 participants were screened and 5,380 scans were performed; of which 5,279 
were regular scans and 101 follow-up scans 16. In this section, the probabilities of screening 
outcomes and risk for detecting lung cancer in round 4 were calculated based on the regular 
scan results alone. An overview of these probabilities based on the definitive screening results 
of round 4 is presented in the online data supplement (see Table S1).
Risk stratification based on the results of the first three screening rounds
Based on the regular scan results of the first three rounds, three subgroups were identified: 
(1) participants with only negative results; (2) participants with ≥1 indeterminate, but never 
a positive result; and (3) participants with ≥1 positive result (Table 1). Those from group 1 
were slightly younger (57.0 vs 58.0 years, p<0.001) compared with the participants of the 
other subgroups. Participants with ≥1 positive result had smoked statistically significant 
slightly more pack-years than the other subgroups (p=0.02). No significant differences were 
observed between gender and baseline smoking status among the subgroups (p=0.66 and 
p=0.23, respectively).
Participants with ≥1 indeterminate result, but never a positive result (OR 1.89, p=0.001), and 
participants with ≥1 positive result (3.77, p<0.001; Table 2) had a significantly higher OR of 
receiving a non-negative scan result (e.g., an indeterminate or a positive result) in round 4 
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compared with the group with solely negative results in the first three rounds (the reference 
group).
In univariate analysis, only the screening history (p<0.001) and smoked pack-years (p=0.01) 
significantly predicted the regular scan result in round 4, while gender (p=0.70), age (p=0.13) 
and baseline smoking status (p=0.75) did not. In multivariate analysis, screening history 
and smoked pack-years remained significant predictors (p<0.001 and p=0.02, respectively): 
the model suggests that screening history and pack-years are positively associated with the 
screening outcome in the fourth round (see online supplementary Table S4). Interaction 
between subgroups and smoked pack-years was not significant (p=0.89).
In round 4, 43 participants were diagnosed with 46 screening-detected lung cancers. OR for 
detecting lung cancer in round 4 differed between the subgroups as well: relative to the group 
with only negative results, the group with ≥1 indeterminate result (but never a positive result) 
had an OR of 2.77 (p<0.001) for detecting lung cancer in round 4 (Table 3). No lung cancer 
was detected in the group with ≥1 positive result. None of the following factors predicted 
significantly the detection of lung cancer in round 4: gender (p=0.71), age (p=0.10), starting 
age of smoking (p=0.20), smoking status (0.28) or pack-years smoked (0.09; all data not 
shown). Multivariate analysis showed no statistically significance for age and pack-years 
smoked.
A total of 22 (51.2%) of the participants with screen-detected lung cancer in round 4 had 
solely negative scan results in the first three screening rounds, and in 20 (90.9%) of those 
participants lung cancer was detected in a new nodule (data not shown). The remaining 21 
(48.8%) screen-detected lung cancers in round 4 were detected among participants with at 
least one indeterminate scan result in the previous three screening rounds, and in 12 (57.1%) 
of those participants lung cancer was detected in a new nodule (data not shown).
Participants with only negative regular scan results were stratified by pack-years smoked. 
Therefore, six categories were made: <25, 26–30, 31–35, 36–40, 41–45 and >45 years. For 
each category, the risk for lung cancer detection in the fourth round was calculated. The first 
five categories had a lung cancer risk between 0.2% (the first category) and 0.7% (the fifth 
category). In other words, the risk for detecting lung cancer in the fourth round for those who 
smoked less than 45 pack-years was lower than 0.7%. For those who smoked more than 45 
pack-years (n=1091), lung cancer detection rate in round 4 was 1.1% (p=0.04). No correlation 
was observed between pack-years smoked and lung cancer detection rate in the final round 
(all data not shown) for the other subgroups.
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Risk stratifications based on the previous screening round
Round 4 was performed 2.5 years after the third screening round and 5.5 years after the 
baseline scan. Participants with a negative scan result in round 3 were  significantly younger 
at baseline than those with an indeterminate or a positive third round result (57.0 years vs 
59.0 and 59.0 years, p<0.001; Table 4). The probability for detecting lung cancer in the fourth 
round differed between participants with a negative scan result and an indeterminate scan 
result: 0.6% vs 3.7%, respectively (p<0.001; Tables 5 and 6). No lung cancer was detected in 
round 4 in the small group with a positive scan result in round 3. 
Participants with a screen-detected lung cancer
Across all four screening rounds, 243 out of 7,582 participants were diagnosed with a total of 
255 screening-detected lung cancers. Participants with a screening-detected lung cancer were 
significantly older (61 vs 58 years, p<0.001) and had smoked more pack-years (44.0 vs 38.0 
years, p<0.001) than those without a screening-detected lung cancer. Of those with screen-
detected lung cancers, 28.4% had ≥1 indeterminate scan result (but never a positive test result 
initially) and 71.6% had ≥1 positive scan result (this group also contains those with once a 
negative or an indeterminate result) before diagnoses of lung cancer. No differences were seen 
in gender (p=0.98), baseline smoking status (p=0.61) or in BMI between participants with or 
without screening-detected lung cancer (p=0.38; all data not shown).
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3.4. DISCUSSION
This study demonstrated that individual’s screenings history can be used as a risk stratification 
tool for their further screening regime. The probability for screening outcome in the fourth 
round differs across previous screening test result(s). Also, the risk for detecting lung cancer 
in the fourth screening round differs based on the previous screening outcome(s).
Previous NELSON results showed that the risk for detecting lung cancer in the subsequent 
second and third rounds differed among the baseline scan result 23. Those with an indeterminate 
or a positive baseline scan result had a higher risk for detecting lung cancer in round 2 or 3, 
compared with those with a negative baseline scan result. In this study, the results indicated 
that the probability for non-negative (ie, indeterminate or positive) scan result in the fourth 
round was higher for those with ≥1 indeterminate (but never a positive result) and those with 
≥1 positive result in the first three rounds, compared with those with only negative results in 
the first three rounds. Furthermore, it was demonstrated that having an older age and have 
smoked more pack-years smoked were both significant predictors for non-negative result. 
These results were in line with our previous study results 23. None of the lung cancers detected 
in round 4 was detected in the group with previously ≥1 positive scan result. Moreover, the 
risk for detecting lung cancer in the final fourth round was non-significantly higher for those 
with an indeterminate or a positive definitive screening result compared with solely negative 
screening results (OR of 2.95 and 2.10, respectively). 
The combined results of the previous screening rounds turned out to predict the screening 
outcome (scan results or lung cancer detection risk) in the fourth screening round. The third 
round test result predicted the fourth round test result after an interval of 2.5 years; for those 
with a negative third scan, a subsequent round with a 2.5 years interval seemed even short, 
as the lung cancer risk was <1% (as across all screening rounds) 16 23. Moreover, those with 
previous solely negative scan results and those with a third negative scan result may not need 
to be screened for more than 2.5 years, as the lung cancer detection rates were <0.7% or 
1.1% at most for the fourth round, respectively. However, in almost 90%of those with solely 
negative scan results, the lung cancer was detected in a new nodule. Although malignant new 
nodules might be fast growing, detection at early stage with LDCT seems possible 24. 
Furthermore, it was showed that having an indeterminate scan result gives a higher risk for 
a non-negative scan result and a higher risk for lung cancer detection in the final round. 
However, only a minority of the indeterminate nodules turn out to be malignant. With the 
growing evidence, cut-off points of the nodule management should be evaluated regularly to 
further optimise the ratio between benefits (eg, mortality reduction) and harms (e.g., false 
positive, unnecessary work-up) of the protocol. Moreover, cancer can evolve from nodules 
which are not seen before on the scan (e.g., from new nodules). One explanation could be 
‘field cancerisation’, in which it is assumed that large areas of the bronchial epithelium are 
affected by smoking, leading to areas with metaplasia and dysplasia which sometimes turn out 
to be cancer and sometimes not. Moreover, it is known that in heavy smokers nodules appear 
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and disappear and come up in different pulmonary areas and are not always malignant. 
Although only the NELSON trial used increasing screening intervals, the NLST showed in 
a recent retrospective analysis that participants with a negative baseline result had a lower 
incidence of lung cancer at baseline as well as a lower lung cancer detection rate in the 
subsequent rounds (0.34%) compared with all screened participants (1.0%).7 Furthermore, 
the lung cancer incidence and mortality for those with solely negative screening results was 
even lower than for those with a negative baseline screening. Their findings suggested that for 
the larger part of the screened population, it may lead to a better harm–benefit ratio to offer 
risk-based incidental screening rounds to participants with different screening intervals. In 
the NELSON trial, end results and cost-effectiveness analyses, and therefore the harm–benefit 
ratios of screening scenarios, are yet unknown. However, the current study concludes that 
previous screening history seems to be useful for risk stratification and to refine the screening 
protocol for subgroups with different risks for lung cancer 23, 24, 28. 
Major strengths of this study are the large-scale, population-based randomised study design 
and its volumetric-based nodule management, leading to three initial screening outcomes. 
However, in this substudy, small numbers of screening-detected lung cancers were found in 
the fourth round and some subgroups had small numbers of participants. Furthermore, a 
subselection of screened participants was used: participants should have been screened in one 
of the three screening rounds as well as in the final screening round. Additionally, almost 1500 
participants were lost to follow-up (no actual addresses) in the fourth round, since additional 
informed consent was required to perform the screening round 16.
In conclusion, the screening test result(s) might have major implications on the total number 
of scans needed for those who undergo lung cancer screening. This is useful for the further 
optimisation of the harm–benefit ratio of a lung cancer screening programme. 
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SUPPLEMENTARY MATERIALS
Table 1: possible combinations of regular scan results across the first three rounds 
Possible 
combinations 
Round 
1
Round 
2
Round 
3 
N Subgroup
N N N 3,826 ALL NEGATIVE
X N N 15 ALL NEGATIVE
N X N 6 ALL NEGATIVE
N N X 9 ALL NEGATIVE
Total per subgroup 3,856
I I I 17 ≥1X INDETERMINATE, NEVER 
POSITIVE
I I N 64 ≥1X INDETERMINATE, NEVER 
POSITIVE
I N I 78 ≥1X INDETERMINATE, NEVER 
POSITIVE
I N N 773 ≥1X INDETERMINATE, NEVER 
POSITIVE
N I N 180 ≥1X INDETERMINATE, NEVER 
POSITIVE
N N I 197 ≥1X INDETERMINATE, NEVER 
POSITIVE
N I I 22 ≥1X INDETERMINATE, NEVER 
POSITIVE
X I N 4 ≥1X INDETERMINATE, NEVER 
POSITIVE
X I X 1 ≥1X INDETERMINATE, NEVER 
POSITIVE
I X N 5 ≥1X INDETERMINATE, NEVER 
POSITIVE
I N x 1 ≥1X INDETERMINATE, NEVER 
POSITIVE
Total per subgroup 1,342
N I P 1 ≥1X POSITIVE
N P I 1 ≥1X POSITIVE
N P N 13 ≥1X POSITIVE
N N P 6 ≥1X POSITIVE
N X P 1 ≥1X POSITIVE
I P N 11 ≥1X POSITIVE
I N P 9 ≥1X POSITIVE
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Possible 
combinations 
Round 
1
Round 
2
Round 
3 
N Subgroup
I I P 2 ≥1X POSITIVE
I P I 5 ≥1X POSITIVE
P N N 24 ≥1X POSITIVE
P I N 4 ≥1X POSITIVE
P I I 2 ≥1X POSITIVE
P N I 1 ≥1X POSITIVE
P X I 1 ≥1X POSITIVE
Total per subgroup 81
TOTAL 5,279
X: In case a participant did not receive screening in a screening round 
N = negative screening result 
I = indeterminate screening result
P = positive screening result 
Table 1: continued. Possible combinations of regular scan results across the first three rounds
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ABSTRACT
 
Background
Debate about implementing lung cancer screening in Europe is ongoing. In this study, the 
cancer stage and treatment shift in the largest European trial, the Dutch-Belgian Lung Cancer 
Screening Trial (NELSON), were investigated. Furthermore, the generalizability of the trial 
was assessed. 
Method
15,792 participants were evenly randomized into a screen group (7,900) with screening 
offered at year 1, 2, 4 and 6.5, and into a control group (7,892) that received no screening. 
The histopathological and treatment characteristics of the first 100 lung cancers diagnosed in 
each study group were compared. Next, the epidemiological, histopathological and treatment 
characteristics of the male NELSON control group lung cancers (n=86) were compared with 
the lung cancers diagnosed in the comparable Dutch birth cohort (1928 to 1953, n= 20,884). 
Results
Screen group lung cancers were significantly more often diagnosed in stage I (59.0% vs. 19.0%) 
and less in stage IV (6.0% vs. 48.0%) compared to the control group (p<0.001). Relative to 
no screening, in the screen group more adenocarcinomas (45.0% vs. 27.0%; p<0.001) were 
observed. Surgical treatment was given more often to the screen group, regardless of the stage, 
compared to the control group (67.7% vs. 24.5%, p<0.001). Lung cancers in the NELSON male 
control group were diagnosed at a slightly earlier stage compared to Dutch male comparable 
birth cohort lung cancer patients (stage I or stage II, 29.1% vs. 32.5%;  p<0.001). 
Conclusions
CT screening in the NELSON trial has led to a substantial shift in cancer stage at time of 
diagnosis and it has led to more treatment to be curative (mainly through surgery). As the 
actual difference in stage between the NELSON control group and the Dutch comparable 
birth cohort is small, it is expected that the NELSON results will be generalizable for the target 
population.
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4.1. INTRODUCTION
Lung cancer is a major public health problem world-wide 1, 2. Despite advances in therapy, the 
five-year survival for clinically detected lung cancer is still at 16-18%1. Smoking is the most 
important risk factor for lung cancer and smoking cessation is considered to be the most 
effective strategy to reduce the risk of lung cancer 3. However, the prevalence of smoking is still 
high, and even increasing world-wide 4. Moreover, currently half of the lung cancers are being 
diagnosed in former smokers 5, 6. This highlights the need for other additional prevention 
methods. The National Lung Screening Trial (NLST) presented with the historical results 
that Computed Tomography (CT) screening and subsequent treatment for lung cancer in 
high-risk subjects can reduce lung cancer mortality with 20% 7. Based upon these results, the 
United States Preventive Screening Task Force (USPSTF) requested an independent review 
and a modelling study to investigate the long-term harms and benefits of different screening 
policies. At this moment, the USPTFS recommends annual screening for lung cancer with CT 
in persons aged 55 through 80 years, with a smoking history of 30 pack-years and currently 
smoke or have quit within the 15 past years 8, 9. Although CT screening for lung cancer has been 
implemented in the United States, the debate about implementing it in Europe is ongoing 10. 
In Europe, thus far none of the lung cancer screening trials have shown mortality reduction 11-
13. However, none of these trials were sufficiently powered (in terms of sample size) to identify 
a significant mortality benefit. The largest European trial, the Dutch-Belgian Lung Cancer 
Screening Trial (NELSON) has sufficient power to investigate whether CT screening leads to 
a lung cancer mortality reduction of at least 25% after ten years of follow-up compared to no 
screening 14.  The NELSON trial is currently in the stage prior to the mortality analysis 15, 16. 
A possible mortality benefit will depend on factors such as whether more early stage and less 
advanced stage lung cancers are diagnosed  in the screen arm (the so called cancer stage shift), 
and whether the early detection enhanced the chances of curative treatment  from disease. In 
the NELSON trial, 69.4% of the screening-detected lung cancers are detected in stage I and 
9.8% in stage IIIb/IV 14, 17, 18. This stage distribution appears to be favorable compared with 
that of the National Lung Screening Trial (61.6% and 20.0%, respectively) 7, 19. However, to 
detect a ‘true cancer stage shift’, a comparison of all the screen group lung cancers regarding 
the cancer stage should be made with those lung cancers observed in the control group that 
did not receive any form of screening. 
The aims of this study are (1) to investigate the characteristics (histopathological and 
treatment) of the lung cancers diagnosed in the control group, (2) to compare them with 
those lung cancers detected in the screen group, and (3) to assess the generalizability of the 
results of the NELSON trial by comparing the lung cancers diagnosed in the control group 
with the lung cancers diagnosed in the Dutch population. 
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4.2. METHODS 
NELSON study
In brief, the NELSON is a population-based, randomized-controlled lung cancer screening 
trial 15. Recruitment took place between September 2003 and the second half of 2006, in 
which addresses of subjects aged between 50 and 74 years were obtained from the population 
registries of seven districts in the Netherlands and 14 municipalities in Belgium 16. Eligible 
where those aged between 50 and 74 years, who had smoked more than 15 cigarettes per day 
for more than 25 years or more than 10 cigarettes per day for more than 30 years, and were 
still smoking or quit smoking less than or equal to 10 years ago. Respondents who met the 
criteria for eligibility received an invitation to participate and an informed consent form. A 
total of 15,792 persons were randomized (1:1) in a screening group (n=7,900) and in a control 
group (n=7,892) 20. Screening took place at year one, two, four and six and a half. The control 
group received usual care (no screening). 
Nodule management strategy
In short, the screening protocol was based on the assessment of volume, nodule growth 
(defined as change in volume of ≥25%) and volume doubling time (VDT) of the nodules 15, 21, 
22. Results were defined as: 1) negative (new nodule <50mm3 or a previous detected nodule 
with growth <25% and VDT >600 days); 2) indeterminate (new nodules 50-500mm3 or 
previously detected nodule with growth ≥25% and VDT of 400-600 days); and 3) positive 
(new nodules >500mm3 or previously detected nodule with growth ≥25% and VDT <400 
days). Those with a negative screening result were screened at the next screening round. 
Those with an indeterminate result were referred for a short-term follow-up scan (depending 
on the protocol between 6 weeks and 3 months) until the screening outcome was negative or 
positive. Those with a positive result were referred to a pulmonologist for a diagnostic work-
up and treatment according to the Dutch National guidelines. If their diagnostic work-up was 
truly positive, the medical data was collected prospectively. If there was no lung cancer, the 
participants were referred to the next regular screening round. 
Study participants
For this sub study, from both study groups the first 100 lung cancer diagnoses were selected 14, 
18. In case of the screen group as well as Dutch as Belgian lung cancer patients were included. 
In case of the control group, only Dutch lung cancer patients were included as no information 
at time of analyses from the Belgian control group was available. The histopathological and 
treatment data of these participants were retrieved from their medical files. 
For the comparison between the lung cancers diagnosed in the Dutch NELSON control 
group and lung cancers diagnosed in the Dutch population, a selection of the Dutch Cancer 
Society (NKR) was made of subjects belonging to the same birth cohort as the NELSON 
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trial (1928 to 1953) and with a lung cancer diagnosis between 2005 and 2008 (comparable 
to the time frame of the NELSON trial). The NKR provided data about the epidemiological 
characteristics (year of birth, year of diagnosis, age at diagnosis, time between diagnosis and 
first treatment (in years), time between the first treatment and sub sequent treatments until 
treatment number eight (in years), vital status at 1st January 2014, year of death and follow-
up time (in days)), histopathological characteristics (base for the diagnosis, localization, 
morphology, differentiation grade, clinical and pathological TNM, first three locations of the 
metastasis, numbers of investigated lymph nodes, numbers of positive lymph nodes, whether 
mediastinoscopy was performed and the outcome) and treatment characteristics (which 
treatment was given (the first eight treatments), and the complications after lung cancer 
surgery) of the lung cancers diagnosed in the general population as well as in the NELSON 
trial. 
In all cases, the histological features of the lung cancers were coded according to the 
International Classifications of Diseases, 10th edition (ICD-10). In the NELSON trial the 
disease stage was determined by using the seventh edition of the TNM staging. 
Definitions 
Current smokers were those who had smoked in the last seven days before completing the 
general health questionnaire and those who were still smoking. Former smokers were those 
who have quit smoking for 10 years or less. Pack-years were defined as 20 cigarettes smoked 
per day for 1 year. Lung cancers diagnosed by a pulmonologist within 12 to 24 months 
(depending on the screening round) after a positive screening were defined as screen-
detected lung cancers. Interval cancers were lung cancers diagnosed in the screen group after 
a negative screening and before the next screening round. 
Statistical analysis
Continuous variables were tested for normality by using the Kolmogorov-Smirnov test and 
examining the Q-Q plots. In case the tested variables were distributed normally, the mean and 
95% confidence interval (CI) was used to describe the variables. In case the tested continues 
variables were distributed non-normally, they were described by using medians and Inter 
Quartile Ranges (IQRs). Differences between the continuous variables were tested by using 
a Mann-Whitney U test or by analysis of variance. Differences between the categorical 
variables were tested by using a Mann-Whitney U test or Kruskal-Wallis test. For nominal 
variables, a χ2-test or the Fisher’s exact test were used. The associations of gender, age at 
randomization, pack-years smoked and smoking status at randomization with the stage of 
disease and histology of the lung cancers were assessed through univariate analyses for which 
logistic regression was used. For all analysis, a p-value of <0.05 was considered as statistically 
significant, and IBM SPSS Statistics V.21 was used for all analyses.
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4.3. RESULTS
Comparison of the lung cancers diagnosed in the screen group and control group 
The lung cancers in the screen group were on average diagnosed a year earlier than the lung 
cancers diagnosed in the control group (2005 vs. 2006, p<0.001; Table 1). No differences 
were observed in age at diagnosis, proportion of males, proportion of current smokers at 
randomization or smoked pack-years at time of randomization between the two study groups 
with lung cancer. 
Table 1: baseline characteristics of the first 100 control group and screen group participants with lung 
cancer
Control group 
participants with lung 
cancer 
Screen group 
participants with lung 
cancer
P-value
n % n %
Total participants 98 - 96 - -
 Total lung cancer 100 - 100 - -
Males 84 84.0 80 80.0 0.69
Age at diagnosis (median, IQR) 64.5 10.2 65.7 10.7 0.89
Year diagnosis (median, IQR) 2006 1.0 2005 1.0 <0.001
Current smokers1 63 64.3 54 56.2 0.25
Smocked pack-years1 (median, IQR) 43.2 21.0 43.7 24.8 0.17
1at time of randomization 
Relative to control group lung cancers, significantly more lung cancers in the screen group 
were diagnosed at stage I (59.0% vs. 19.0%) and less in stage IV (6.0% vs. 48.0%; Table 2). 
Also, the proportion of stage III cancers differed substantially between the two study groups 
(14.0% vs. 23.0%, respectively for the screen and control group). A higher proportion of 
adenocarcinomas (45.0% vs. 27.0%) and bronchoalveolar carcinomas (BACs; 3.0% vs. 0.0%) 
were observed in the screen group compared to the control group, respectively (p<0.001). 
In the control group, a significantly higher proportion of squamous cell carcinomas (SQMs; 
25.0% vs. 21.0%), large cell carcinomas (LCCs; 19.0% vs. 11.0%) and small cell carcinomas 
(SCLCs; 18.0% vs. 2.0%) was observed. All SCLCs in the control group were detected in stage 
4, while in the screen group 11.2% were detected in stage 2, 16.7% in stage 3 and 72.2% in 
stage 4. 
The number of smoked pack-years was the only significant predictor for adenocarcinoma in 
univariate analysis (p=0.03): those who smoked more pack-years had a higher chance for an 
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adenocarcinoma lung cancer diagnosis. In case of LCCs only the smoking status significantly 
predicted lung cancer diagnosis in univariate analysis (p<0.001); those who were current 
smokers at time of randomization had a higher risk for a LCC diagnosis, compared to the 
former smokers. In case of SQMs, current smokers had borderline significantly a higher risk 
for a SQM diagnosis than former smokers (p=0.05). In SCLCs and BACs none of the following 
variables predicted the outcome: gender (p=0.99 and p=0.39), current smokers (p=0.19 and 
p=0.85), age at diagnosis (p=0.68 and p=0.68) and smoked pack-years (p=0.45 and p=0.86), 
respectively.  
Table 2: tumor characteristics of the first 100 lung cancers in the control and screen group
Control group 
lung cancers
Screen group lung 
cancers
P-value
n % n %
Stage at diagnosis <0.001
 Ia 9 9.0 55 55.0
 Ib 10 10.0 5 5.0
 IIa 8 8.0 11 11.0
 IIb 2 2.0 - -
 IIIa 17 17.0 15 15.0
 IIIb 6 6.0 8 8.0
 IV 48 48.0 6 6.0
 Total 100 100.0 100 100.0
Histology <0.001
 Adenocarcinoma 27 27.0 45 45.0
 SQM 25 25.0 21 21.0
 BAC - - 3 3.0
 Large cell carcinoma 19 19.0 11 11.0
 SCLC 18 18.0 2 2.0
 No diagnosis possible 4 4.0 5 5.0
 NSCLC, not specified 3 3.0 2 2.0
 Others 41 4.0 112 11.0
 Total 100 100.0 100 100.0
Localization 0.1
Left 38 38.0 30 30.0
Right 59 59.0 69 69.0
Both sides 3 3.0 - -
Others - - 13 1.0
Total 100 100. 100 100.0
SQM: squamous cell carcinoma; BAC: bronchoalveolar carcinoma; SCLC: small cell carcinoma; NSCLC: 
non-small cell carcinoma
1Others were: 3 large-cell neuro-endocrine tumor and 1 small cell neuro-endocrine tumor; 2 others 
were: 3 adenosquamous, 3 carcinoid, 1 mixed SCLC/NSCLC, 3 large cell neuro-endocrine tumor, 1 
pleiomorph carcinoma; 3 1 screen-detected lung cancer was located in the carina 
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Stage I cancers stratified for each study group showed that the proportion of stage Ia cancers 
was the highest for the screen group (91.7% vs. 47.4%, p <0.001) compared to the control 
group. The histology was comparable between the two study groups with stage I cancers 
(p=0.13; Table 3). 
Screen group lung cancer patients received more often a (potentially curative) surgical 
treatment regardless of the stage (67.7% vs. 24.5%, p<0.001). Even if stratified for stage Ia, 
screen group participants more often received a (potentially curative) surgical treatment than 
control group participants (82.7% vs. 50.0%, p=0.06; data not shown). No difference was seen 
in age at diagnosis, smoking status and co-morbidity between the screen group and control 
group participants with stage Ia cancer. 
Comparison of the NELSON control group lung cancers versus the lung cancers diagnosed 
in the comparable Dutch birth cohort 
Between 2005 and 2008 in the same birth cohort 32,132 lung cancers were diagnosed. Of 
this group, 65.0% were males and 35.0% were females. Due to risk-based selection in the 
NELSON trial, the proportion of female participants was 14.0%. Therefore, further analyses 
were restricted to male lung cancer patients only. 
Lung cancer patients in the comparable Dutch male birth cohort were diagnosed with lung 
cancer approximately one year later than the NELSON control group lung cancer patients 
(2007.0 vs. 2006.0, p=0.06; Table 4). Compared to the same Dutch birth cohort with lung 
cancer, the lung cancers diagnosed in the control group were diagnosed in a slightly earlier 
stage (stage I or stage II, 29.1% vs. 32.5%, p<0.001; Table 5). Age at time of diagnosis was 
not a significant predictor for the stage of lung cancer at time of diagnosis (p=0.38, data not 
shown). 
No significant difference was observed in the first treatment given to a lung cancer patient 
between the general Dutch population and the NELSON control group (p=0.97); surgery was 
given in 23.2% vs. 22.5%, and chemotherapy in 50.2% vs. 53.5% respectively. 
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Table 3: histology and cancer stage distribution of stage Ia en Ib lung cancers, by study group of the 
NELSON trial  
Stage at 
diagnosis
Control group lung 
cancers
Screen-detected 
lung cancers
P-value1
n % n % <0.0013
Ia
 Adenocarcinoma 3 33.3 272 49.1 0.294
 SQM 3 33.3 10 18.2
 BAC - - 3 5.5
 Large cell 
 Carcinoma
- - 4 7.3
 SCLC - - - -
 No diagnosis 
 possible 
3 33.3 5 9.1
 NSCLC, not 
 Specified
- - - -
 Others - - 6 10.9
 Total 9 100.0 55 100.0
Ib 0.175
 Adenocarcinoma 4 40.0 3 60.0
 SQM 5 50.0 - -
 BAC - - - -
 Large cell 
 Carcinoma
1 10.0 1 20.0
 SCLC - - - -
 No diagnosis 
 possible 
- - - -
 NSCLC, not 
 Specified
- - - -
 Others - - 1 20.0
 Total 10 100.0 4 100.0
1×-test
2Screen group includes one interval cancer 
3Difference in cancer stage between the two study groups  
4Difference in histology between two study groups with stage Ia cancer
5Difference in histology between two study groups with stage Ib cancer
Cancer stage and treatment shift
107
IV
Table 4: baseline characteristics of the NELSON control group participants with lung cancer and of the 
comparable Dutch birth cohort with lung cancer (diagnosed between 2005 and 2008) 
NELSON control 
group lung cancers 
General Dutch 
population lung 
cancers 
p-value 
n % n %
Total participants 84 -   20,646 -
Total lung cancer 86 - 20,884 -
Age at diagnosis, (median, IQR) 65.4 11.4 68.0 11.0 0.26
Year diagnosis, (median, IQR) 2006 1.0 2007.0 2.0 0.06
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Table 5: tumor characteristics of the male lung cancers in the NELSON control group and male lung 
cancer patients from the Dutch comparable birth cohort
Control group 
lung cancers 
Dutch 
comparable 
birth cohort lung 
cancers
P-value
n % n %
Stage at diagnosis <0.001
 Ia 8 9.3 1,379 7.2
 Ib 9 10.5 1,805 9.4
 IIa 6 7.0 166 0.9
 IIb 2 2.3 964 5.0
 IIIa 14 16.3 2,254 11.8
 IIIb 5 5.8 3,513 18.4
 IV 42 48.8 9,043 47.3
 Total 86 100.0 19,1241 100.0
Histology 0.04
 Adenocarcinoma 24 27.9 4993 24.0
 SQM 22 25.6 5643 27.1
 BAC - - 340 1.6
 Large cell 
 carcinoma
14 16.3 3100 14.9
 SCLC 15 17.4 3031 14.5
 No diagnosis 
 possible 
4 4.7 1636 7.8
 NSCLC, not 
 specified
3 3.5 1705 8.2
 Others 4 4.7 396 1.9
 Total 86 100.0 20,844 100.0
1In 1,760 cases the stage at time of diagnosis was missing
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4.4. DISCUSSION
 
The study shows that screening has not only led to a stage shift in terms of early detection of 
lung cancer (stage I lung cancers increased by 41.0%), but also to less advanced staged (stage 
IV) lung cancers by 42.0%, compared to no screening. Furthermore, the proportion of stage 
Ia cancers are significantly the highest among the screen group lung cancers, compared to 
the control group lung cancers (91.7% vs. 8.3%). Comparison with the NLST shows, that 
the stage shift in the NELSON is substantially more favorable: more stage I cancers (60.0% 
vs. 50.0%), and less stage IV cancers (6.0% vs. 21.7%) were detected in the NELSON trial 7, 
14, 17-19. The NELSON trial used the 7th TNM staging system, whereas the NLST used the 6th 
TNM staging system, which might explain part of this difference 23. On the other hand, in the 
NELSON trial fewer females were randomized (due to study selection criteria), compared to 
the NLST (16.5% vs. 41.0%), while females are diagnosed with lung cancer at a lower stage 
24. Furthermore, the NELSON screening protocol consisted of increasing screening intervals 
between the four screening rounds (1, 2, and 2.5 years), whereas the NLST screening protocol 
consisted of three annual screening rounds 15, 25. However, the current NELSON analysis 
includes only the first 100 lung cancer’s diagnosis of each study group. Thereby, the second 
screening round was still running in the screen group. Altogether, this sub study showed that 
it seems that the NELSON screening strategy is at least as capable as the NLST to diagnose 
lung cancer at a more favorable stage compared to the current setting (no screening) in the 
Netherlands and Belgium. In general, compared to the European trials, the NELSON trial 
shows a more favorable stage shift 12, 13, 26. This may be explained by the substantially larger 
sample size and a different screening strategy. The DLCST used an adapted version of the 
NELSON screening strategy 11. Relative to the Danish Lung Cancer Screening Trial (DLCST), 
no difference in stage is observed.
Inherent to a stage shift is the so called “histology shift”. Debate is ongoing whether the early 
detection of lung cancers is based on the detection of lung cancer in an early stage, or rather 
an increased detection of slow-growing tumors (e.g. adenocarcinomas and BACs) 27-29. Several 
studies have reported that up to 25% of the CT detected lung cancers are relatively slow-
growing, and that up to 80% of such indolent cancers are adenocarcinomas or BACs 29-32. In 
the current NELSON analysis, 48.0% of the screen group lung cancers are relatively slow-
growing tumors, 93.8% of which are adenocarcinomas. Detection of more relatively slow-
growing tumors may lead to weakening the effect of screening and may result in unnecessary 
diagnosis and over-treatment 27, 33. However, in the NELSON trial less female participants 
were included. It is known that adenocarcinomas are the most prevalent tumor histology 
among females 24. Furthermore, screening has also led to more SCLCs to be diagnosed at a 
lower stage compared to no screening. Further studies, for example by use of Microsimulation 
Screening Analysis (MISCAN) modelling, are needed to investigate the histology shift in more 
depth and to determine the proportion of overdiagnosed lung cancers in the NELSON trial. 
A favorable cancer stage shift is important, as it is know that early detection of lung cancer 
is related to the possibility of surgical resection and a better survival 2, 7, 8, 30. In the NELSON 
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trial, the screen group lung cancer patients received a surgical treatment 2.8 times more 
often regardless of stage at time of diagnosis than the control group lung cancer patients. 
Almost the same portion of screen group lung cancer patients were treated surgically (alone 
or with chemotherapy and/or radiotherapy) as in the NLST 7. Compared to the ITALUNG 
trial less screen-detected lung cancers were treated surgically in the NELSON trial (67.7%% 
vs. 85.4%) 34. However, in comparison with the current NELSON analysis, the sample size in 
ITALUNG was 2.4 times smaller, and therefore a comparison should be made with precaution. 
Nevertheless, implementation of lung cancer screening will probably lead to more surgical 
treatment options of lung cancer. And it will open a new area of investigations in surgical 
resections of small sized tumors. 
Furthermore, this study shows that screen group stage Ia cancer patients received a surgical 
treatment slightly more often than the stage Ia control group patients. Clinically, most lung 
cancers are diagnosed in an advanced disease stage 2. To be diagnosed with a stage I cancer as 
a control group participant, the control group participant should typically have been under 
the supervision of a specialist for any reason (e.g. COPD treatment). In this sub study, no 
difference was observed in age at diagnosis or in co-morbidity (e.g. COPD) between both 
study group subjects with a stage Ia cancer. It is unknown what caused the difference in 
treatment in the stage I lung cancers. 
Additionally, in interpreting the mortality results of a screening trial, it is also necessary to 
know whether the study population was representative of the target population. Previous 
publications reveal that the NELSON control group participants were slightly younger, 
healthier, higher educated and more willing to participate in a screening program, compared 
to those who were eligible to participate but did not 35. This led to modest differences in 
mortality compared to the eligible non-responders. The observed differences were small 
and it is assumed that it is unlikely that it will influence the generalizability of the NELSON 
trial. However, it was unknown until then whether the control group lung cancers were 
representative of the lung cancers observed in the general population. Current study shows 
that the lung cancers outside the NELSON are diagnosed slightly in a higher stage than in the 
NELSON control group. One potential explanation is the study eligibility in which subjects 
with a history of cancer (lung cancer in the past five years or longer than five years ago but 
still under treatment, or those with renal cancer, melanoma or breast cancer) or those with 
a moderate or bad self-reported health who were unable to climb two flight of stairs and 
those with a CT chest examination less than one year ago before they filled in the NELSON 
questionnaire, were excluded from participation in the NELSON trial 15, 16. As the actual 
difference in stage between the NELSON control group and the Dutch comparable birth 
cohort is small, it is expected that the NELSON results will still be generalizable for the target 
population. 
Major strengths of this study are the population-based recruitment and verified lung cancer 
diagnosis by obtaining medical records of each lung cancer patient. Limitation of the current 
NELSON analysis is that at the moment it is not possible to investigate the correlation 
between stage shift, treatment shift and lung cancer mortality (reduction). Furthermore, there 
is the obstacle of the lack of data about the general health and smoking related health of the 
comparable Dutch birth cohort. 
In conclusion, current NELSON analysis shows that LDCT screening has so far led to a 
substantial favorable shift in cancer stage at time of diagnosis. Implementation of lung cancer 
screening will lead to a higher rate of early stage lung cancers, and subsequently a shift in 
treatment options from mainly advanced disease stage treatment (e.g. palliative) to curative 
treatment (mainly surgery). 
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ABSTRACT
Background 
Individuals who are younger have a high socioeconomic background and/or have a healthy 
lifestyle are more inclined to participate in screening trials. This form of bias may affect the 
generalizability of study results to the target population. This study aimed to investigate the 
generalizability of the NELSON lung cancer screening trial to the Dutch population.
Methods 
People at high risk for developing lung cancer were identified by sending a health questionnaire 
to 606,409 persons aged 50–74 years, based on population registries. Eligible subjects received 
an invitation to participate (n = 30,051). 15,822 subjects agreed to participate and were 
randomized, whereas 15,137 did not respond (so called eligible nonresponders). Baseline 
characteristics and mortality profiles were compared between control group participants and 
eligible nonresponders.
Results 
Participants had better self-reported health (p=0.02), were younger, more physically active, 
higher educated, and more often former smokers compared with eligible nonresponders (all 
p<0.001). No differences were seen in self-reported outcomes of pulmonary tests, history 
of lung cancer, and smoked pack-years. Mortality due to all-causes (p<0.001) and mortality 
classification separately was lower among participants. However, the proportion of subjects 
death due to cancer was higher among participants (62.4% vs. 54.9%).
Conclusions 
Modest differences in baseline characteristics between participants and eligible nonresponders, 
led to minor differences in mortality profiles. However, group sizes were large and therefore it 
seems unlikely that these small differences will influence the generalizability of the NELSON 
trial. Results of the NELSON trial can roughly be used to predict the effect of population-
based lung cancer screening.
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5.1. INTRODUCTION
Lung cancer is a major public health problem worldwide, due to its high incidence and 
poor 5-year survival rate of less than 15% 1. Smoking cessation offers the best prospects for 
reducing the risk of developing lung cancer 2. Although smoking prevalence is decreased 
in Europe3, the residual effects of smoking on lung cancer risk remains notable in former 
smokers and a significant proportion of lung cancers are now diagnosed in former smokers 
4, 5. For this group, primary prevention is not meaningful. However, if lung cancer is detected 
in an early stage, treatment options are generally more promising 6. The National Lung 
Screening Trial demonstrated that computed tomography (CT) screening can reduce lung 
cancer mortality by 20% compared with chest radiography 7. In the United States, this finding 
has led the United States Prevention Service Task Force to recommend lung cancer screening 
for current and former smokers, if quit within the past 15 years, aged 55 through 80 years 
with a smoking history of at least 30 pack-years 8. However, many issues remain regarding 
the technical and logistical aspects of screening, cost–effectiveness and generalizability. In 
Europe, no lung cancer screening trial has yet demonstrated a significant reduction in lung 
cancer mortality 9-11. However, the largest European trial, the Dutch-Belgian lung cancer 
screening trial (NELSON), is still ongoing. The NELSON trial investigates whether screening 
using LDCT can reduce lung cancer mortality by at least 25% at 10 years of follow-up 12, 
13. Major differences between the NELSON trial and the National Lung Screening Trial are 
that NELSON (1) offers no screening to control group participants, (2) has different intervals 
between screening rounds, and (3) uses different management protocols for nodules and 
abnormalities 12, 14. In interpreting the results of screening studies, it is important to know 
whether study participants were representative of the target population, as volunteers who 
are healthier and more concerned about their own health are more willing to participate in 
screening programs 15-17. This form of bias may affect the generalizability of the study results, 
as the studied subjects may differ from the target population for screening. 
So far, previous studies have indicated that participants of lung cancer screening studies are 
younger, 16, 18, 19 less likely to be current smokers, 15, 17, 19, 20 more physically active and higher 
educated 15, 18, 19 compared with nonparticipants. Other cancer screening studies indicated that 
higher socioeconomic status and “healthy lifestyle” predicts screening participation 18, 21-24. 
Screening trial participants also had lower incidence of cancer 15, 17, diabetes 15, cardiovascular 
15, and respiratory 15 diseases, than nonparticipants. One pilot study of lung cancer screening 
even showed that participants had a lower mortality rate for all types of cancer besides lung 
cancer, cardiovascular diseases, and noncancerous diseases other than cardiovascular and 
respiratory diseases compared with nonparticipants 16. However, lung cancer mortality was 
higher among participants. This mortality difference might be explained by selection bias; 
attendees of screening programs may have more awareness of being at risk of developing lung 
cancer, which may increase their interest in screening 16, 25.
So far, previous research showed that the NELSON study population is younger, has a 
better general health, has a higher proportion of current heavy smokers and is slightly lower 
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educated compared with the general Dutch population 17. However, less is known about 
potential differences in physical activity, alcohol consumption, smoking-related symptoms, 
the effect on the mortality profile of participants and eligible nonparticipants (the so-called 
eligible nonresponders; Fig. 1). The aim of this study was to investigate whether differences 
in characteristics and mortality profiles of participants of the NELSON study, and eligible 
nonresponders exist. The results of this study are relevant for the interpretation of the 
forthcoming mortality analyses of the NELSON trial.
5.2. METHODS
NELSON Trial
In the NELSON trial, 15,822 high-risk volunteers were randomized (1:1) to screening (n = 
7,915) using LDCT at respectively baseline and 1, 3, and 5.5 years after baseline, or to no 
screening (n = 7,909) 26.The NELSON study aims to investigate whether screening using 
LDCT can reduce lung cancer mortality by at least 25%. The study design and conduct 
were published previously 27-29. The NELSON trial was approved by the Dutch Minister of 
Health after positive advice from the Dutch health Council and by the Ethics Boards of the 
participating centers. 
Study Population
Population-based recruitments
During the recruitment phase, which occurred in two waves (during the second half 
of 2003 and the second half of 2005), addresses of subjects aged between 50 and 74 years 
were obtained from the population registries of seven districts in the  Netherlands and 14 
municipalities around Leuven in Belgium 28. These subjects received a questionnaire about 
their general health, medical check-ups and history, physical activity, body weight and length, 
smoking history, alcohol consumption, family history of cancer, education and their opinion 
on screening programs in general.
General health was determined by the subjects “ability to climb two flights of stairs” (yes, no, 
don’t know) and how they would describe their health: excellent, very good, good, moderate, 
or severe. Questions regarding smoking-related symptoms of lung disease were: did you have 
symptoms of coughing/sputum/wheezing/dyspnea for at least 3 months this year? (yes, no).
Questions on medical history and check-ups were as follows: was one of the following 
diagnostic procedures performed last year, 1–5 year, or greater than or equal to 5 years ago: 
(1) chest x-ray, pulmonary function test, CT-scan of the chest or sputum test?, (2) did you 
undergo lung surgery (e.g., pneumonectomy or lobectomy)?, (3) were you diagnosed with 
cancer and if so, when (less than 5 years ago, greater than or equal to 5 years ago, or greater 
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than or equal to 5 years ago and still under treatment)? and (4) what type of cancer were 
you diagnosed with (lung cancer, breast cancer, kidney cancer, melanoma, or other type)? 
Furthermore, physical activity was assessed as follows: how many times a week are you 
physically active for greater than or equal to 30 minutes (daily, 5–6 times, 2–4 times, 1 time, 
or less than 1 time a week). Alcohol consumption was assessed by asking how much alcohol 
was consumed at once (in pints) and at which base: daily, 5–6 times a week, 3–4 times a 
week, 1–2 days a week, 1–3 days a month, less than 1 glass a month or never. Willingness to 
participate in screening programs was assessed for prostate cancer, colon cancer, diabetes, 
cholesterol and cardiovascular diseases (yes, no, do not know) and their opinion on an 
acceptable number of persons to screen to detect one case of lung cancer at early stage (10, 
100, 1000, 10,000, 100,000, or 1,000,000). The highest completed level of education was 
determined through a single question with seven options: primary education, lower technical 
or vocational education, general secondary education, secondary technical or vocational 
education, senior general secondary education or pre-university education, higher technical 
or vocational education and university. The questionnaire also assessed smoking in detail 28, 30. 
Finally, each person’s body mass index was calculated (weight/length2).
A total of two recruitment rounds were necessary to reach the required number of participants.
The questions of the first questionnaire were slightly changed for the second wave using the 
experience of the first response. The overall response rate for the first questionnaire was 24.9% 
12.
Respondents who met the eligibility criteria (n=30,051) received an invitation to participate, 
a second questionnaire, an information leaflet and informed consent form for the NELSON 
trial 28. The eligibility criteria were as follows: age 50–75 years, smoking history of greater than 
or equal to 15 cigarettes per day for greater than or equal to 25 years or greater than or equal to 
10 cigarettes for greater than or equal to 30 years, and were still smoking or had quit less than 
or equal to 10 years ago. Exclusion criteria were: a moderate or bad self-reported health and 
inability to climb two flight of stairs, a body weight greater than or equal to 140 kg, a history 
of renal, melanoma or breast cancer, lung cancer diagnosed less than 5 years ago or greater 
than 5 years ago but still receiving treatment, or a chest CT examination within the past year 
28. In addition, the second questionnaire assessed smoking habits and exposure to asbestos in 
more detail.
Eligible responders who provided informed consent and completed the second questionnaire 
(n=15,822, response rate of 51.1%) were randomized (1:1) to either the screen group or the 
control group. 
Inclusion in this substudy
For this substudy, subjects randomized to the control group (n=7453) were compared with 
eligible subjects who did not participate (n=13,661). Subjects randomized to the screen group 
were excluded because of the potential effect of screening on their mortality profiles and the 
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embargo on mortality outcomes of this group. Furthermore, this substudy was limited to 
Dutch subjects, as only Dutch mortality data was available at the time of analyses.
Mortality Data
Anonymised mortality data for both groups were obtained via Statistics Netherlands. January 
2013 was chosen as end date of this substudy, at which point 99.1% of the subjects were 
traceable. To obtain mortality data, this study population was matched using four variables: 
sex, date of birth, zip code, and date of obtaining addresses. This led to an accuracy of almost 
98% in matching.
Person-years were calculated as the time between obtaining the addresses of the subject and 
subject’s date of death or the end date of this study, whichever came first.
To analyze mortality profiles, we classified the causes of death by disease groups, using 
the International Classification of Diseases, 10th edition: all-causes, all cancer causes, 
cardiovascular diseases, respiratory diseases, and noncancer diseases other than cardiovascular 
or respiratory diseases.
Statistical Analyses
Baseline characteristics of control group subjects and eligible nonresponders were retrieved 
from the first questionnaire. Differences in baseline characteristics were assessed using the 
following tests: for continuous variables, normality was tested using the Kolmogorov–Smirov 
test and differences between the two groups were assessed by using the Mann– Whitney U 
test, as appropriate. For nominal variables, the χ2 test was used and the Mann–Whitney U test 
was used for categorical variables.
Classified mortality data were compared between the two groups by using the χ2 test. For all 
analyses, p values less than 0.05 were considered statistically significant. SPSS version 21 and 
STATA 13 special edition were used to perform the analyses.
Chapter V
124
Figure 1. recruitment of the NELSON study participants and the selection for  this substudy.
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5.3. RESULTS 
A total of 7,453 Dutch control group participants were compared with 13,661 Dutch eligible 
nonresponders (Table 1). Participants were younger (p<0.001), more often male (p<0.001), 
had better self-reported general health (p=0.02), higher level of physical exercise (p<0.001) 
and a higher level of education (p<0.001). Participants also consumed more alcohol (p<0.001) 
and consisted of higher proportion of former smokers (p<0.001). However, most differences 
in proportions were small. 
Small differences were also seen in smoking-related characteristics (Table 2). Smoking 
duration was lower among participants (p<0.001), whereas numbers of cigarettes smoked per 
day was higher among participants (p<0.001). However, no differences were observed in the 
number of pack-years smoked between participants and eligible nonresponders. Participants 
started smoking at a younger age (p<0.001) and were more willing to quit smoking than 
eligible nonresponders (p<0.001). Among current smokers, participants were more often 
in an advanced stage- according to the stages of change- to quit smoking compared with 
eligible Nonresponders (p<0.001). Participants reported significantly more smoking-related 
symptoms (p=0.04) and had undergone a pulmonary function test more often (p<0.001). 
However, no differences were seen in the self-reported outcome of these pulmonary function 
tests (p=0.28).
During the study period, the all-cause mortality rate among eligible nonresponders was 
higher compared with the participants (p<0.001; Table 3).The eligible nonresponders had a 
higher mortality rate due to all types of cancer (p=0.002), cardiovascular diseases (p<0.001), 
respiratory diseases (p=0.018), and noncancerous diseases other than cardiovascular or 
respiratory (p<0.001). However, the proportion of deaths due to cancer was higher among 
participants (62.4% vs. 54.9%). Higher educational achievement was significantly associated 
with higher mortality from all types of cancer (χ2 17.3; p<0.001). Furthermore, a longer 
follow-up was seen for participants (10 years vs. 9 years).
Participants were significantly more likely to participate in any of the mentioned screening 
programs compared with the eligible nonresponders (all p<0.001, data not shown). The 
median physical distance from home to one of the nearby participating screening centers was 
significantly less for eligible nonresponders than for participants (16.9 km versus 17.9 km; 
p=0.003).
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Table 1: baseline characteristics of NELSON control group participants and eligible non-responders. 
Control group 
participants
Eligible non-responders p-value
Total N = 7,453 Total N = 13,661
% n/N % n/N
Age (years),  
median (IQR) 
57.0 (8.0) 7,453 58.0 (9.0) 13,661 < 0.001
Male 84.2 6,275/7,453 80.6 11,013/13,661 < 0.001
General health 0.02
  Excellent/very Good 15.2 1,124/7,393 14.2 1,913/13,477
  Good 66.6 4,922/7,393 66.7 8,984/13,477
  Moderate/poor 18.2 1,347/7,393 19.1 2,580/13,477
Physical exercisea < 0.001
High 44.5 3,292/7,398 48.5 6,533/13,459
Moderate 44.8 3,318/7,398 39.8 5,354/13,459
 Low 10.7 788/7,398 11.7 1,572/13,459
BMI, median (IQR) 25.9 (4.2) 7,177/7,453  25.8 (4.4) 12,932/13,661 0.16
Education levelb < 0.001
Lowest 11.0 806/7,352 18.1 2,410/13,339
 Low 37.4 2,750/7,352 41.4 5,530/13,339
 Medium 23.3 1,712/7,352 20.6 2,750/13,339
High 28.3 2,084/7,352 19.9 2,649/13,339
Alcoholc, median (IQR) 15.7 (83.9) 6,754/7,453 13.8 (83.9) 11,705/13,661 < 0.001
Smoker status < 0.001
Current smoker 54.8 4,077/7,434 60.4 8196/13,578
Former smoker 45.2 3,357/7,434 39.6 5382/13,578
History of lung cancer 4.7 344/7,396 4.4 594/13,502 0.40
Person-years of 
observation, median (IQR)
10.0 (2.0) 7,453 9.0 (2.0) 13,661 < 0.001
Data were presented as % (n/N) unless stated otherwise.
aPhysical activity: high was defined as greater than or equal to 5 times active for greater than or equal to 
30 minutes a week, moderate was defined as greater than or equal to 1 but
less than 5 times active for greater than or equal to 30 minutes a week and low was defined as less than 
1 time active for greater than or equal to 30 minutes a week.
bEducation level: lowest: only elementary; low education: Lower technical or vocational education and 
general secondary education; medium education level: secondary technical
or vocational education and senior general secondary education; high education level: higher technical 
or vocational education and university.
cAlcohol consumption in glasses per week.
BMI, body mass index.
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Table 2: smoking related characteristics of NELSON control group participants and eligible non-
responders
Control group 
participants
Eligible non-responders p-value
Total N = 7,453 Total N = 13,661
% n/N % n/N
Pack-years, median (IQR) 37.9 (19.8) 37.9 (21.5) 0.07
Smoking duration < 0.001
≤ 35 yrs 38.2 2,838/7,437 35.7 4,859/13,594 
36-40 yrs 31.8 2,363/7,437 30.4 4,136/13,594 
41-45 yrs 19.5 1,451/7,437 20.7 2,816/13,594 
> 45 yrs 10.5 785/7,437 13.1 1,783/13,594 
No. of cigarettes smoked 
per day 
< 0.001
 ≤ 15 22.1 1,642/7,439 24.2 3,282/13,604
16-20 28.3 2,101/7,439 29.5 4,016/13,604
21-25 26.8 1,994/7,439 25.3 3,444/13,604
26-30 11.0 822/7,439 9.4 1,283/13,604
31-40 6.9 513/7,439 7.1 965/13,604
>40 4.9 367/7,439 4.5 614/13,604
Starting age of smoking < 0.001
≤ 14 yrs, n (%) 16.0 1,189/7422 15.0 2,000/13,537 
15-19 yrs, n (%) 65.0 4,845/7422 64.0 8,718/13,537 
20-24 yrs, n(%) 16.0 1,184/7422 17.0 2,338/13,537 
>25 yrs, n (%) 3.0 204/7422 4.0 481/13,537 
Motivated to quit 
smokinga
93.3 4,854/5,201 91.4 7,555/8,269 < 0.001
Stage of Changeb < 0.001
Precontemplation phase 33.2 1,725/5,201 39.3 3,249/8,269
 Contemplation phase 14.1 736/5,201 13.7 1,129/8,269
Preparation 7.3 379/5,201 7.5 621/8,269
Action 4.7 244/5,201 4.3 359/8,269
Maintenance 40.7 2,117/5,201 35.2 2,911/8,269
Smoking related 
symptomsc
0.04
Yes, ≥1 53.8 2,777/5,157 52.0 4,279/8,229
Spirometry
 Yes 59.2 2978/5,029 53.2 4,186/7,873 < 0.001
Result of spirometryd 0.28
Normal (%) 81.3 1,867/2,296 82.5 2,522/3,058
Abnormal (%) 18.7 429/2,296 17.5 536/3,058
Data were presented as % (n/N) unless stated otherwise.
aMotivated to quit smoking: comparison between subjects who are current smokers only.
bStage of change: precontemplation phase: does not want to stop, wants to stop but not in the next 5
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years, wants to stop but not in the next year, wants to stop but not in the next 6
months. Contemplation phase: wants to stop in the next 6 months. Preparation: wants to stop in the next 
1 month. Action: stopped less than 6 months ago. Maintenance: stopped greater
than 6 months ago.
cSmoking-related symptoms: coughing, sputum, dyspnea, and wheezing.
dSpirometry: comparison between subjects with spirometry only.
Table 3: mortality rates (per 1.000 person-years) by causes of NELSON control group participants and 
eligible non-responders
Cause of death Control group Eligible non-
responders
Mortality 
rate ratio
 p-value
% Rate % Rate
All cancer types 62.4 6.32 54.9 7.59 0.83 0.002
Cardiovascular diseases 
(CVD)
20.2 2.05 24.0 3.32 0.62 <0.001
Respiratory diseases 4.4 0.45 5.3 0.73 0.61 0.018
Noncancerous diseases 
other than CVD or 
respiratory diseases
12.9 1.30 15.8 2.19 0.59 <0.001
All causes 9.1 10.11 11.2 13.83 0.73 <0.001
ap-value for mortality rate ratio = 1. 
CVD, cardiovascular diseases. 
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5.4. DISCUSSION
This study investigated differences in characteristics and mortality profiles of participants of 
the NELSON trial and eligible nonresponders. Results of this study are essential to determine 
whether mortality results of the NELSON trial are generalizable to the target Dutch population 
for lung cancer screening.
Participants of the NELSON trial were significantly younger, had better self-reported health, 
were more physically active, and higher educated compared with eligible nonresponders, 
although the differences in proportions were modest. These results are in line with previous 
studies in cancer screening trials 15, 16, 18, 19. Furthermore, men were more likely to participate 
in the NELSON trial, whereas more women participated in the Danish Lung cancer Screening 
Trial (DLST) 18.
Different recruitments methods may explain the differences in study populations between 
NELSON trial and DLST: the NELSON trial was designed to recruit only men at first, because 
of fewer Dutch women met the smoking-related inclusion criteria of the NELSON study. 
However, in the second recruitment women were also invited to allow the NELSON study 
results to be generalizable to women. In contrast, the DLST recruited both sexes from the start 
of the study. Such overrepresentation of women participating in screening trials is also seen 
by others and may be because women are more used to screening from other cancer screening 
programs 31.
In the NELSON study, number of pack-years smoked between the two groups was similar, 
but participants were more often former smokers 17.This is in contrast with the DLST and 
an Italian lung cancer screening trial, in which current smokers were overrepresented 16, 18. 
However, the DLST also reported that despite active smoking, participants were more willing 
to quit smoking than nonparticipants (a representative sample from the Danish population), 
suggesting that smokers who are motivated to quit smoking are more inclined to volunteer in 
a screening trial 18.
Eligible nonresponders had a higher all-cause mortality and mortality due to four other 
mortality classifications. However, the relative proportion of subjects that died due to all 
types of cancer was higher among participants. This might be explained by alcohol abuse, 
which is associated with higher socioeconomic status, e.g., higher educational achievement 
32. Higher alcohol consumption is associated with a higher relative risk for death from cancer 
33. Another explanation might be that participants reported more smoking-related symptoms, 
which may have led to more general practitioner consults. This may have led to the higher 
proportion of former smokers among participants and could have facilitated the detection 
of cancer, cardiovascular, and respiratory diseases. This may have resulted in early treatment 
of smoking-related diseases among NELSON participants and may have led to lower 
mortality rates compared with eligible nonresponders. However, the slightly younger age, 
better self-reported health, and healthier lifestyle among participants may have had a bigger 
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contribution to these differences in mortality profiles and resulted in a significantly longer 
follow-up among participants. As mentioned, participants were more likely to participate in 
any of the mentioned screening programs compared with the eligible nonresponders. Higher 
education levels may have led to more awareness of their risk for lung cancer and influenced 
the decision to participate in the NELSON trial. In addition, there were more former 
smokers among participants. It has been previously reported that active smoking is a barrier 
to participate in screening for lung cancer 20, 34. Notable, living further from participating 
screening center, participants in the NELSON trial were more willing to participate than the 
eligible nonresponders. In contrast, the Lung-SEARCH screening trial reported that half of 
the responders found inability to travel the most significant reason not to participate 25.
The main strengths of this study are: (1) the large number of participants and eligible 
nonresponders, (2) access to all the completed first questionnaires of subjects, (3) the 
availability of mortality data from Statistics Netherlands, and (4) a long follow-up duration of 
10 years. Finally, so far no large lung screening trial using LDCT has studied the differences 
in baseline characteristics and potential effect on mortality profiles between participants and 
eligible nonresponders. This study was limited by the fact that Statistics Netherlands could 
only provide aggregated mortality data. Therefore, it was not possible to perform multivariate 
analyses. Furthermore, all questionnaire data were self-reported, as in other studies 7. The 
questionnaires included few questions on socioeconomic class and no questions on ethnic 
background or psychosocial profile.
In conclusion, differences in age, health, lifestyle, and socioeconomic class can lead to a 
healthy participant effect, i.e., a different study outcome than would have been observed if 
the characteristics of participants were similar to that of the target population. As expected, 
the distribution of participant characteristics in the NELSON study suggest that the study 
population is somewhat younger, healthier (e.g., more physically active, less current smokers), 
higher educated and more willing to participate in a screening program. These differences 
have influenced the mortality outcome of participants and eligible nonresponders. But, these 
differences are modest and therefore it seems unlikely that these differences will influence the 
generalizability of the main results of the NELSON trial.
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ABSTRACT
Background 
Primary outcome of the Dutch-Belgian lung cancer screening trial (NELSON) is lung cancer-
specific mortality. Accurate assessment of the cause of death (CoD) is crucial. As death 
certificates regarding the CoD can be inaccurate, a clinical expert committee (CEC) was 
formed to assign the CoD. In this study, the medical files of deceased lung cancer patients 
were reviewed and the outcomes were compared with official death certificates. 
Methods 
The first 266 completed medical files of Dutch deceased participants who were diagnosed 
with lung cancer during the study or of those with lung cancer on the death certificate were 
selected and blinded towards arms and patients identity. The end product of the review 
process consisted of six possible categories which defined the graduation of certainty that 
lung cancer was the primary CoD. The percentage agreement and the Cohen’s kappa statistics 
between the two CEC-members were calculated. The sensitivity and specificity of the official 
death certificates were determined. 
Results 
The results indicated that, the overall concordance and the Cohen’s kappa between the 
CEC-members were 86.1% and 0.57 (0.45–0.69, p < 0.001), respectively. This level increased 
with the numbers of cases evaluated. The sensitivity and the specificity of the official death 
certificate were 92.6% and 98.8%; 6.5% cases were reclassified to lung cancer specific death, 
which is lower than in the National Lung Screening trial (22.0%).
Conclusions 
Concluding, each death should be reviewed by at least two members. So far, in the NELSON 
trial, possible biases related to lung cancer death seem relatively small.
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6.1. INTRODUCTION
In cancer screening trials, the cause of death (CoD) is often determined by a review committee 
of medical scientists who (independently) review the blinded medical files of the deceased 
participants and achieve consensus regarding the underlying cause of death 1-4. This is done 
to overcome different biases, as sticky-diagnosis (if more cancers are being diagnosed in 
the screening group, it’s likely that more death are attributed to that cancers compared to 
the control group with no screening), and slippery-linkage bias (where deaths are due to 
the screening process, but are not traced back to screening and are certified as due to other 
causes). This also should overcome the variable sensitivity and specificity of the official death 
certificates which depends on the accuracy of the certifying clinicians 5-7.
A clinical expert committee (CEC) was formed to independently, and in a uniform and blinded 
matter to review the first 266 completed medical files of deceased lung cancer participants of 
the NELSON trial − the Dutch Belgian lung cancer screening trial 8, 9. Furthermore, these files 
and official death certificates were compared.
6.2. METHODS
Pilot study
Previously, a pilot study (n=50) by a uniform classification (review committee vs. death 
certificates) demonstrated an agreement of 90% (Cohen’s kappa 0.65) 9. The sensitivity and 
specificity of the official death certificates for lung cancer specific mortality were 95.2% and 
62.5%, respectively, what implied that the final NELSON outcomes should be established with 
predetermined criteria and an independent review of blinded cases.
Selection of subjects
For this study, all Dutch deceased participants who were diagnosed with lung cancer (during 
the study or at autopsy), deceased participants who were in the diagnostic work-up for lung 
cancer, and participants with a notation of lung cancer on the death certificate (International 
Classification of Diseases and related health problems (ICD) version 10:34) were selected. 
Lung cancer cases and the death certificates were obtained through linkages with the National 
Cancer Registry of the Netherlands (100% coverage), and Statistics Netherlands (100% 
coverage; 2003–2014), respectively. Thereafter, it was verified if the participant had indeed 
been diagnosed with lung cancer, during a separate procedure. All relevant medical data 
pertaining to the CoD (all outpatient and discharge letters, radiology and pathology reports, 
and place of death) was collected.
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The NELSON clinical expert committee
The CEC consisted of an independent pulmonologist-oncologist and a pathologist specialized 
in lung oncology. In cases with no consensus, a third reviewer (a clinical epidemiologist 
specialized in screening) was consulted9.
The CoD review process
After blinding the medical files for patients identity and study arm, they were uploaded onto a 
secure online database. The end product of the evaluation consisted of six possible categories 
which defined the graduation of certainty that lung cancer was the primary cause of death, 
which is based upon the CoD review process followed in the European Randomized Screening 
for Prostate Cancer trial 10. After reaching consensus between the two CEC-members, and the 
third reviewer, the end product was considered as the golden standard (Figure 1). At all time, 
the reviewers had no access to the official death certificates.
After the evaluation, the nonconsensual cases were discussed plenary to reach consensus. If it 
was not possible to reach consensus a third reviewer was consulted. After reaching consensus, 
first, it was checked if the files were also reviewed in the pilot study [9]. If yes, the consensus 
of both studies were compared. The nonconsensual cases, were re-evaluated by the committee 
and the clinical epidemiologist from the pilot study. The final agreement after the meeting 
was considered as the golden standard. In case the files were not reviewed in the pilot study, 
the consensus reached by the committee was considered the golden standard. After reaching 
consensus over all cases, the final outcome was compared with the primary CoD on the 
official death certificate by the first author. In case the CoD on the official death certificate 
was ‘lung cancer death’ and the CoD reviewed CoD was ‘death due other cause of death than 
lung cancer’, the committee and the clinical epidemiologist reviewed these files again and 
discussed it in a meeting.
Analysis
The primary CoD was defined as ‘the disease that initiated the chain of morbid events 
directly leading to death’. Lung cancer mortality, was defined as ‘definitely’ or ‘probable 
lung cancer death’. All other four possible categories (‘possible’, ‘unlikely’, ‘definitely no 
lung cancer death’, and ‘intercurrent death with lung cancer as contributing factor’) were 
considered as ‘another CoD’. CEC-members Cohen’s Kappa represented the percentage 
agreement between the CEC-members. Sensitivity (true positives (lung cancer death 
assigned by both sources) divided by the sum of true positives and false negative diagnoses 
according to the official death certificates) and specificity (true negatives (other cause of 
death assigned by both sources) divided by the total death due to other cause according 
to the official death certificates) were calculated. All continuous variables were presented 
as medians and interquartile ranges (IQR), as appropriate. Differences between variables 
were calculated by using the Median Test or ANOVA (continuous variables), chi-square test 
(nominal), and Kruskall-Wallis test (categorical). For all analysis SPSS version 21 was used.
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Figure 1. an overview of the CoD review process. 
Endpoint verfication
141
VI
1These 217 cases were not reviewed in the pilot study and therefore no comparison was possible with 
the pilot study.
2 In these 3 cases the participants did not give permission to obtain their official death certificate. 
Therefore no comparison with the official death certificate was possible.
Red dotted line: after discussing 7 cases in a meeting with a third reviewer from the pilot study and the 
two CEC members, in 4 cases the initial outcome of the CoD review process was changed.
6.3. RESULTS 
In total, 266 medical files of Dutch deceased participants, who deceased between 28th August 
2004 and 26th April 2014, were selected for the review (Table 1).
Agreement between the CEC-members based on six possible categories was reached in 71.1% 
(189/266) of the online reviewed cases. Divided in a lung cancer death (definitely or probably 
lung cancer death), agreement between the two members was reached in 86.1% of the cases 
(Cohen’s kappa of 0.57 (95% CI, 0.45–0.69, p < 0.001)). Nonconsensual cases were discussed 
in a meeting. Reasons of disagreement were: recently received lung cancer treatment (n=1), 
autopsy revealed lung cancer death (n=2), other possible CoD (n=2), too little information 
(n=2), intercurrent death with another CoD (n=2), another CoD was more obvious (n=2), 
and reports were available about progressive tumor (n=26). No third reviewer was required 
to reach consensus.
Compared to the pilot study (in which 49 comparable cases were evaluated by two different 
reviewers), in seven out of 49 cases there was a disagreement (Fig. 1). These cases were re-
evaluated and discussed in a meeting by the CEC and the third reviewer. In four cases the 
outcome of the CoD review process was changed to ‘definitely lung cancer death’. Reasons for 
these changes were: autopsy showed lung cancer death (n=2), euthanasia because of cerebral 
metastasis of lung cancer (n=1) and all the clinicians who treated the patient addressed the 
death of the patient to lung cancer (n=1).
From 266 participants, three participants did not provide informed consent to obtain their 
official death certificate. Therefore, the consensus reached in the CoD review process will be 
used as the primary CoD for these cases.
When the official death certificates noted ‘lung cancer death’, but the CoD review process 
noted it as another CoD’, a third independent review took place (n=21). In three cases the 
outcome of the COD review committee was changed to ‘lung cancer death’. In all the three 
cases the patient suffered from metastasized lung cancer with no treatment options. The 
overall sensitivity and specificity of the death certificates were 92.6% and 98.8%, respectively. 
Death review resulted in a reclassification of 12.2% (32/263) of the cases (Table 1).
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Table 1: Causes of death by the reviewers after consensus meeting and the official certificates 
Death certificates Cause of death Review committee Total
LC death Other cause of death
n (%) n (%)
LC death 212 (80.6) 17 (6.5) 229 (87.1)
Other cause of death 15 (5.7) 19 (7.2) 34 (12.9)
Total 227 (86.3) 36 (13.7) 263 (100.0)
LC: lung cancer 
LC death: definitely LC death or probable LC death
Other cause of death: possible LC death, unlikely LC death, definitely no LC death and intercurrent 
death with LC as contributing factor
Reasons for reclassification of “other CoD” to “lung cancer death” were: cases with severe metastatic 
lung cancer (n=8), lung cancer diagnosis shortly before death (n=5), died during work-up for lung 
cancer and autopsy showed lung cancer death (n=1) and died from complication after a thoracotomy 
for lung cancer treatment (n=1).
Reasons for reclassification of “lung cancer death” to “other CoD” were: other malignancy (n=7), multiple 
cardiovascular and respiratory problems (n=3), cardiovascular problems (n=3), too little information 
(n=1) and other causes (n=3). 
6.4. DISCUSSION
In this study, medical files of deceased NELSON lung cancer participants were reviewed 
concerning the underlying CoD and were compared with the official death certificates. 
Weak to moderate agreement of 86.1% (Cohen’s kappa of 0.57) between the two committee 
members was reached, what underlies the need for a CoD committee. As expected, the level 
of agreement increased with the numbers of cases evaluated (data not shown) 9.
The National Lung Screening Trial (NLST) 3, 4, which also used a death review committee to 
verify the CoD, showed a comparable sensitivity and specificity of the official death certificates 
(NLST: 91% and 97%, and NELSON 92.7% and 98.8%, respectively). However, the NLST 
review was not restricted to the files of lung cancer patients only 4. Secondly, only one member 
reviewed the medical files of the NLST first. In case of concordance with the death certificate 
this was considered as certified. In the NELSON trial, two members reviewed each file, 
independently. Furthermore, less official death certificates were re-classified in the NELSON 
trial compared to the NLST (12.2% vs. 26.0%). The NLST showed a higher reclassification of 
deaths to lung cancer specific deaths than the NELSON trial (22.0% vs. 6.5%). Dutch clinicians 
and Statistics Netherlands may have a more uniform method in reporting the cause of death. 
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Furthermore, the NLST showed that the mortality benefit of screening did not significantly 
change with reviewing the CoD 4. For the NELSON trial, we are waiting the final results and 
the CoD review process will be continued until then.
The National Lung Screening Trial (NLST) 3, 4, which also used a death review committee to 
verify the CoD, showed a comparable sensitivity and specificity of the official death certificates 
(NLST: 91% and 97%, and NELSON 92.7% and 98.8%, respectively). However, the NLST 
review was not restricted to the files of lung cancer patients only 4. Secondly, only one member 
reviewed the medical files of the NLST first. In case of concordance with the death certificate 
this was considered as certified. In the NELSON trial, two members reviewed each file, 
independently. Furthermore, less official death certificates were re-classified in the NELSON 
trial compared to the NLST (12.2% vs. 26.0%). The NLST showed a higher reclassification of 
deaths to lung cancer specific deaths than the NELSON trial (22.0% vs. 6.5%). Dutch clinicians 
and Statistics Netherlands may have a more uniform method in reporting the cause of death. 
Furthermore, the NLST showed that the mortality benefit of screening did not significantly 
change with reviewing the CoD 4. For the NELSON trial, we are waiting the final results and 
the CoD review process will be continued until then.
Strengths of this study are the blinded (for study arm and official death certificate) and uniform 
review process by the independent reviewers that had access to participant’s complete medical 
file. A potential limitation is the selection of the first 266 deceased participants from whom all 
medical data was collected, what possibly over represents participants with an aggressive lung 
cancer leading to more assignable death due to lung cancer and few cases to be reclassified. 
Secondly, a subset of deaths was selected for the CoD review (e.g. participants with a diagnosis 
of lung cancer or with a notation of lung cancer on the death certificate), what may increase the 
likelihood of lung cancer as cause of death. Furthermore, participants with another CoD were 
excluded, what introduces some uncertainty about the generalizability of the results for the 
whole deceased NELSON population. However, reviewing all deaths is too time-consuming. 
In conclusion, for large randomized cancer screening trials it is necessary to review the 
cancer-specific cause of death because the official death certificate report’s varying accuracy 
(sensitivity and specificity). In the NELSON trial, the results indicated that possible biases 
related to lung cancer death seem relatively small. Furthermore, it is recommended that a 
uniform and blinded death review should be done by at least two independent members.
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ABSTRACT
Background
The primary outcome of the Dutch-Belgian lung cancer screening trial (NELSON) is lung 
cancer-specific mortality for which an accurate assessment of the cause of death (CoD) is 
crucial. Because death certificates regarding the cause of death can be inaccurate, a clinical 
expert committee (CEC) was formed to assign the CoD. In this study, the medical files of 
deceased lung cancer patients were reviewed and the outcomes were compared with official 
death certificates. 
Methods
The first 266 completed medical files of Dutch deceased participants who were diagnosed with 
lung cancer during the course of study or of those with lung cancer on the death certificate 
were selected and blinded towards arms and patients identity. The end product of the review 
process consisted of six possible categories which defined the graduation of certainty that 
lung cancer was the primary CoD. The percentage agreement and the Cohen’s kappa statistics 
between the two CEC members were calculated. The sensitivity and specificity of the official 
death certificates were determined. 
Results
The overall concordance and the Cohen’s kappa between the CEC members were 86.1% and 
0.57 (0.45-0.69, p<0.001), respectively. Level of agreement between the two CEC members 
increased with the numbers of cases they evaluated. The sensitivity and the specificity of the 
official death certificate were 92.6% and 98.8%; 6.5% cases were reclassified to lung cancer 
specific death, which is lower than in the National Lung Screening trial (22.0%).  
Conclusion
It is recommended that death review of each case should be determined by at least two 
members, independently and in a uniform and blinded matter.  So far, in the NELSON study, 
possible biases related to lung cancer death seem relatively small. 
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INTRODUCTION
Lung cancer mortality is the primary outcome of lung cancer screening trials that investigate 
the (cost)-effectiveness of a cancer screening programme 1-3. In cancer screening programmes, 
the cause of death (CoD) is often determined by a review committee 4-6. The review committee 
usually consists of clinicians or other medical scientists who (independently) review the 
blinded medical files of the deceased participants and achieve consensus regarding the 
underlying cause of death (UCoD). This is done to overcome different biases, as sticky-
diagnosis (where more cancers are being diagnosed in the screening group and therefore 
deaths are more likely to be attributed to that cancer compared to the control group with no 
screening), and slippery-linkage bias (where deaths are due to the screening process, e.g. a 
diagnostic thoracotomy, which are not traced back to screening but are certified as due to 
other causes and may lead to an overestimation of the beneficial effects of screening). Also, 
to overcome the variable sensitivity and specificity of the official death certificates which 
depends on the accuracy of the certifying clinicians 7-9. 
The largest lung cancer screening trial in Europe is the Dutch-Belgian lung cancer screening 
trial (NELSON), which aims to investigate whether LDCT screening reduces lung cancer 
mortality by 25% or more compared to no screening 3, 10, 11. A clinical expert committee (CEC) 
was formed to review the medical files of the deceased NELSON lung cancer participants, 
independently, and in an uniform and blinded fashion 12. 
The aim of this study is to evaluate the first 268 reviewed medical files of the deceased 
NELSON lung cancer participants by the CEC, as well as the comparison between these files 
and official death certificates. 
METHODS
The NELSON trial
In brief, the NELSON trial is a sufficiently powered, randomized-controlled lung cancer 
screening trial with the aim to investigate whether LDCT screening reduces lung cancer 
mortality by ≥25% in high-risk subjects for developing lung cancer compared to no screening 
3, 13, 14. Initially, 15,822 participants were randomized (1:1). However, through linkages with 
the national cancer registries of the Netherlands and Belgium, and the death registries of 
the Netherlands and Belgium (Statistics Netherlands and the Flemish Agency for Care and 
Health, respectively), it appeared that 30 participants died before randomization and should 
therefore be ruled out from further analysis; 15 of these belonged to the screening group 
and 15 to the control group. The actual number of randomization are: 15,792 participants 
(7,900 in to a screening group and 7,892 in to a control group). LDCT screening took place 
at baseline, and after one, two and two-and-a-half years. Control group received usual care. 
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In our previous report 12 , a CoD review process protocol was developed and tested in a pilot 
study. In brief, in the pilot study the medical files of the first 50 deceased NELSON lung 
cancer participants were reviewed independently by two members. The files were blinded for 
patients identity and study arm. The final outcome after the review process was compared 
with the CoD according to the official death certificates. An agreement of 90% (Cohen’s kappa 
0.65) was seen, which demonstrated a uniform classification. The sensitivity and specificity 
of the death certificates for lung cancer specific mortality were 95.2% and 62.5%, respectively. 
Furthermore, it implied that the final outcome of the NELSON trial should be established 
with predetermined criteria and an independent review of blinded cases. 
Identification of the deceased participants
Subjects of the CoD review process were: 1) all deceased participants who were diagnosed 
with lung cancer (during the study or at autopsy), 2) deceased participants who were in the 
diagnostic work-up for lung cancer, and 3) participants with a notation of lung cancer on the 
death certificate (International Classification of Diseases and related health problems (ICD) 
version 10:34). The lung cancer cases were identified through linkages with the national 
cancer registry of the Netherlands (100% coverage), and the death certificates were obtained 
(100% coverage) from the Statistics Netherlands from 2003 until 2014. For all identified 
subjects, firstly it was verified whether the participant had indeed been diagnosed with lung 
cancer during the course of study (e.g. after randomization) or at autopsy. This verification 
process was performed separately from the CoD review process and will not be addressed 
in this manuscript. Hereafter, all relevant medical data pertaining to the CoD was collected. 
The relevant medical data consisted of: all information provided by the general practitioner, 
outpatient visit letters, discharge letters, reports of radiology, nuclear medicine, pathology 
and microbiology, laboratory results, autopsy reports, and date and place of death. 
The clinical expert committee of the NELSON trial 
The CEC consisted of a pulmonologist-oncologist and a pathologist specialized in lung 
oncology (both were not involved in the NELSON trial or in care of the patients). In cases 
were no consensus was reached, a third reviewer (a clinical epidemiologist specialized in 
screening) was consulted 12. 
The CoD review process 
The medical files were blinded for participant’s identity and study arm by an individual who 
was not a member of the CEC. Hereafter, the files were uploaded onto a secured online database 
so that each member of the CEC could independently review the files. The evaluation process 
performed by the members was guided by the use of a decisional flowchart and a detailed 
list of criteria that guide the decision-making process uniformly, which has been used in the 
pilot study (both available in the appendix) 12. The end product of the evaluation consisted 
of six possible categories which defined the graduation of certainty that lung cancer was the 
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primary cause of death (supplementary material, Table 1). This graduation of certainty is 
based upon the CoD review process followed in the European Randomized Screening for 
Prostate Cancer trial (ERSPC) 15. 
After completing the evaluation online, the nonconsensual cases were discussed plenary to 
reach consensus. Next, it was first checked if the files were also reviewed in the pilot study 
[12]. If this was the case, the consensus of the CoD review process was compared with the 
consensus reached in the pilot study. In case of no agreement, the files were re-evaluated by 
the two CEC members and by the clinical epidemiologist from the pilot study and discussed 
in a meeting. The agreement after the meeting was considered as the golden standard. In case 
the files were not reviewed in the pilot study, the consensus reached by the two CEC members 
was considered the golden standard. 
After reaching consensus over all cases, the final outcome of the CoD review process was 
compared with the primary CoD on the official death certificate by the first author. In case 
the CoD on the official death certificate was ‘lung cancer death’ and the CoD reviewed CoD 
was ‘death due other cause of death than lung cancer’, the two CEC members and the clinical 
epidemiologist reviewed these files again and discussed it in a meeting. At all time, the 
reviewers had no access to the official death certificates. 
Analysis 
For this study, the first 268 completed medical files of Dutch deceased participants with lung 
cancer were included. The primary cause of death was defined as ‘the disease that initiated 
the chain of morbid events directly leading to death’. The primary endpoint of the study, lung 
cancer mortality, was defined as ‘definitely’ or ‘probable lung cancer death’. All other four 
possible categories (‘possible’, ‘unlikely’, ‘definitely no lung cancer death’, and ‘intercurrent 
death with lung cancer as contributing factor’) were considered as ‘death due to other 
causes’. Agreement between the two CEC members was expressed in percentage agreement 
in Cohen’s Kappa 16. A Cohen’s kappa of 1 and 0 indicated a ‘perfect agreement’ and ‘no 
agreement’, respectively. Sensitivity and specificity of the death certificates compared with the 
CoD review process consensus were calculated. Sensitivity: proportion of true positives (lung 
cancer death assigned by both sources) divided by the sum of true positive and false negative 
diagnoses according to the official death certificates. Specificity: proportion of true negatives 
(other cause of death assigned by both sources) divided by the total death due to other causes 
according to the official death certificates. None of the continuous variables tested by using the 
Kolmogorov-Smirnov test and examining Q-Q-plots were distributed normally. Therefore, 
the variables were described by using medians and interquartile ranges (IQR). Differences 
between the continuous variables across the groups were calculated by using the Median Test 
or ANOVA. Differences between nominal variables were calculated by using a chi-square test. 
Differences between categorical variables were tested by using Kruskall-Wallis Test. For all 
analysis IBM SPSS version 21 was used. 
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Figure 1: an overview of the CoD review process 
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1These 217 cases were not reviewed in the pilot study and therefore no comparison was possible with 
the pilot study. 
2 In these 3 cases the participants did not give permission to obtain their official death certificate. 
Therefore no comparison with the official death certificate was possible. 
Red dotted line: after discussing 7 cases in a meeting with a third reviewer from the pilot study and the 
two CEC members, in 4 cases the initial outcome of the CoD review process was changed. 
RESULTS
In total, 266 medical files of Dutch deceased participants were selected and reviewed by the 
CEC. The selected medical files showed that the participants died between 25th April 2004 
and 26th April 2014. According to the information received from Statistics Netherlands only, 
in the same period 1,589 NELSON participants (10%) deceased (all-cause mortality). 
The selected deceased participants were slightly older compared to the non-deceased 
participants at baseline (62.1 years vs. 58.0 years), less often females (12.8% vs. 17.3%), more 
often current smokers at baseline (67.3% vs. 54.9%) and had smoked more pack-years at 
baseline (43.7 years vs. 38.0 year; Table 1). 
For 248 out of 266 cases, the place of death was known. In 65.3% (166/248) the place of death 
was outside the hospital: 75.3% (125/166) at home, 13.3% (22/166) in a hospice and 9.0% 
(15/166) in a nursing home. In 83.1% (221/266) of the cases it was known whether an autopsy 
was performed: 4.5% (10/221) had no autopsy compared to 95.5% (211/221) with autopsy. In 
45.1% (120/266) of the cases it was known whether the patient received palliative sedation or 
euthanasia; in 12.5%(15/120) palliative sedation was given and in 8.3% (10/120) euthanasia 
was performed. 
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Table 1. characteristics of non-deceased NELSON participants vs. deceased NELSON participants 
Non-deceased 
participants1 
Selected 
deceased 
participants
Other 
deceased 
participants
p-value 
N 14,200 266 1,326
Age at baseline, years <0.001
 Median 58.0 62.1 62.1
 IQR 7.8 9.1 9.5
Age at death, years 0.08
 Median NA 67.0 67.6
 IQR NA 9.5 10.2
Gender, n (%) <0.001
 Female 2,454 (17.3) 34 (12.8) 105 (7.9)
Smoking status at baseline, 
n (%)
 Smokers 7,793 (54.9) 179 (67.3) 776 (58.5) <0.001
Pack-years smoked at 
baseline, years (IQR)
38.0 (19.8) 43.7 (26.0) 39.2 (24.0) 0.002
1For these analysis non-deceased NELSON participants were defined as 15,792 randomized participants 
– all deceased participants. 
Agreement between the reviewers of the CEC
In Table 2a an overview is presented of all the possible outcomes of separate review of the 
CoD of each CEC member before a consensus meeting took place. In  71.1%(189/266) of the 
cases there was an agreement between the two CEC members. The cases with disagreement 
(n=77) were discussed in a meeting. No third review was required to reach consensus in any 
of the cases. 
Table 2b, presents an overview of separate review of the CoD by each CEC member, before a 
consensus meeting took place, divided in a lung cancer specific death (definitely or probably 
lung cancer death) and in other CoD (possible, unlikely or definitely no lung cancer death, 
and intercurrent death with lung cancer as contributing factor). Agreement between the 
two CEC members was reached in 86.1% of the cases, which corresponds with a Cohen’s 
kappa of 0.57 (95%CI, 0.45-0.69, p<0.001). In 37 (28+9) cases no agreement was reached 
and these cases were discussed by the two CEC members in a consensus meeting. Reasons of 
disagreement are pointed out in Table 3. 
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Table 3: reasons of disagreement between the two CEC members
Reasons N %
Reports about progressive tumor or stage IV tumor were available until 
death 
26 70.3
Underwent recently lung cancer treatment 1 2.7
Autopsy reports showed lung cancer as CoD 2 5.4
Other CoD are possible according to the medical data 2 5.4
Too little information 2 5.4
Intercurrent lung cancer death with another CoD 2 5.4
Another CoD was clear 2 5.4
Total 37 100
CoD: cause of death 
After reaching consensus, the files were compared with reviewed files from the pilot study. In 
seven out of 49 cases there was no agreement between the outcome of the CoD review process 
and the pilot study (Figure 1). Therefore, these seven cases were re-evaluated and discussed 
in a meeting by the two CEC members and by the clinical epidemiologist from the pilot 
study. In four cases the outcome of the CoD review process was changed from ‘intercurrent 
death with lung cancer as contributing factor (2x)’, ‘other cause of death’ and ‘possible LC 
death’ to ‘definitely lung cancer death’. Reasons for these changes were: in two cases an autopsy 
was performed with lung cancer death as the CoD, in one case euthanasia was performed 
because of cerebral metastases of lung cancer and in one case all the specialists who treated 
the patients addressed the death of the patients from lung cancer. 
Comparison of the reviewed medical files with the official death certificates
From 266 participants, three participants did not provide informed consent to obtain their 
official death certificate. Therefore, no comparison of the medical files of these 3 participants 
could be made with the official death certificates. For these three cases, the consensus reached 
in the CoD review process will be used as the primary CoD. 
In cases in which the official death certificates noted ‘lung cancer death’, but the CoD review 
process noted it as ‘death due to other cause’, a third independent review took place (n= 21). 
In four cases the outcome of the COD review committee was changed to ‘lung cancer death’. 
Eventually, in 12.2% (32/263) of the cases there was no concordance with the official death 
certificate. 
The overall sensitivity and specificity of the death certificates were 92.6% and 98.8%, 
respectively. Death review resulted in a reclassification of 12.2%  of the cases ( Table 4). In 
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15 out of these 32 (46.9%) cases, the CEC reclassified the CoD to a lung cancer specific death 
instead of ‘other CoD’ as noted on the official death certificate. Reasons of this reclassification: 
eight participants had a severe metastatic lung cancer, five participants were diagnosed with 
lung cancer shortly before death, in one case the participant was in work-up for lung cancer 
and the autopsy showed the cause of death was lung cancer death and one participant died 
from complications after a thoracotomy for lung cancer treatment. In the other 17 cases 
(53.5%), the CEC reviewed the CoD as ‘another CoD’, while according to the official death 
certificate the UCD was lung cancer death. The other CoDs were: another malignancy was also 
present (7x), cardiac cause of death (3x), multiple (lung) problems (3x), too little information 
of the final phase (1x) and other clear causes (3x). 
Table 4: causes of death by the reviewers after consensus meeting and the official certificates 
Death certificates Cause of death Review committee Total
LC death Other cause of death
n (%) n (%)
LC death 212 (80.6) 17 (6.5) 229 (87.1)
Other cause of death 15 (5.7) 19 (7.2) 34 (12.9)
Total 227 (86.3) 36 (13.7) 263 (100.0)
LC: lung cancer 
LC death: definitely LC death or probable LC death
Other cause of death: possible LC death, unlikely LC death, definitely no LC death and intercurrent 
death with LC as contributing factor
DISCUSSION
In this study, medical files of deceased NELSON lung cancer participants were reviewed and 
compared with the official death certificates. An agreement between the two CEC members of 
86.1% (Cohen’s kappa of 0.57) was reached. The outcome of the review process was compared 
with the official death certificates: the overall sensitivity and the specificity of the official death 
certificates were 92.6% and 98.8%, respectively. 
This study showed a weak to moderate agreement between the two CEC members before a 
consensus meeting took place. This addresses the need of more than one reviewer, and should 
be recommended for end-point verifications in large screening trials with cancer-specific 
mortality as outcome. In cases with disagreement, all relevant medical data was available to 
reach consensus. In accordance with our expectations, the level of agreement slightly increased 
with the numbers of cases they evaluated: the so-called ‘learning effect’ (data not shown) 12. 
The National Lung Screening Trial (NLST), also used a death review committee to verify the 
UCoD of the deceased participants 6, 17. The NLST reviewed 42% of the deaths (1,642 out of 
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3,877) and showed a sensitivity of 91% and a specificity of 97% of the official death certificates. 
This is comparable with the NELSON trial. However, their endpoint verification differed from 
the NELSON trial. The NLST used a broader selection of participants whose medical files 
were reviewed: not only participants with a notation of lung cancer on the death certificate 
and of those occurring among participants ever diagnosed with lung cancer were selected, 
but, for example, also participants with a cancer of interest, that might be misdiagnosed as 
no lung cancer 17. Secondly, after selecting the cases of interest, the first step in the NLST was 
that only one member reviewed the medical files. If there was concordance with the death 
certificate the reviewed CoD was considered as certified. However, in the NELSON trial each 
medical file was reviewed independently by two members of the CEC. Also, so far, in the 
NELSON trial 12.2% of official death certificates were re-classified, while in the NLST it was 
26.0%. The NLST showed a higher reclassification of deaths to lung cancer specific deaths 
than the NELSON trial (22.0% vs. 6.5%). This may suggest that in the Netherlands a higher 
accuracy of clinicians is seen regarding reporting deaths related to lung cancer or due to 
other causes of death. However, in the NELSON trial, so far, fewer cases have been reviewed. 
Furthermore, the NLST showed that the mortality benefit of screening did not significantly 
change with reviewing the CoD. As the primary endpoint results of the NELSON trial have 
not yet been analyzed, the CoD review process will be continued and is until then not known 
by study arm. 
In the Detection And screening of early lung cancer with Novel imaging TEchnology (DANTE) 
trial, 78% of all the death certificates were cross-checked with hospital records and/or with 
written reports provided by the attending physicians or by the general practitioner 1. In event 
of a doubtful case, the ‘death cause review panel’ was presented with all available medical 
records (blinded for patients’ assignment to the LDCT or control group) during formal case 
review sessions to reach a consensus about the CoD. In the Danish Lung Cancer Screening 
Trial (DLCST), the medical history of the deceased participants was also obtained, and a 
‘death review board’ was formed to establish the cause of death 18. However, in both trials a 
protocol about the death review process and information regarding reclassifications after the 
review off the CoD are not available. So, therefore, no comparison of the death review can be 
made with the DANTE and DLCST trial. 
Strengths of this study are the blinded and uniform review process 12. This allowed the reviewers 
to evaluate the medical file without the knowledge whether the participant was randomized 
in the screen arm or control arm. Furthermore, during the review process, the CEC members 
and the third reviewer were blinded for what the outcome on the death certificate was. 
Moreover, in the CEC members and the third reviewer had access to participant’s complete 
medical file. 
Potential limitations of the present study relates to the sample size and the selection of subjects 
of this study. The first 268 deceased participants from whom all medical data was collected 
were selected. This may have introduced a selection bias of participants with an aggressive 
lung cancer leading to more assignable death due to lung cancer. This could also explain why 
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compared to the NLST fewer official death certificates were re-classified. Secondly, a subset 
of deaths was selected for the CoD review (e.g. participants with a diagnosis of lung cancer 
or with a notation of lung cancer on the death certificate), with the chance of selection on 
the likelihood of lung cancer as cause of death. Also, as excluding all the other participants 
who died of another CoD, it is unknown whether the results of the CoD review process are 
generalizable for the whole deceased NELSON population. However, reviewing all death cases 
is very time-consuming and therefore many large cancer screening trials choose to review 
only deaths in specific cancer patients 6, 19, 20. Another limitation is that it is not yet allowed to 
analyze the data by study arm and the pending lung cancer mortality analysis. 
In conclusion, for large randomized cancer screening trials it is necessary to review the 
cancer-specific cause of death because the official death certificate report’s varying accuracy 
(sensitivity and specificity). In the NELSON trial, so far, a high overall sensitivity and 
specificity of the official death certificates was observed; in other words possible biased related 
to lung cancer death seem relatively small. Furthermore, it is recommended that the death 
review of each case should be done by at least two members, independently and in a uniform 
and blinded matter. 
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SUPPLEMENTARY MATERIALS 
Table 1: classification of the cause of death12
Cause of death Definition 
Definitely LC death Death certainly as a direct result of (second
primary) lung cancer, a paraneoplastic
syndrome or a diagnostic or therapeutic
intervention, including euthanasia and
palliative sedation. No clear other cause of
death is present
Probable lung cancer
Death
Participants with (second primary) lung cancer
with evidence of locoregional or distant
disease progression or a paraneoplastic
syndrome. It is uncertain whether this is the
final direct cause of death. No clear other cause of death is 
present
Possible lung cancer
Death
Participants with (second primary) lung cancer
with evidence of locoregional or distant
disease progression or a paraneoplastic
syndrome and one or more coinciding
malignancies. It is not possible to determine
which malignancy was the primary cause of
death
Unlikely lung cancer
Death
Participants with (second primary) lung
cancer, but without evidence of locoregional or
distant disease progression, a paraneoplastic
syndrome or death as a result of an
intervention for lung cancer. No clear other
cause of death is present
Definitely no lung
cancer death
The cause of death is definitely not a direct or
indirect result from (second primary) lung
cancer, a paranoplastic syndrome or an
intervention for lung cancer. Another cause of
death is present.
Intercurrent death
with lung cancer as
contributing factor
Only use this option when the cause of death
cannot be classified as listed above. The cause
of death is definitely not a direct result from
(second primary) lung cancer. Another cause of death is 
present and lung cancer contributed to the death of the 
patient
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GENERAL DISCUSSION
In the first paragraph, the main results of the following topics are summarized and interpreted: 
I) the optimization of the NELSON screening rounds; II) the interim stage shift results of the 
NELSON trial; and III) the cause of death of the NELSON participants. The methodological 
considerations are discussed in the second paragraph. Finally, the general conclusions and 
implications for further research are mentioned in the third paragraph.
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PART I: THE OPTIMIZATION OF THE NELSON SCREENING ROUNDS
I. Added value of a fourth screening round 
Main research question 
1. What is the added value of a fourth screening round with an interval of 2.5 years 
after the previous three screening rounds? 
Main results 
All participants from the screen group without lung cancer who were still alive in 2009 (to 
our best knowledge) (n=6,735) received an invitation to participate in the additional fourth 
Computed Tomography (CT) lung cancer screening round that was initiated from 2009 to 
2012 1. In total, 80.7% (5,437/6,735) accepted the invitation, of whom 97.1% (5,279/5,437) 
attended the final screening round. 
In total, 5,380 CT scans were performed of which 5,279 were regular round scans and 101 
were follow-up scans to assess the volume-doubling time (VDT) of indeterminate nodules. 
The lung cancer detection rate in the fourth screening round was 0.8% (43/5,380). The 
positive predictive value (PPV) was 41.0% and the false-positive rate after positive screening 
was 59.0%. 
In this final screening round, 46 screened-detected lung cancers were detected in 43 
participants. Of these cancers, 60.9% were diagnosed in stage I, 15.2% in stage II, 10.8% in 
stage III, and 13.1% in stage IV. Approximately half of the lung cancers in round four were 
adenocarcinomas, 21.7% were squamous cell carcinomas (SQM), 8.7% bronchoalveolar 
carcinomas (BAC), 6.5% small cell carcinomas (SCLC), 8.7% non-small cell carcinomas not 
otherwise specified (NSCLC NOS), and in 4.4% no histological diagnosis was possible. 
The adenocarcinomas tended to be more frequently detected in lower stage (stage I-IIIa) 
compared with SCLC which were mostly diagnosed in stage III/IV (p=0.06). Age (p=0.81), 
gender (p=0.38), current smoking (p=0.89) and starting age of smoking (p=0.28) had no 
influence on the stage at time of diagnosis. 
In the 2.5 years between the third and fourth screening round, 28 participants were diagnosed 
with an interval cancer. The majority of these participants (16/28) received the diagnosis in 
the last six months before the final fourth screening round took place. Participants with an 
interval cancer in the first 24 months were slightly younger than the participants with an 
interval cancer in the last six months (64.2 vs. 65.4 years, p=0.05). 
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Interpretation of the results 
Compared to the first three rounds, the participation rate in the final screening round was 
slightly lower 1-3. The original NELSON study protocol consisted of only three CT screening 
rounds 4. Therefore, it was necessary to obtain a second informed consent form for this 
additional screening round. Only those participants who were still alive after the third 
screening round and from whom the updated addresses were known were invited to participate 
in the additional fourth screening round. Excluded were those diagnosed with lung cancer 
in the first three rounds, an interval cancer and those who passed away in the meanwhile 2, 
3, 5. Thus, the high non-response rate may have been caused by factors such as lung cancer 
diagnosis, the traceability of participants (e.g. updated information about the whereabouts 
could not be retrieved for a small percentage of the study population), and less interest for an 
additional fourth screening round at the time of dispatching the invitation, which was almost 
six years after randomisation and about 2.5 years after completing the first three screening 
rounds. In this study, it was also observed that participants with solely negative screening 
results were possibly more interested to participate in the additional fourth screening round 
compared to those with at least one non-negative result (and without lung cancer) in the first 
three rounds. Moreover, a higher proportion of current smokers at randomisation attended 
the final screening round compared with former smokers. This may support the idea that 
lung cancer screening may have an unintended health certificate effect (e.g. a negative screen 
outcome permits to continue smoking) in some participants 6. Therefore, a smoking cessation 
intervention should be integrated with lung cancer screening. 
The lung cancer detection, PPV and false-positive (FP) rates did not significantly differ between 
the four screening rounds 2, 3, 5. However, the true positive (TP/ FP) ratio tended to improve 
across the first three rounds from 0.69 to 0.83 and declined in the fourth screening round 
to 0.69. This was caused by a slightly (non-significant) increased FP rate in the final round 
compared to the third screening round (from 54.5% to 59.0%). The longer screening interval 
of 2.5 years may have led to more abnormalities of which the discrepancy between benign and 
malignant was not obvious. However, a lower proportion of screening in round four led to 
an indeterminate or positive scan result than screening in round three. This could be due to 
the NELSON nodule management screening protocol, in which the radiologists were allowed 
to categorize stable abnormalities across the previous screening rounds as negative in the 
final screening round 4, 7. So far, it is unknown if these stable abnormalities have progressed 
to an interval cancer diagnosis after the final screening round. Another explanation of lower 
proportion of indeterminate or positive scan results in the final screening might be the high 
interval cancer rate in the last six months before the fourth screening round took place. 
In total 2.0% of the scans across the four screening rounds were positive, which is comparable 
to the Danish Lung Cancer Screening Trial (DLCST) 8, 9. The DLCST used an adapted version 
of the NELSON nodule management protocol. Compared to the National Lung Screening 
Trial (NLST), the overall positive screening result (2.0% vs. 24.4%) and the false positive rate 
(59.4% vs. 96.4%) after a positive screening was substantially lower in the NELSON trial 10, 11. 
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This difference can be explained through the use of a volumetric nodule management protocol 
in the NELSON trial, in which the volume, the volume growth and VDT of the nodule was 
determined to evaluate the potential malignancy of the nodule 4, 12, while in the NLST the 
nodules were classified according to their diameter 13. Moreover, the NELSON nodule protocol 
allowed the radiologists to first categorize the nodule into three categories, depending on a 
set of features of the nodule defined prior to screening as negative, indeterminate or positive. 
After a follow-up scan, the indeterminate screening result was classified as negative or positive. 
In contrast, the use of the NLST nodule management protocol resulted in two categories: 
negative or positive 13. The NELSON approach in which a third category (indeterminate) and 
a volumetric nodule approach were used, probably led to less positive scan results and to less 
false-positive results after a positive screening result 3, 5. The NELSON cumulative lung cancer 
detection rate is 3.2%, which is comparable to the DLCST, which used five annual screening 
rounds 1, 8. Relative to the NLST, the lung cancer detection rate in the NELSON trial was 
higher (2.4% vs. 3.2%). However, the NLST only had three annual screening rounds and the 
NELSON screening protocol consisted of four screening rounds with increasing screening 
lengths 10, 11. 
Previous NELSON analyses 2, 3 showed that the 2-year screening interval after the second 
round did not lead to significantly more advanced stage lung cancer compared to the 1-year 
screening interval after the baseline screening 3. However, the 2.5-year screening interval led to 
significantly more stage IIIb/IV cancers compared to a 1-year screening interval 1. Moreover, 
the interval cancer rate was the largest in the 2.5-year screening interval: 1.47 times higher 
than in a 2-year screening interval. In the last six months before the fourth screening round 
took place the interval cancer rate was 1.3 times higher than in the first 24 months after the 
third screening round, suggesting that a 2.5-year interval is too long. 
Relative to the other lung cancer screening trials, the cumulative stage distribution of the 
screen-detected lung cancers appears to be more favorable in the NELSON trial: more cancers 
are diagnosed in stage I (69.4%) compared to the NLST (61.6%) and the DLCST (68.1%), 
and less cancers are staged IIIb/IV (9.8% vs. 20.0% and 15.9%, respectively) 8-11. These 
findings should be interpreted with caution, as the 7th edition of the TNM staging system was 
used in the NELSON trial, whereas the 6th edition was used in the NLST, complicating the 
comparison. The 7th edition led more cancers to be categorized in a lower stage than according 
to the 6th edition 14. On the other hand, fewer females were included in the NELSON trial, 
while females with lung cancer have a more favorable prognosis and are more often diagnosed 
with relatively slow-growing cancers 15. Furthermore, the overdiagnosis rate has yet to be 
determined in the NELSON trial. In the NLST 18.5% of the screen-detected lung cancers are 
being reported as overdiagnosis 16. 
Conclusion 
A 2.5-year screening interval after a third screening round reduces the effect of screening. 
In the final screening round, significantly more advanced staged lung cancers were detected 
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as compared to a 1-year screening interval. A similar unfavorable stage distribution of the 
screen-detected lung cancers was noted when compared to a 2-year screening interval, 
however not statistically significant. Not only were there more interval cancers diagnosed in 
the 2.5-year screening interval compared to one-year and two-year screening intervals, but 
the largest proportion of interval cancers was diagnosed in the last six months of the 2.5-year 
screening interval. 
II. Risk stratification
Main research question 
2. Which NELSON subgroups with different risks for detecting lung cancer can be 
identified based on their previous screening history? 
Main results 
The probabilities for the screening outcome and risk for detecting lung cancer in the fourth 
screening round were calculated based on the regular scan results of the first three rounds 
and of the third scan result only 17. The regular scan results are the initial screening results of 
each round, in contrast to follow-up scans, which were performed to determine the growth in 
order to classify the indeterminate scan result as negative or positive. 
Risk stratifications based on the results of the first three screening rounds
Only those participants who were screened in both the first three rounds and as well as in 
the fourth screening round were included in this analysis. Three subgroups were identified 
based on the regular scan results of the first three rounds: 1) participants with only negative 
scan results (n=3,856); 2) participants with at least one indeterminate scan result, but never a 
positive scan result (n=1,342); and 3) participants with at least one positive scan result (n=81). 
Participants with only negative scan results were significantly younger than the other two 
subgroups (57.0 year vs. 58.0 year, p>0.001). The third subgroup had smoked slightly more 
pack-years than the other subgroups (38.7 years vs. 38.0 years, p=0.02). The second subgroup 
(odds ratio (OR) 1.89, p=0.001) and the third subgroup (OR 3.77, p<0.001) had significantly 
higher ORs to receive a non-negative (indeterminate or a positive scan result) scan result in 
the fourth screening round compared to the first subgroup with solely negative scan results 
so far. 
In multivariate analysis, screening history (p<0.001) and smoked pack-years (p=0.02) 
remained significant predictors for the regular scan result in the final fourth screening round. 
No interaction was found between the variables screening history and smoked pack-years 
(p=0.89). 
The OR for detecting lung cancer in the final fourth screening round for the second subgroup 
2.77 (p<0.001) relative to first subgroup with solely negative scan results so far. In the final 
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screening round, no lung cancer was detected in third subgroup. 
In total, 43 participants had a screen-detected lung cancer in round four. So far, 51.2% (22/43) 
of these participants had solely negative scan results in the previous three screening rounds. 
In 20 out of these 22 participants, the screen-detected lung cancer arose from a newly detected 
nodule in the final screening round. The other 21 participants with a screen-detected lung 
cancer in round four, had in the first three screening rounds at least one indeterminate but 
never a positive scan results. In 12 out of these 21 participants the lung cancer was detected in 
a newly detected nodule in the final round. 
Participants with only negative scan results in the first three rounds were stratified for their 
smoked pack-years. Six categories were made: ≤25 years, 26 to 30 years, 31 to 35 years, 36 to 
40 years, 41 to 45 years and >45 years. A history of smoked pack-years of up to 45 years led 
to a lung cancer risk detection in the fourth screening round of between 0.2% and 0.7%. For 
those who smoked more than 45 pack-years (n=1,091), the lung cancer detection rate in the 
fourth round was 1.1% (p=0.04). 
Risk stratification based on the scan results of the third round only 
The probability for detecting lung cancer in the fourth round for the participants with a negative 
third scan result was 0.6%, which was significantly lower compared to the participants with 
an indeterminate scan result in round three (3.7%, p<0.001). No lung cancer was detected 
among those participants with a positive scan result in the third round. 
Participants with a screen-detected lung cancer
Across all four screening rounds, 243 out of 7,582 participants were diagnosed with a total of 
255 screen-detected lung cancers. Those with a screen-detected lung cancer were older (61.0 
years versus 58.0 years, p<0.001) and had smoked more pack-years (44.0 versus 38.0 years, 
p<0.001) compared with those without a screen-detected lung cancer. 
Furthermore, when regular scan results from all four screening rounds were combined, in 
28.4% from the screen-detected lung cancers cases had ≥1 indeterminate scan result (but 
never a positive test result initially) and 71.6% had ≥1 positive scan result (this group also 
contains those with once a negative or an indeterminate result) before diagnoses of lung 
cancer.
Interpretation of the results
The probability for receiving a non-negative scan result in the fourth screening round for 
those with at least one indeterminate (but never a positive scan) result and for those with at 
least one positive result in the first three screening rounds was higher compared to those with 
only negative scan results in the first three screening rounds. Furthermore, higher age and 
more pack-years smoked were both significant predictors for a non-negative scan result in 
the final screening round. As found in previous analysis of the first three screening rounds 3. 
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Retrospectively, for those with solely negative scan results in the first three rounds and for 
those with a negative third round scan result, the risk for detecting lung cancer in round four 
was lower than 1%. This lung cancer detection risk is approximately the same as across all the 
screening rounds for the whole screen group: 0.9% in round 1, 0.8% in round 2, 1.1% in round 
3 and 0.8% in round 4 1-3. In other words, those with previous solely negative scan results and 
those with a third negative scan result may not require subsequent screening for more than 
2.5 years. 
On the other hand, almost 90% of the participants in the group with solely negative scan 
results had a screen-detected lung cancer in the fourth screening round which grew from 
a nodule first described in the fourth screening round (new nodule). One explanation of 
evolving lung cancer from a new nodule is the “field cancerization” theory, in which it is 
assumed that large areas of the bronchial epithelium are affected by smoking, leading to areas 
with metaplasia and dysplasia which sometimes can turn into cancer. Furthermore, Walter 
et al. showed that at each screening round (round two and round three) about 5-7% of the 
screened participants had a new solid nodule in the NELSON trial 18. This new nodule had a 
higher probability of malignancy even at a small size compared to baseline nodules: in round 
two and three a total of 1,222 new solid nodules were registered in 787 participants. In 49 
(6%) participants the lung cancer grew from a new solid nodule, which represents 4% of all 
the new solid nodules. Moreover, new solid nodules with a volume of larger than 27mm3 had 
a lung cancer probability of 3.1% to 16.9%. This volume cutoff is smaller than the cut-off of 
50mm3 in the NELSON nodule management protocol 4. In conclusion, they suggested a more 
aggressive follow-up strategy in fourth round screen-detected lung nodules than baseline 
nodules with a short term follow-up for growth assessment. So, the risk for detecting lung 
cancer after an interval of 2.5 year is 1.1% at the most but on the other hand more lung cancers 
are detected in a new solid nodule which needs a more aggressive follow-up. Modeling will 
hopefully provide more insight in the best scenario. 
Only the NELSON trial used different screening intervals in one screen group until now. 
Therefore, comparison with other lung cancer screening trials is difficult. However, in a recent 
retrospective analysis the NLST did show that participants with a negative baseline scan result 
had a lower incidence of lung cancer at baseline as well as a lower lung cancer detection 
rate in the second and third screening round (0.34%), compared to all screened participants 
(1.0%) 19. Furthermore, it showed that those with solely negative scan results across the three 
screening rounds had an even lower lung cancer incidence and mortality rate than those with 
a negative baseline scan result. This suggests that is it indeed possible to identify subgroups 
with significantly different lung cancer probabilities based on the screening history. 
In conclusion, screening history might be used for further risk stratification of subjects who 
undergo lung screening and it may lead to a better harm-benefit ratio for a large part of the 
screened population (e.g. reducing the number of scans needed). 
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PART II: INTERIM STAGE SHIFT RESULTS IN THE NELSON TRIAL
III. Cancer stage shift and treatment shift 
Main research question 
3. What is the level of cancer stage and treatment shift between the two study groups? 
Main results
The first 100 lung cancers diagnosed in the screen group were compared with the first 100 
diagnosed lung cancers in the control group. The lung cancers in the screen group were 
diagnosed a year earlier on average than the lung cancers diagnosed in the control group 
(2005 vs. 2006, p<0.001). 
More favorable outcomes were observed in the screen group, when comparing the screen and 
control group: more stage I (59.0% vs. 19.0%) and less stage IV (6.0% vs. 48.0%) lung cancers 
were found in the screen group. Furthermore, a higher proportion of adenocarcinomas (45.0% 
vs. 27.0%) and bronchoalveolar carcinomas (BAC; 3.0% vs. 0.0%) were observed in the screen 
group (p<0.001). Also,  significantly lower proportions of squamous cell carcinomas (SQM; 
21.0% vs. 25.0%), large cell carcinomas (11.0% vs. 19.0%) and small cell carcinomas (SCLC; 
2.0% vs. 18.0%) were observed in the screen group compared to the control group (p<0.001). 
Stage I cancers stratified for each study group showed that the proportion of stage Ia cancers 
was the highest for the screen group (91.7% vs. 47.4%, p <0.001) compared to the control 
group. No differences were found in histology of stage I (p=0.13) lung cancers between the 
screen and control group. 
Screen group lung cancer patients received a (potentially curative) surgical treatment more 
often regardless of the stage (67.7% vs. 24.5%, p<0.001). Even stratified for stage Ia, screen 
group participants received more often a (potentially curative) surgical treatment than control 
group participants (82.7% vs. 50.0%, p=0.06; data not shown). No difference was seen in age 
at diagnosis, smoking status and co-morbidity between the screen group and control group 
participants with stage Ia cancer. 
Compared to the same Dutch birth cohort with lung cancer, the lung cancers diagnosed in the 
control group were diagnosed in a slightly earlier stage (stage I or stage II, 29.1% vs. 32.5%, 
p<0.001). No difference was observed in the first lung cancer treatment between the lung 
cancer patients of the NELSON control group or the comparable Dutch birth cohort. 
Interpretation of the results
CT screening for developing lung cancer in high risk subjects has led to a shift in terms 
of early detection of lung cancer compared to no screening. Not only were more cancers 
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detected at an early stage (stage I), but also less advanced staged cancers were found (stage IV) 
in the screen group. Furthermore, early detection of lung cancer enhanced the probability of a 
(surgical) treatment that is more likely to be curative in the screen group. 
Compared to the NLST, the cancer stage shift in the NELSON trial is substantially more 
favorable: more stage I cancers (60.0% vs. 50.0%), and less stage IV cancers (6.0% vs. 21.7%) 
were detected in the NELSON 1-3, 5, 10, 11. The NELSON trial used the 7th TNM staging system, 
whereas the NLST used the previous 6th TNM staging system, which might explain part of this 
difference 14. On the other hand, in the NELSON trial fewer women were randomized (due 
to study selection criteria) compared to the NLST, while women are often diagnosed with 
lung cancer at a lower stage 15. Furthermore, the NELSON screening protocol consisted of 
increasing screening intervals between the four screening rounds, while the NLST screening 
protocol consisted of three annual screening rounds 4, 13. However, current NELSON analysis 
includes only the first 100 lung cancers of each study group. Thereby the second screening 
round was still running in the screen group. Altogether, this sub study showed that it seems 
that the NELSON screening strategy is at least as capable as the NLST to diagnose lung cancer 
at a more favorable stage compared to the current setting (no screening) in the Netherlands 
and Belgium. 
Studies have shown that up to 25% of the CT screen-detected lung cancers are relatively slow-
growing tumours of which up to 80% are adenocarcinoma or BAC 16, 20, 21. In the current 
NELSON analysis, 48.0% of the lung cancers in the screen group are relatively slow-growing 
tumours, of which 93.8% are adenocarcinomas. Detection of more relatively slow-growing 
tumours may lead to weakening of the effect of screening and may result in overdiagnosis 
and overtreatment 16, 22. On the other hand, screening has also led to more SCLC being 
diagnosed in a lower stage compared to the control group lung cancers. Further studies are 
needed to investigate the histology shift in more depth and to determine the proportion of 
overdiagnosed lung cancers in the NELSON trial. 
As lung cancer is mostly diagnosed clinically in an advanced and often metastasized stage, 
it is surprising to observe that in 19.0% of the lung cancer cases in the control group it was 
diagnosed in stage I. To be diagnosed in such a low cancer stage, the participant should have 
been under any kind of supervision of a specialist (e.g. treatment of COPD). However, this 
aspect was not investigated in this sub study. 
Furthermore, screen group participants with a stage Ia lung cancer underwent more often a 
surgical treatment than control group participants with a stage Ia lung cancer. No difference 
was seen in age at diagnosis or in co-morbidity (such as cardiovascular diseases or COPD) 
between these groups of participants. 
This sub study showed that clinically diagnosed lung cancer in the comparable general 
Dutch population was diagnosed slightly at a higher stage than in the NELSON control 
group participants. One potential explanation is the study eligibility in which subjects with a 
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history of cancer (lung cancer in the past five years or longer than five years ago but still under 
treatment, or those with renal cancer, melanoma or breast cancer) or those with a moderate 
or bad self-reported health who were unable to climb two flight of stairs and those with a CT 
chest examination less than one year ago before they filled in the NELSON questionnaire 
were excluded from participation in the NELSON trial 4, 23. As the actual difference in stage 
between the NELSON control group and the Dutch comparable birth cohort is small, it is 
expected that the NELSON trial end results will be generalizable for the target population. 
In conclusion, LDCT screening in the NELSON trial has so far led to a substantial favorable 
shift in cancer stage at time of diagnosis. Implementing of lung cancer screening will lead 
to higher rate of early stage lung cancers, and subsequently a shift in treatment options 
from mainly advanced disease stage treatment (e.g. palliative) to curative treatment (mainly 
surgery).
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PART III: THE CAUSE OF DEATH OF THE NELSON PARTICIPANTS
IV. Healthy participant effect and mortality profile 
Main research question 
4. What are the differences in characteristics and mortality profile of NELSON 
participants and eligible non-responders? 
Main results 
A total of 7,435 Dutch control group participants and 13,661 Dutch eligible non-responders 
were compared regarding background variables such as age, educational level, and smoking 
history 24. Non-responders were those who met the eligibility criteria of the NELSON trial but 
who did not provide informed consent and who did not participate in the trial. 
The NELSON participants were younger (p<0.001), more often male (p<0.001), had a better 
self-reported general health (p=0.002), had a higher level of physical exercise (p<0.001), had 
a higher level of education (p<0.001), and were more often former smokers (p<0.001) as 
compared to the Dutch eligible non-responders. 
Smoking duration was lower among participants (p<0.001), whereas numbers of cigarettes 
smoked per day was higher among participants (p<0.001). Participants started smoking at a 
younger age (p<0.001) and were more willing to quit smoking than eligible non-responders 
(p<0.001). Among current smokers, participants were more often in an advanced stage- 
according to the stages of change- to quit smoking compared with eligible non-responders 
(p<0.001). Participants reported significantly more smoking-related symptoms (p = 0.04) and 
had undergone a pulmonary function test more often (p<0.001). However, no differences 
were seen in the self-reported outcome of these pulmonary function tests (p=0.28).
Until January 2013, significantly more Dutch eligible non-responders deceased than NELSON 
control group participants (11.2% vs. 9.1%, p<0.001). The mortality rate due to all types of 
cancer (7.59 vs. 6.32, p=0.002), cardiovascular diseases (3.32 vs. 2.05, p<0.001), respiratory 
diseases (0.73 vs. 4.4, p=0.018), and non-cancerous diseases other than cardiovascular and 
respiratory (2.19 vs. 1.30, p<0.001) was highest in the Dutch eligible non-responders. The 
proportion of deaths due to cancer was higher among participants (62.4% vs. 54.9%). 
Interpretation of the results
This study determined whether the NELSON trial end results (mortality results) are 
generalizable to the target Dutch population for lung cancer screening. 
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In line with previous cancer screening trials 25-34, a small healthy participant effect in the 
NELSON trial was observed: the NELSON participants were significantly slightly younger, 
had a better self-reported health, were more psychically active, and were higher educated 
compared with eligible non-responders. 
In contrast to the DLCST and the ITALUNG, less current smokers participated in the 
NELSON trial 26, 28. On this matter, the DLCST reported that despite more active smoking, 
DLCST participants were more willing to quit than non-participants (a representative sample 
from the Danish population), suggesting that smokers who are motivated to quit smoking 
are more inclined to volunteer in a screening trial 28. This is supported by our finding that 
among current smokers, participants were more often in an advanced stage -according to 
the staged of change- to quit smoking compared with eligible non-responders. On the other 
hand, other studies have shown that active smoking is a barrier to undergo screening for lung 
cancer 30, 35. Moreover, those with a lower socio-economic status and a lower educational level 
are more likely to smoke. Future studies are needed to further assess the interactions between 
socioeconomic status and active smoking on attitudes toward lung cancer screening
Eligible non-responders had a higher all-cause mortality and mortality due to four other 
mortality classifications. However, the relative proportion of subjects that died due to all types 
of cancer was higher among participants. This might be explained by a higher alcohol abuse 
among participants, which is associated with a higher relative death from cancer 36. Moreover, 
higher alcohol consumption is also related with a higher socioeconomic status and a higher 
educational level of achievement 37. Another explanation could be that the participants 
reported more smoking-related symptoms, (e.g. dyspnea and hemoptysis) which may have 
led to more doctor consults. Hence, may leading to more participants to quit smoking 
and could have facilitated the detection and early treatment of cancer, cardiovascular, and 
respiratory diseases. However, the younger age, healthier lifestyle, a higher educational level 
and a better self-reported health among participants may have led to a higher contribution 
to the difference in mortality profiles between the NELSON participants and eligible non-
responders. 
In conclusion, the NELSON study participants are somewhat younger, healthier, higher 
educated and more willing to participate in a screening program than the eligible non-
responders as expected . These differences have influenced the mortality outcomes of both 
groups. However, the differences are modest and therefore it seems unlikely that these 
differences will influence the overall generalizability of the main results of the NELSON trial 
towards the target population. 
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PART IV: CAUSE OF DEATH VERIFICATION PROCESS 
Main research question 
5. What is the outcome of the Cause of Death verification process in the NELSON trial, 
and how does it relate to the official death certificates? 
Main results 
The clinical expert committee (CEC) of the NELSON trial consists of mainly two members 
who independently of each other reviewed 266 medical files of Dutch deceased NELSON 
trial participants 38. A decisional-flow chart and a detailed list of criteria were used to make a 
decision in a uniform matter 39.
Based on six possible outcomes (defining the graduation of certainty that lung cancer was 
the primary cause of death (CoD)) an agreement between the two members was reached in 
71.1%. Divided in a lung cancer specific death (definitely or probably lung cancer death) and 
in other CoD (possible, unlikely or definitely no lung cancer death, and intercurrent death 
with lung cancer as a contributing factor) agreement between the two members was reached 
in 86.1%. The latter corresponds with a Cohen’s kappa of 0.57 (95%CI, 0.45-0.69, p<0.001). 
Cases without agreement were discussed in a consensual meeting. No third reviewer was 
necessary to reach consensus. 
Compared to a previously performed pilot study, in which two members of the NELSON trial 
tested the utility of the decisional flow-chart, seven out of 49 cases showed no agreement in the 
CoD 39. These seven cases needed a re-evaluation by the CEC and the clinical epidemiologist 
from the pilot study. 
Comparison of the CoD by the CEC and the CoD according to the official death certificates 
showed an overall sensitivity and specificity of the death certificates of 92.6% and 98.8%, 
respectively. CoD review by a CEC resulted in a reclassification of 12.2% of the cases. In 15 
out of these 32 (46.9%) cases, the CEC reclassified the CoD to a lung cancer specific death 
instead of ‘other CoD’ as noted on the official death certificate. In the other 17 cases (53.5%), 
the CEC reviewed the CoD as ‘another CoD’, while according to the official death certificate 
the UCD was lung cancer death. 
Interpretation of the results
In the NELSON trial all medical files of the selected deceased participants were independently 
reviewed by two members (in a blinded and uniform manner). A weak to moderate agreement 
between the two members was observed, which slightly increased with the number of cases 
they evaluated. This underlies the need that each death should be reviewed by at least two 
independent experts. The results are in line with the NLST, in which 42% of the deaths were 
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reviewed and a sensitivity of 91% and a specificity of 97% of the official death certificates were 
reported 40, 41. However, in their death review process initially only one member reviewed the 
medical files. Only those cases without concordance with the official death certificate were 
reviewed by a second member. 
Furthermore, less deaths were re-classified in the NELSON trial compared to the NLST 
(12.2% vs. 26.0%) 40, 41. The NLST showed a higher reclassification of deaths to lung cancer 
specific deaths than the NELSON trial (22.0% vs. 6.5%). This may suggest that in the 
Netherlands a higher accuracy of clinicians is seen regarding reporting deaths related to lung 
cancer or due to other causes of death. However, in the NELSON trial, so far, fewer cases 
have been reviewed. Moreover, the NLST showed that the mortality benefit of screening did 
not significantly change with reviewing the CoD 41. As the primary endpoint results of the 
NELSON trial have yet to be analyzed, the CoD review process will be continued and is until 
then not known by study arm. 
Comparison with other lung cancer screening trials (DLCST and DANTE) was not possible, 
as in both trials a protocol about the death review process and information regarding 
reclassification after the review of the CoD was not available 8, 42. 
In conclusion, for large randomized cancer screening trials it is necessary to review the 
cancer-specific cause of death due to the official death certificate reports varying accuracy 
(sensitivity and specificity). In the NELSON trial, so far, the results indicated that possible 
biases related to lung cancer death seem relatively small. Furthermore, it is recommended that 
the death review of each case should be done by at least two members, independently and in 
a uniform and blinded manner. 
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Strengths 
Population-based randomized-controlled trial 
One of the main strengths of this study is the population-based randomized-controlled setting 
of the trial, in which large numbers of participants are randomly allocated to either the screen 
or control group 4. The use of this study design is considered the most preferable one 43. Only 
in a randomized-controlled setting, disease-specific mortality between the screened and the 
unscreened population can be compared, without lead-time, length-time and overdiagnosis 
biasing the comparison between the two groups. Moreover, randomisation is assumed to lead 
to a comparable distribution of both known and unknown factors in the two groups which 
are being compared. Observational studies are prone to different biases and thus to erroneous 
study results 44. 
Secondly, in volunteer-based recruitment, volunteers are unlikely to be representative of the 
target population. Moreover, those not motivated to volunteer may be particularly important 
to reach. A population-based recruitment method has therefore been used in the NELSON 
trial 4, 6, 23. It allows the results to be generalizable to the whole target population. 
Comparison with no intervention 
Another major strength of this study is that the control group never received any form 
of screening or contact with the screening site 4. For example in the Danish Lung Cancer 
Screening Trial (DLCST) the control group received annually spirometry and attended 
yearly the screening site at which the smoking status was determined along with other 
assessments 9. The NELSON control group received usual care, which consists of no regular 
chest examinations by a chest radiography or CT scan. This allows an unbiased lung cancer 
incidence comparison between the two study groups. However, as mentioned in this thesis, 
the NELSON control group participants were for example younger, healthier and were more 
often former smokers than the eligible non-responders. This might overestimate the impact 
of screening.
The nodule management and screening protocol 
The volumetric-based nodule management with the inclusion of an indeterminate test result 
in the NELSON trial has led to less false-positive results compared to the other lung cancer 
screening trials, which used a diameter-based nodule management 1, 5, 8, 10-12, 45. Less false-
positive results means less invasive diagnostic procedures necessary to distinguish between a 
benign and malignant nodule. Moreover, it has led to identification of subgroups with different 
risks for detecting lung cancer in a subsequent screening round 3, 17. These findings are useful 
to optimize the harm-benefit ratio of a lung cancer screening programme. For example, not 
all eligibles for a CT lung cancer screening need to undergo it on yearly base. Some may have 
a better harm-benefit ratio if they undergo screening with a longer screening interval. 
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The NELSON trial is the only lung cancer screening trial with the use of increasing screening 
intervals in one screen group 4, 12. Therefore, it has a unique opportunity to investigate the test 
characteristics and cost-effectiveness of each screening round over time 1, 2, 5. Consequently, 
this information is also useful to optimize the harm-benefit ratio of a lung cancer screening 
programme. 
The follow-up period 
The NELSON trial intends to have a long follow-up period of ten years before the mortality 
analysis will follow 4. To observe a lung cancer incidence difference in both groups over time, 
and to assess the excess incidence rate and the overdiagnosis ratio, it is necessary to have a 
long follow-up period 16, 46. 
Finally, the cause of death (CoD) review process is being performed in a blinded and uniform 
matter 39. This allows the reviewers to evaluate the medical files without the knowledge 
whether the participant was randomized in the screen group or control group. During the 
review process all relevant medical data was accessible online by all members of the review 
committee. Moreover, during the review process the review committee had no access to the 
official death certificates, allowing them not to be biased. 
Limitations
Study protocol 
Regardless of the important strengths of this study, there are also some limitations. Lung 
cancer screening has been argued as a teachable moment for smoking cessation. At baseline 
some smoking related questions were assessed from the whole study population. The impact 
of screening on smoking abstinence was investigated previously by follow-up questionnaires 
after two and four years of the start of the study 6, 47. The results suggested that lung cancer 
screening was a potential teachable moment for smoking cessation. However, this was only 
assessed in a small sample and there is a remaining concern that participants may experience 
a false feeling of reassurance after lung cancer screening. 
In the first recruitment only males were invited to participate in the NELSON trial resulting 
in less females being included in the NELSON trial compared to some other lung cancer 
screening trials 4, 9, 13. Our results are therefore mostly applicable to males in general, although 
post-hoc analysis of the NLST showed only weak evidence for differences in the impact of 
lung cancer screening by sex 48. 
Self-reported data was used to recruit study participants. Self-reported data is a commonly 
used method for data collection, however the use of self-reported data is often under 
discussion at is depends on how accurately the (retrospective) data is reported by the subject 
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49. Furthermore, questions about the socioeconomic class were limited, and no questions were 
asked about the ethnic background or psychosocial profile as it is known that among the non-
Caucasian subjects the participation rate in screening programs is lower 50-53. 
The participation rate 
As expected in a long running screening trial, the participation rate in the screen group 
dropped from the first to the final fourth screening round. One explanation therefore is that a 
large number of participants was not traceable by the end of the third screening round. During 
the study course, the last update of the actual addresses of the study participants was held in 
2006 during an intensive period with retrieving updated information from approximately 100 
communities, while the end of the third round was in 2009. Unfortunately, at the moment of 
dispatching the second informed consent and an invitation letter to participate in the added 
fourth screening round, it was not possible to have direct access to their actual addresses by a 
linkage with the GBA administration. Therefore, it is unknown whether these non-responders 
were willing to participate or not. 
Eligible non-responders
Next, only aggregated data was available from Statistics Netherlands for the eligible non-
responders group to compare it with the mortality outcome of the NELSON control group 
participants. Therefore, it was not possible to perform multi-variate analyses in detail. However, 
mortality profile differences between the NELSON control group participants and eligible 
non-responders are modest and will therefore probably not influence the generalizability of 
the NELSON trial end results. 
Cause of death verification process
Currently, only the medical files of deceased NELSON study participants with lung cancer 
are being reviewed concerning their cause of death 39. Medical files of deceased participants 
without lung cancer are not being reviewed by the clinical expert committee. Therefore, 
it is unknown whether the cause of death process outcome is generalizable to the whole 
study population. On the other hand, cancer-specific death verification is a commonly used 
approach as verifying all death cases is very time-consuming 40, 54. 
Pending mortality analysis 
The NELSON screening strategy is at least as capable as the NLST to diagnose lung cancer at 
a more favorable stage compared to the control group with no intervention. Moreover, it has 
led to a shift in treatment options from mainly advanced disease stage treatment to curative 
treatment. However, at this moment it is impossible to investigate the correlation between 
stage shift, treatment shift and lung cancer mortality reduction. 
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General conclusions from this thesis 
- A 2.5-year screening interval after a third screening round seems to reduce the possible 
effect of lung cancer screening. The screen-detected lung cancers were significantly 
more often diagnosed in an advanced disease stage compared to a one-year screening 
interval. 
- The screening history may be used as a risk stratification tool to refine the screening 
protocol for subgroups of people who undergo screening. 
- Low-dose Computed Tomography screening in the NELSON trial has led to a favorable 
cancer stage shift between the screened group and unscreened group. Subsequently, 
screening has also led to more treatment (e.g. curative) options for lung cancer. 
- A small healthy participant effect has been observed in the NELSON trial. Although 
the actual numerical differences were minimal. Therefore, the study results seem 
applicable to the target population. 
- Comparison of the independently reviewed blinded medical files (for patients’ 
identity and study group) of the deceased NELSON participants with the official death 
certificates showed that possible biases related to lung cancer death seem relatively 
small. It is recommended that each death should be reviewed independently by at least 
two clinical experts. 
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General recommendations for research and implementation 
- Future research is recommended to investigate how to reach the population who 
is (not) willing to participate, as it necessary to increase the participation of those 
who are expected to benefit the most from lung cancer screening. Moreover, the 
target population is a unique population consisting of long-term smokers who have 
increased risk to have smoking-related comorbidities and may experience stigma and 
battle nicotine addiction. 
- Recruitment of a high risk group based on smoking history requires the willingness 
of participants to share information of their smoking history. Future research should 
focus on obtaining this crucial information (e.g. web based registration system or 
personal contact). 
- Screening history seems to be a useful risk stratification tool; however this should be 
investigated further, for example in the currently implemented lung cancer screening 
in the United States. Moreover, it is unknown if a longer screening-interval for certain 
subgroups is cost-effective. 
- The National Lung Screening Trial (NLST) and the NELSON trial used the two most 
significant predictors of lung cancer risk: age and smoking history. However, addition 
of other epidemiological risk factors, such as used in the UK Lung Cancer Screening 
pilot trial (UKLS) (a 5-year lung cancer risk of ≥5% based on the LLPv2) should be 
tested in a pilot study, as this may increase the cost-effectiveness of a lung cancer 
screening programme. 
- The lung cancer detection rates and the stage distribution of the screen-detected lung 
cancers in the NELSON trial are at least as favorable as in the NLST. However, the 
mortality analyses of the NELSON trial are pending. These results are necessary to 
verify the mortality reduction as shown by the NLST. 
- Pooling data of the European lung cancer screening trial is suggested to obtain more 
information about the cost-effectiveness of several subgroups. 
- Screening leads to more cancers being detected at an early stage. This opens the field 
and need for more development of minimal invasive treatment options in early lung 
cancer. 
- Smoking cessation is not only the most effective primary prevention method for lung 
cancer, but it is also for cardiovascular diseases and Chronic Obstructive Pulmonary 
Disease (COPD). When implementing lung cancer screening, smoking cessation 
counseling or a smoking cessation program should be an integrated part of it. 
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- An evaluation should be done to estimate the demand of specialists related to a lung 
cancer screening programme (e.g. general practitioners, radiologists, pulmonologists 
and pathologists) in Europe. Furthermore, structured data collection is necessary for 
a successful screening program. 
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SUMMARY
 
Lung cancer is the leading cause of cancer death among males and second leading cause of 
cancer death among females worldwide. The most important risk factor for lung cancer is 
smoking, causing approximately 85% of all lung cancer cases. Smoking cessation or refraining 
from smoking is the most effective way to prevent lung cancer. Although the prevalence of 
smoking has decreased, approximately a quarter of the Dutch population above 18 years 
of age is a current smoker. Moreover, half of the lung cancer cases are currently diagnosed 
in former smokers. Clinically, lung cancer is often diagnosed in an advanced stage with a 
five-year lung cancer survival of approximately 15%. This underlines the need for secondary 
prevention for lung cancer: lung cancer screening. The United States Preventive Services 
Task Force (USPSTF) requested an independent review and an investigation of the long-term 
benefit and harms of different lung cancer screening policies. On the basis of this review and 
modelled screening policies, lung cancer screening has been implemented in the United States. 
However, in Europe there is a consensus to wait for the mortality results of the NELSON trial, 
the largest European lung cancer screening trial. 
Part I: the optimization of the NELSON screening rounds
The aim of the first research question was to investigate the added value of a fourth screening 
round with an interval of 2.5 years after the previous three screening rounds (Chapter II). 
Lung cancers diagnosed in the final screening round were compared with the lung cancers 
diagnosed in the second screening round (with a one-year screening interval) and with the 
lung cancers diagnosed in the third screening round (with a two-year screening interval). After 
a 2.5-year screening interval, significantly more lung cancers were diagnosed in an advanced 
stage compared with a 1-year screening interval. A similar unfavorable stage distribution of 
lung cancers was observed compared to a 2-year screening interval, though statistically not 
significant. Furthermore, a higher proportion of interval cancer was diagnosed in the 2.5-
year screening interval than in the 1-year and 2-year screening interval. Moreover, the largest 
proportion of interval cancers in the 2.5-year screening interval was diagnosed in the last six 
months before the final screening round took place. 
In the next chapter (Chapter III), it was investigated whether subgroups with different risk 
for a non-negative screening result and/or lung cancer detection in the fourth screening 
round could be identified based on their test results in the previous screening rounds. The 
probability of a non-negative result in the fourth screening round was the lowest for those 
with solely negative results, compared to those with at least one indeterminate (but never a 
positive) or at least one positive result in the first three rounds. Furthermore, those subjects 
with previous solely negative results and those with a third negative scan result may not 
require screening for more than 2.5 years, as the lung cancer detection rates in these groups 
were <1% in the fourth screening round. The use of previous screening test results to refine 
the screening protocol may lead to a better harm-and-benefit ratio for a large part of the 
screened population (such as reducing the number of scans needed). 
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Part II: interim stage shift results in the NELSON trial 
In Chapter IV, the level of cancer stage and treatment shift between the two study groups 
were investigated. The first 100 lung cancers diagnosed in both study groups were compared. 
Low-dose CT screening has led to a shift in terms of early detection of lung cancer compared 
with no screening. Not only were more stage I cancers diagnosed in the screen group, but also 
fewer stage IV cancers were diagnosed as compared with the control group. Subsequently, 
this stage shift has enhanced the probability of a curative treatment. The NELSON screening 
strategy is at least as capable as the NLST screening strategy to diagnose lung cancer at a more 
favorable stage compared to no screening. Yet it is unknown whether significant lung cancer 
and all-cause mortality reductions can be achieved amongst the NELSON study participants.
 
Part III: the cause of death of the NELSON participants
In the first section of this part (Chapter V), the differences in baseline characteristics and 
mortality outcome of the NELSON control group participants with the eligible non-responders 
for the NELSON trial were investigated. As expected, the NELSON study participants were 
somewhat younger, healthier, higher educated and more willing to participate in a screening 
program than the eligible non-responders. These differences influenced the cause of death 
of both groups slightly: the eligible non-responders had a higher all-cause mortality and 
mortality due to four other cause of death (cancer-related death, cardiovascular-related death, 
respiratory-disease related death, and other-cause related death). However, actual numerical 
differences were small and investigated subjects were large, and therefore it seems unlikely 
that it will influence the generalisability of the trial results. 
In the last section of this part (Chapter VI) the process of the verification of the Cause 
of Death (CoD) of the deceased NELSON study participants as well as the comparability 
with the official death certificates as provided by Statistics Netherlands were investigated. 
After an independent and uniform review of the blinded medical files of the deceased lung 
cancer patients, a weak to moderate agreement was observed between the two members. 
The agreement increased with the number of cases evaluated, which underlines the need to 
review all relevant death cases independently by at least two experts. Comparison of the CoD 
review process outcome with the official death certificates showed an overall sensitivity and 
specificity of the death certificates of 92.6% and 98.8%, respectively. In 12.2% of the cases 
the CoD was reclassified by the review committee, in which 46.9% of the cases the CoD was 
reclassified to a lung cancer specific death. In the NELSON trial, the results indicated that 
possible biases in CoD related to lung cancer seem relatively small. 
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DISCUSSION 
 
In Chapter VII, the main results were summarized and interpreted. Furthermore, the 
methodological considerations are discussed in the second part of Chapter VII and in the 
last paragraph, the general conclusion draw from this thesis and the implication for further 
research are presented. 
In the first part of this thesis, the NELSON trial results showed that a 2.5-year screening 
interval might reduce the effect of screening compared to a 1-year and a 2-year screening 
interval; more advanced stage lung cancers and more interval cancers were diagnosed during 
the 2.5-year screening interval. Furthermore, three NELSON subgroups were identified with 
significantly different risks for a non-negative (an indeterminate or a positive) scan result and 
a different risk for detecting lung cancer in the final screening round. These risks were based 
upon their previous screening history during the first three screening rounds. In line with 
these results, the NLST showed in a retrospective analysis that it is indeed possible to identify 
subgroups with significantly different lung cancer probabilities based on their screening 
history. Therefore, screening test results may be a useful risk stratification tool to refine the 
screening protocol. 
In the second part of this thesis, a substantial shift in cancer stage at time of diagnosis was 
shown as a result of low-dose CT screening in the NELSON trial so far. Implementation of CT 
lung cancer screening will lead to higher rates of early stage lung cancers, and subsequently a 
shift in treatment options from palliative to curative (mainly surgery). Thus far, it is unknown 
whether these findings indicate sufficient lung cancer and all-cause mortality reduction 
amongst NELSON study participants. 
As expected, a small healthy participant effect was observed in the NELSON trial. This may 
have influenced the mortality outcome of the study participants compared with the eligible 
non-responders (those who were eligible to participate in the trial but did not participate 
or did not fill in the informed consent form). Furthermore, the comparison of the cause of 
death as reviewed by a clinical expect committee in the NELSON trial with the official death 
certificates showed a high overall sensitivity and specificity. Therefore, possible biases related 
to lung cancer death seem relatively small. Moreover, it is suggested that each death case 
should be reviewed independently by two experts. 
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SAMENVATTING
 
Van alle kanker-gerelateerde sterfte is longkanker de voornaamste doodsoorzaak onder 
mannen en onder vrouwen de een na voornaamste doodsoorzaak. De belangrijkste oorzaak 
voor longkanker is roken. Ongeveer 85% van de longkankers worden veroorzaakt door roken. 
Stoppen met roken of nooit beginnen aan is de meest effectieve preventie van longkanker. 
Ondanks het feit dat de prevalentie van roken is afgenomen, rookt ongeveer een kwart van 
de Nederlandse bevolking van 18 jaar en ouder. Bovendien wordt tegenwoordig ongeveer 
de helft van de longkankers vastgesteld in ex-rokers. Klinisch wordt longkanker doorgaans 
in een laat stadium ontdekt, waarbij vijf jaar na de diagnose slechts 15% nog in leven is. 
Dit benadrukt de noodzaak voor de vroege opsporing- en behandeling van longkanker, 
oftewel longkankerscreening. In de Verenigde Staten wordt al gescreend op longkanker. Deze 
beslissing is deels gebaseerd op de eindresultaten van de grootste studie op het gebied van 
longkankerscreening - The National Lung Screening Trial (NLST) -  en deels op de uitkomsten 
van een modeleerstudie naar de voor- en nadelen van longkankerscreening welke op verzoek 
van de United States Preventive Services Task Force (USPSTF) werd uitgevoerd. In Europa 
wacht men de resultaten af van de grootste Europese studie - de NELSON studie-  alvorens 
een besluit te nemen of longkankerscreening ingevoerd zal worden. 
Deel I: optimaliseren van de NELSON screeningsrondes 
 
Het doel van de eerste onderzoeksvraag was om te bepalen welke toegevoegde waarde 
een vierde, en tevens de laatste, screeningsronde met een interval van 2,5-jaar na de 
derde screeningsronde heeft (Hoofdstuk II). De longkankers gediagnosticeerd in de 
laatste screeningsronde werden vergeleken met zowel de longkankers gediagnosticeerd 
in de tweede screeningsronde (met een 1-jaar screeningsinterval) als met de longkankers 
gediagnosticeerd in de derde screeningsronde (met een 2-jaar screeningsinterval). De 
longkankers gediagnosticeerd in de vierde screeningsronde zijn statistisch significant in een 
verder gevorderd stadium vergeleken met de longkankers gediagnosticeerd in de tweede 
screeningsronde. Hetzelfde werd ook gezien in vergelijking met derde screeningsronde, 
echter was dat verschil niet statistisch significant. Daarnaast werden er meer intervalkankers 
gediagnosticeerd na een 2,5-jaar screeningsinterval vergeleken met een 1-jaar en een 2-jaar 
screeningsinterval. Bovendien werden de meeste intervalkankers in de laatste zes maanden 
van het 2,5-jaar screeningsinterval gediagnosticeerd. 
Vervolgens is er op basis van de eerdere scanuitslagen retrospectief onderzocht of er 
subgroepen van studiedeelnemers geïdentificeerd konden worden met verschillende risico’s op 
ofwel een niet-negatieve uitslag (dat wil zeggen een twijfelachtige of een positieve scanuitslag) 
dan wel op longkankerdetectie in de laatste screeningsronde (Hoofdstuk III). De kans op 
een niet-negatieve scan uitslag in de laatste screeningsronde was voor de deelnemers met 
enkel negatieve scanuitslagen statistisch significant het laagst wanneer dat wordt vergeleken 
met a) deelnemers met tenminste één twijfelachtige (maar nooit een positieve scanuitslag) 
uitslag en b) deelnemers met tenminste één positieve scanuitslag. Bovendien was het 
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longkankerdetectierisico voor de vierde screeningsronde minder dan 1% bij deelnemers met 
negatieve scanuitslagen in de eerste drie screeningsronden en bij deelnemers met alleen een 
negatieve uitslag in de derde ronde. Dit suggereert dat deze deelnemers wellicht gedurende 
een periode van minimaal 2,5 jaar geen screening hoeven te ondergaan. Het gebruik van 
de screeningshistorie zou mogelijk kunnen leiden tot een betere verdeling van de mogelijke 
voor- en nadelen voor een groot deel van de te screenen populatie (bijvoorbeeld vermindering 
van het benodigde aantal scans). 
Deel II: tussentijdse vergelijking van de longkankerstadiumverdeling in de NELSON 
studie 
 
In Hoofdstuk IV zijn de stadiumverdeling en behandeling van de in de screen- en controlegroep 
gediagnosticeerde longkankers onderzocht. Hiervoor zijn de eerste honderd longkankers, 
zoals gediagnosticeerd in beide groepen, met elkaar vergeleken. Screening middels CT-
scan heeft geleid tot de vroegere opsporing van longkanker ten opzichte van geen screening 
(controle groep). Er werden niet alleen meer longkankers in stadium I gediagnosticeerd, maar 
ook minder longkankers in stadium IV in de screengroep ten opzichte van de controlegroep. 
Dit heeft geleid tot meer curatieve behandelingsopties in de screengroep. Concluderend lijkt 
het, in vergelijking met de NLST, ook mogelijk om middels het gebruik van het NELSON 
studieprotocol om longkankers in een vroegere stadium te diagnosticeren. Tot zover is het 
echter onduidelijk of de vroege opsporing van longkankers in de NELSON screengroep-
deelnemers ook leidt tot een reductie in longkanker- en totale sterfte.  
Deel III: doodsoorzaken onder de NELSON studiedeelnemers
 
In Hoofdstuk V zijn de baselinekenmerken- en sterfte uitkomst van de NELSON 
controlegroep-deelnemers vergeleken met de ‘eligible non-responders’ (personen die geschikt 
waren voor deelname maar uiteindelijk niet hebben deelgenomen of geen toestemming 
hebben verleend). Zoals verwacht zijn de NELSON studiedeelnemers jonger, gezonder, hoger 
opgeleid en meer bereid om deel te nemen aan een screeningsprogramma dan de ‘eligible non-
responders’. Deze verschillen hebben bovendien geleid tot verschil in doodsoorzaak tussen 
beide groepen: de totale sterfte, onderverdeeld naar sterfte als gevolg van de classificaties 
kanker, hart- en vaatziekten, longziekte of een andere doodsoorzaak was het hoogst voor de 
‘eligible non-responders’. Het procentuele verschil was klein en aantal onderzochte personen 
groot en daarom is het onwaarschijnlijk dat deze verschillen de generaliseerbaarheid van de 
eindresultaten zal beïnvloeden. 
In Hoofdstuk VI is er onderzocht of de door een onafhankelijke commissie beoordeelde 
doodsoorzaken van de NELSON studiedeelnemers overeenkomen met de officiële 
doodsoorzaken. De onafhankelijke commissie bestond hoofdzakelijk uit twee commissie 
leden die de geblindeerde medische statussen op een uniforme wijze beoordeelden. Tussen 
beide commissieleden was de overeenkomst zwak tot middelmatig. De overeenkomst 
tussen beide commissieleden verbeterde wel naarmate zij meer statussen beoordeelden. Een 
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vergelijking van de doodsoorzaken zoals geverifieerd door de commissieleden en de officiële 
doodsoorzaken liet een sensitiviteit en een specificiteit zien van respectievelijk 92.6% en 
98.8%. In 12.2% van de casussen werd de doodsoorzaak gewijzigd; waarvan in 46.9% het heeft 
geleid tot het wijzigen van de doodsoorzaak naar een longkanker-specifieke doodsoorzaak. 
Een mogelijke vooringenomenheid gerelateerd aan de longkankersterfte lijkt dus relatief klein 
te zijn in de NELSON studie. 
DISCUSSIE
 
In Hoofdstuk VII zijn de hoofdresultaten samengevat en bediscussieerd. Daarnaast zijn 
achtereenvolgens de methodologische overwegingen, de algemene conclusies van dit 
proefschrift en de implicaties voor verder onderzoek besproken. 
De resultaten in het eerste gedeelte van dit proefschrift toonden aan dat een 2,5-jaar 
screeningsinterval waarschijnlijk het effect van screening vermindert in vergelijking met 
een 1-jaar of een 2-jaarscreeningsinterval. Na een 2,5-jaar screeningsinterval werden 
meer longkankers gediagnosticeerd in een latere stadium en in dit interval werden 
meer intervalkankers gediagnosticeerd. Daarnaast werden er drie NELSON subgroepen 
geïdentificeerd met significant verschillende risico’s op een niet-negatieve uitslag (dat wil 
zeggen een twijfelachtige of een positieve scanuitslag) dan wel op longkankerdetectie in de 
laatste screeningsronde. Hetzelfde werd onderzocht door de NLST, welke in een retrospectieve 
analyse heeft laten zien dat het inderdaad mogelijk is om subgroepen te identificeren met 
significant verschillende risico’s op longkankerdetectie gebaseerd op hun screeningshistorie. 
Concluderend, de screeningshistorie zou een behulpzame risico-stratificatietool kunnen zijn 
om het screeningsprotocol te optimaliseren. 
In het tweede gedeelte van dit proefschrift werd aangetoond dat, tot zover, longkanker screening 
middels CT-scan binnen de NELSON studie heeft geleid tot een substantiële shift in de 
stadium van de longkankers ten opzichte van geen screening (controle groep). Implementatie 
van longkankerscreening middels CT-scan zal leiden tot meer longkankerdiagnoses 
in een vroege stadium en daarbij tot een shift in behandeling waarbij meer curatieve 
behandelingsmogelijkheden zijn. Alhoewel, het is op dit moment nog onduidelijk of deze 
gunstige resultaten ook leiden tot een significante longkanker- en totale sterftereductie in de 
NELSON screengroep-deelnemers. 
Zoals verwacht is er een klein ‘healthy participant effect’ waargenomen in de NELSON 
studie, welke heeft geleidt tot een verschil in sterfte uitkomst ten opzichte van de ‘eligible 
non-responders’. Verder toonde de vergelijking tussen de door een onafhankelijke commissie 
beoordeelde doodsoorzaken van de NELSON studiedeelnemers en de officiële doodsoorzaken 
een hoge sensitiviteit en specificiteit aan. Een mogelijke vooringenomenheid gerelateerd aan 
de longkankersterfte lijkt dus relatief klein te zijn in de NELSON studie. Tenslotte wordt er 
aanbevolen dat elk overlijden door minimaal twee commissie leden onafhankelijk van elkaar 
beoordeeld zou moeten worden. 
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